WO2022146027A1 - 헤테로아릴 유도체 화합물 및 이의 용도 - Google Patents
헤테로아릴 유도체 화합물 및 이의 용도 Download PDFInfo
- Publication number
- WO2022146027A1 WO2022146027A1 PCT/KR2021/020165 KR2021020165W WO2022146027A1 WO 2022146027 A1 WO2022146027 A1 WO 2022146027A1 KR 2021020165 W KR2021020165 W KR 2021020165W WO 2022146027 A1 WO2022146027 A1 WO 2022146027A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino
- pyrrolo
- pyrimidin
- quinoxalin
- methyl
- Prior art date
Links
- -1 Heteroaryl derivative compound Chemical class 0.000 title claims abstract description 93
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 12
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims abstract 10
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims abstract 10
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims abstract 10
- 125000000217 alkyl group Chemical group 0.000 claims description 103
- 150000003839 salts Chemical class 0.000 claims description 89
- 150000001875 compounds Chemical class 0.000 claims description 81
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 80
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 77
- 125000004553 quinoxalin-5-yl group Chemical group N1=CC=NC2=C(C=CC=C12)* 0.000 claims description 68
- WQAWEUZTDVWTDB-UHFFFAOYSA-N dimethyl(oxo)phosphanium Chemical compound C[P+](C)=O WQAWEUZTDVWTDB-UHFFFAOYSA-N 0.000 claims description 58
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 56
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 43
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 34
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 claims description 33
- 125000001475 halogen functional group Chemical group 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 230000003287 optical effect Effects 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 20
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 7
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 102200048928 rs121434568 Human genes 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- HXQZTNCJVZFNBN-UHFFFAOYSA-N 2-N-[5-(1-cyclopropylpyrazol-4-yl)-2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-4-N-(5-dimethylphosphorylquinoxalin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(C(C1=CN(C2CC2)N=C1)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 HXQZTNCJVZFNBN-UHFFFAOYSA-N 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 201000009036 biliary tract cancer Diseases 0.000 claims description 4
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 102200048955 rs121434569 Human genes 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- BCWLGJFAWDEYDT-UHFFFAOYSA-N 2-N-[4-(4-cyclopentylpiperazin-1-yl)-2-methoxy-5-(1-methylpyrazol-4-yl)phenyl]-4-N-(5-dimethylphosphorylquinoxalin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C(N(CC2)CCN2C2CCCC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OC)=C1 BCWLGJFAWDEYDT-UHFFFAOYSA-N 0.000 claims description 2
- VUVKBAKMTNVCQW-UHFFFAOYSA-N 2-N-[4-(4-cyclopentylpiperazin-1-yl)-5-(1-methylpyrazol-4-yl)-2,3-dihydro-1-benzofuran-7-yl]-4-N-(5-dimethylphosphorylquinoxalin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C=C(C2=C3CCO2)NC2=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N2)=C3N(CC2)CCN2C2CCCC2)=C1 VUVKBAKMTNVCQW-UHFFFAOYSA-N 0.000 claims description 2
- DERPACRIQCSFGK-UHFFFAOYSA-N 2-N-[4-(4-cyclopropylpiperazin-1-yl)-2-methoxy-5-(1-methylpyrazol-4-yl)phenyl]-4-N-(5-dimethylphosphorylquinoxalin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C(N(CC2)CCN2C2CC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OC)=C1 DERPACRIQCSFGK-UHFFFAOYSA-N 0.000 claims description 2
- ZCNHTDHODVTUEJ-UHFFFAOYSA-N 2-N-[4-[2-(dimethylamino)ethoxy]-2-methoxy-5-(1-methylpyrazol-4-yl)phenyl]-4-N-(5-dimethylphosphorylquinoxalin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(C)CCOC(C(C1=CN(C)N=C1)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 ZCNHTDHODVTUEJ-UHFFFAOYSA-N 0.000 claims description 2
- PCKDIYRGMSVAJA-UHFFFAOYSA-N 2-N-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(1-methylpyrazol-4-yl)phenyl]-4-N-(5-dimethylphosphorylquinoxalin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(C)CCN(C)C(C(C1=CN(C)N=C1)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 PCKDIYRGMSVAJA-UHFFFAOYSA-N 0.000 claims description 2
- OFEYKQWTMIOYGI-UHFFFAOYSA-N 2-N-[5-cyclopropyl-2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-4-N-(5-dimethylphosphorylquinoxalin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(C(C1CC1)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 OFEYKQWTMIOYGI-UHFFFAOYSA-N 0.000 claims description 2
- PIAJHNLCGINEMZ-UHFFFAOYSA-N 4-N-(2-cyclopropyl-5-dimethylphosphorylquinolin-6-yl)-2-N-[2-methoxy-5-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC2=NC(NC=C3)=C3C(NC3=CC=C4N=C(C5CC5)C=CC4=C3P(C)(C)=O)=N2)=C1OC PIAJHNLCGINEMZ-UHFFFAOYSA-N 0.000 claims description 2
- MAUYPHDNMCRQMQ-UHFFFAOYSA-N 4-N-(2-dimethylphosphoryl-3,4-dimethylphenyl)-2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-(1-methylpyrazol-4-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC(C(C)=C1P(C)(C)=O)=CC=C1NC1=NC(NC(C=C(C2=CN(C)N=C2)C(N2CCN(C)CC2)=C2)=C2OC)=NC2=C1C=CN2 MAUYPHDNMCRQMQ-UHFFFAOYSA-N 0.000 claims description 2
- UURVQASWEJJYSS-UHFFFAOYSA-N 4-N-(4-dimethylphosphoryl-1,5-naphthyridin-3-yl)-2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-(1-methylpyrazol-4-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC(C=NC4=CC=CN=C44)=C4P(C)(C)=O)=N3)=C2OC)=C1 UURVQASWEJJYSS-UHFFFAOYSA-N 0.000 claims description 2
- FJQXLXPTPPBWKZ-UHFFFAOYSA-N 4-N-(4-dimethylphosphorylquinolin-3-yl)-2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-(1-methylpyrazol-4-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC(C=NC4=CC=CC=C44)=C4P(C)(C)=O)=N3)=C2OC)=C1 FJQXLXPTPPBWKZ-UHFFFAOYSA-N 0.000 claims description 2
- UVAQTLPPLVTYKW-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinolin-6-yl)-2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-(1-methylpyrazol-4-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=CC5=C4P(C)(C)=O)=N3)=C2OC)=C1 UVAQTLPPLVTYKW-UHFFFAOYSA-N 0.000 claims description 2
- UTRZTPICDIKOQL-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-(2-methoxy-5-methylphenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC(C=C1)=CC(NC2=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N2)=C1OC UTRZTPICDIKOQL-UHFFFAOYSA-N 0.000 claims description 2
- INTPEIFMCLWHKA-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-(5-methyl-4-morpholin-4-yl-2,3-dihydro-1-benzofuran-7-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC(C=C(C1=C2CCO1)NC1=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N1)=C2N1CCOCC1 INTPEIFMCLWHKA-UHFFFAOYSA-N 0.000 claims description 2
- KJNKFRJHDIMATR-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-ethoxy-5-(trifluoromethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CCOC(C=CC(C(F)(F)F)=C1)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 KJNKFRJHDIMATR-UHFFFAOYSA-N 0.000 claims description 2
- WVNKCQUJNZQAKR-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-(1-methylpyrazol-4-yl)phenyl]-5-(trifluoromethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(NC=C4C(F)(F)F)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OC)=C1 WVNKCQUJNZQAKR-UHFFFAOYSA-N 0.000 claims description 2
- YDYIZIDQFGBYHW-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-(1-methylpyrazol-4-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OC)=C1 YDYIZIDQFGBYHW-UHFFFAOYSA-N 0.000 claims description 2
- ILJYLSOZSJZXKD-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-(1-propan-2-ylpyrazol-4-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC(C)N1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OC)=C1 ILJYLSOZSJZXKD-UHFFFAOYSA-N 0.000 claims description 2
- HEIGJELTAPOYAJ-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-phenylphenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(C(C1=CC=CC=C1)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 HEIGJELTAPOYAJ-UHFFFAOYSA-N 0.000 claims description 2
- CWJBMLOMHMOLLJ-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-pyridin-4-ylphenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(C(C1=CC=NC=C1)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 CWJBMLOMHMOLLJ-UHFFFAOYSA-N 0.000 claims description 2
- YZGDEHCUBPZBGN-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-quinolin-3-ylphenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(C(C1=CC2=CC=CC=C2N=C1)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 YZGDEHCUBPZBGN-UHFFFAOYSA-N 0.000 claims description 2
- PGATUWFRKQVQNZ-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-thiophen-3-ylphenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(C(C1=CSC=C1)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 PGATUWFRKQVQNZ-UHFFFAOYSA-N 0.000 claims description 2
- GRJALNOOLGAUBP-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-5-propan-2-ylphenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC(C)C(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC2=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N2)=C1OC GRJALNOOLGAUBP-UHFFFAOYSA-N 0.000 claims description 2
- ABLUDZCRQFTBFE-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(CC1)CCN1C(C=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 ABLUDZCRQFTBFE-UHFFFAOYSA-N 0.000 claims description 2
- DCXVLTCVCOIXHZ-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-5-(1-methylpyrazol-4-yl)-4-morpholin-4-ylphenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C(N2CCOCC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OC)=C1 DCXVLTCVCOIXHZ-UHFFFAOYSA-N 0.000 claims description 2
- DXFBFPIJDZUUEA-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-5-(1-methylpyrazol-4-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OC)=C1 DXFBFPIJDZUUEA-UHFFFAOYSA-N 0.000 claims description 2
- YEUIAPWZGVPSRY-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-6-(4-methylpiperazin-1-yl)-5-(1,2-oxazol-4-yl)pyridin-3-yl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(N=C(C(NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1)=C1)OC)=C1C1=CON=C1 YEUIAPWZGVPSRY-UHFFFAOYSA-N 0.000 claims description 2
- LAYBUGVKKZQAHC-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[3-(1-methylpyrazol-4-yl)-4-(4-morpholin-4-ylpiperidin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C=C(C=C2)NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2N(CC2)CCC2N2CCOCC2)=C1 LAYBUGVKKZQAHC-UHFFFAOYSA-N 0.000 claims description 2
- DTUIQLFGEKZTFY-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[3-(1-methylpyrazol-4-yl)-4-morpholin-4-ylphenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C=C(C=C2)NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2N2CCOCC2)=C1 DTUIQLFGEKZTFY-UHFFFAOYSA-N 0.000 claims description 2
- XZSAFZVXMLJHKB-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC(N=C1)=CN1C1=CC(C(F)(F)F)=CC(NC2=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N2)=C1 XZSAFZVXMLJHKB-UHFFFAOYSA-N 0.000 claims description 2
- NMFGTCQSXMUMCY-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[4-(4-ethylpiperazin-1-yl)-2-methoxy-5-(1-propan-2-ylpyrazol-4-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CCN(CC1)CCN1C(C(C1=CN(C(C)C)N=C1)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 NMFGTCQSXMUMCY-UHFFFAOYSA-N 0.000 claims description 2
- DKNFZRCETADBSL-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[4-(4-methylpiperazin-1-yl)-2-(2,2,2-trifluoroethoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(C=C1)=CC(OCC(F)(F)F)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 DKNFZRCETADBSL-UHFFFAOYSA-N 0.000 claims description 2
- XTIOYWDVBDSZFH-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[4-[4-(4-ethylpiperazin-1-yl)piperidin-1-yl]-2-methoxy-5-methylphenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CCN(CC1)CCN1C(CC1)CCN1C(C(C)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 XTIOYWDVBDSZFH-UHFFFAOYSA-N 0.000 claims description 2
- GVNANMQJNOGVTL-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-3-(trifluoromethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(CC1)CCN1C(C=C1)=C(C(F)(F)F)C=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 GVNANMQJNOGVTL-UHFFFAOYSA-N 0.000 claims description 2
- DTUGLSHLJPWFHO-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(CC1)CCN1C(C=C1)=CC=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 DTUGLSHLJPWFHO-UHFFFAOYSA-N 0.000 claims description 2
- JIFADNZQVFOYHV-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[4-fluoro-2-methoxy-5-(1-methylpyrazol-4-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C(F)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OC)=C1 JIFADNZQVFOYHV-UHFFFAOYSA-N 0.000 claims description 2
- MFSHMQAQGWFGEO-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[5-(1-ethylpyrazol-4-yl)-2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CCN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OC)=C1 MFSHMQAQGWFGEO-UHFFFAOYSA-N 0.000 claims description 2
- RBCNKVYQARZRJA-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[5-(1-methylpyrazol-4-yl)-2-(2,2,2-trifluoroethoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OCC(F)(F)F)=C1 RBCNKVYQARZRJA-UHFFFAOYSA-N 0.000 claims description 2
- MTEVXMVHHNUFOY-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[5-(1-methylpyrazol-4-yl)-4-morpholin-4-yl-2,3-dihydro-1-benzofuran-7-yl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C=C(C2=C3CCO2)NC2=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N2)=C3N2CCOCC2)=C1 MTEVXMVHHNUFOY-UHFFFAOYSA-N 0.000 claims description 2
- PEMIPMITOFRNHV-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[5-(furan-3-yl)-2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(C(C1=COC=C1)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 PEMIPMITOFRNHV-UHFFFAOYSA-N 0.000 claims description 2
- IVMWLEQDYJRUIO-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[5-ethenyl-2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(C(C=C)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 IVMWLEQDYJRUIO-UHFFFAOYSA-N 0.000 claims description 2
- CZCZHDACGQZSMS-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[5-ethyl-2-methoxy-6-(1-methylpiperidin-4-yl)pyridin-3-yl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CCC(C=C1NC2=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N2)=C(C2CCN(C)CC2)N=C1OC CZCZHDACGQZSMS-UHFFFAOYSA-N 0.000 claims description 2
- GDJMYRVATOLCGG-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[5-ethyl-2-methoxy-6-(4-methylpiperazin-1-yl)pyridin-3-yl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CCC(C=C1NC2=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N2)=C(N2CCN(C)CC2)N=C1OC GDJMYRVATOLCGG-UHFFFAOYSA-N 0.000 claims description 2
- BTIGORFDBZWCRO-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[5-ethynyl-2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(C(C#C)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 BTIGORFDBZWCRO-UHFFFAOYSA-N 0.000 claims description 2
- PYSIOGBWCOQQJJ-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[5-fluoro-2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(CC1)CCN1C(C(F)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 PYSIOGBWCOQQJJ-UHFFFAOYSA-N 0.000 claims description 2
- OZHCAXICPJSLIH-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[5-methyl-4-(4-methylpiperazin-1-yl)-2,3-dihydro-1-benzofuran-7-yl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC(C=C(C1=C2CCO1)NC1=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N1)=C2N1CCN(C)CC1 OZHCAXICPJSLIH-UHFFFAOYSA-N 0.000 claims description 2
- HVQQVKSNIKMBBP-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[5-methyl-4-(4-methylpiperazin-1-yl)-2-(2,2,2-trifluoroethoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC(C(N1CCN(C)CC1)=C1)=CC(NC2=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N2)=C1OCC(F)(F)F HVQQVKSNIKMBBP-UHFFFAOYSA-N 0.000 claims description 2
- OKCUSTFGCAMTSM-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[5-methyl-4-morpholin-4-yl-2-(2,2,2-trifluoroethoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC(C(N1CCOCC1)=C1)=CC(NC2=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N2)=C1OCC(F)(F)F OKCUSTFGCAMTSM-UHFFFAOYSA-N 0.000 claims description 2
- NUPWLMZOECEFRW-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[6-(1-methylpyrazol-4-yl)-5-morpholin-4-yl-3,4-dihydro-2H-chromen-8-yl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C2=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C3OCCCC3=C2N2CCOCC2)=C1 NUPWLMZOECEFRW-UHFFFAOYSA-N 0.000 claims description 2
- ZTNNYNQTMDPJIX-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[6-methyl-5-(4-methylpiperazin-1-yl)-3,4-dihydro-2H-chromen-8-yl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC1=CC(NC2=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N2)=C2OCCCC2=C1N1CCN(C)CC1 ZTNNYNQTMDPJIX-UHFFFAOYSA-N 0.000 claims description 2
- OSXATJVXQGXZLR-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-6-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-1H-pyrrolo[2,3-b]pyridine-4,6-diamine Chemical compound CN(CC1)CCN1C(CC1)CCN1C(C=C1)=CC(OC)=C1NC1=CC(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=C(C=CN2)C2=N1 OSXATJVXQGXZLR-UHFFFAOYSA-N 0.000 claims description 2
- ABJPRXLDSIGVCF-UHFFFAOYSA-N 4-N-(8-dimethylphosphorylimidazo[1,2-a]pyridin-7-yl)-2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-(1-methylpyrazol-4-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC(C=CN4C5=NC=C4)=C5P(C)(C)=O)=N3)=C2OC)=C1 ABJPRXLDSIGVCF-UHFFFAOYSA-N 0.000 claims description 2
- MQMBZUPJOYNPDO-UHFFFAOYSA-N 4-N-(8-dimethylphosphorylimidazo[1,2-a]pyridin-7-yl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(CC1)CCN1C(C=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC(C=CN2C3=NC=C2)=C3P(C)(C)=O)=N1 MQMBZUPJOYNPDO-UHFFFAOYSA-N 0.000 claims description 2
- VZDJTUITWMTLHN-UHFFFAOYSA-N 4-N-(8-dimethylphosphorylimidazo[1,2-a]pyridin-7-yl)-2-N-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(CC1)CCN1C(C=C1)=CC=C1NC1=NC(NC=C2)=C2C(NC(C=CN2C3=NC=C2)=C3P(C)(C)=O)=N1 VZDJTUITWMTLHN-UHFFFAOYSA-N 0.000 claims description 2
- UTOQMQZXZWLKTI-UHFFFAOYSA-N 4-N-(8-dimethylphosphorylquinolin-7-yl)-2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-(1-methylpyrazol-4-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C(C=CC=N5)C5=C4P(C)(C)=O)=N3)=C2OC)=C1 UTOQMQZXZWLKTI-UHFFFAOYSA-N 0.000 claims description 2
- VLSXCXXELFWIIQ-UHFFFAOYSA-N 6-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-5-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-7H-purine-2,6-diamine Chemical compound CC(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC2=NC(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=C3N=CNC3=N2)=C1OC VLSXCXXELFWIIQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- MZRFGZULSNMJTH-UHFFFAOYSA-N CC(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC(N=C2NC(C=CN3C4=NC=C3)=C4P(C)(C)=O)=NC3=C2SC=C3)=C1OC Chemical compound CC(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC(N=C2NC(C=CN3C4=NC=C3)=C4P(C)(C)=O)=NC3=C2SC=C3)=C1OC MZRFGZULSNMJTH-UHFFFAOYSA-N 0.000 claims description 2
- FDRTWUOJFKICJT-UHFFFAOYSA-N CC(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC(N=C2NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=NC3=C2SC=C3)=C1OC Chemical compound CC(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC(N=C2NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=NC3=C2SC=C3)=C1OC FDRTWUOJFKICJT-UHFFFAOYSA-N 0.000 claims description 2
- AOCUGSHNACTVHL-UHFFFAOYSA-N CN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=C(C6CC6)C=CC5=C4P(C)(C)=O)=N3)=C2OCC(F)(F)F)=C1 Chemical compound CN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=C(C6CC6)C=CC5=C4P(C)(C)=O)=N3)=C2OCC(F)(F)F)=C1 AOCUGSHNACTVHL-UHFFFAOYSA-N 0.000 claims description 2
- TUEQMYZGMVPDEN-PMACEKPBSA-N CN1N=CC(C(C(N2[C@@H](C3)CO[C@@H]3C2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OC)=C1 Chemical compound CN1N=CC(C(C(N2[C@@H](C3)CO[C@@H]3C2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OC)=C1 TUEQMYZGMVPDEN-PMACEKPBSA-N 0.000 claims description 2
- OFMQXGVKSDKPEZ-UHFFFAOYSA-N CN1N=CC(C(C=C(C2=C3OCCO2)NC2=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N2)=C3N2CCN(C)CC2)=C1 Chemical compound CN1N=CC(C(C=C(C2=C3OCCO2)NC2=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N2)=C3N2CCN(C)CC2)=C1 OFMQXGVKSDKPEZ-UHFFFAOYSA-N 0.000 claims description 2
- CSCMMVHHWXJLFH-UHFFFAOYSA-N CP(C)(C1=C2N=CC=NC2=CC=C1NC1=NC(NC(C2=C3OCCO2)=CC([N+]([O-])=O)=C3N(CC2)CCC2N(CC2)CCN2C2CC2)=NC2=C1C=CN2)=O Chemical compound CP(C)(C1=C2N=CC=NC2=CC=C1NC1=NC(NC(C2=C3OCCO2)=CC([N+]([O-])=O)=C3N(CC2)CCC2N(CC2)CCN2C2CC2)=NC2=C1C=CN2)=O CSCMMVHHWXJLFH-UHFFFAOYSA-N 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010061825 Duodenal neoplasm Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 208000031852 Gastrointestinal stromal cancer Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000004059 Male Breast Neoplasms Diseases 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
- 208000005410 Mediastinal Neoplasms Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- QDNRGYVNBXVZCV-UHFFFAOYSA-N N-[5-[[4-[(5-dimethylphosphorylquinoxalin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl]prop-2-enamide Chemical compound CN(CC1)CCN1C(C=C(C(NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1)=C1)OC)=C1NC(C=C)=O QDNRGYVNBXVZCV-UHFFFAOYSA-N 0.000 claims description 2
- PPLRSYCGGCWKJV-UHFFFAOYSA-N N-[5-[[4-[(5-dimethylphosphorylquinoxalin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl]propanamide Chemical compound CCC(NC(C=C(C(OC)=C1)NC2=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N2)=C1N1CCN(C)CC1)=O PPLRSYCGGCWKJV-UHFFFAOYSA-N 0.000 claims description 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 208000027868 Paget disease Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 2
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000032383 Soft tissue cancer Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010044002 Tonsil cancer Diseases 0.000 claims description 2
- 208000006842 Tonsillar Neoplasms Diseases 0.000 claims description 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims description 2
- 206010046392 Ureteric cancer Diseases 0.000 claims description 2
- 206010046431 Urethral cancer Diseases 0.000 claims description 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- LFEFSMQPZYTOCA-UHFFFAOYSA-N [4-[4-[[4-[(5-dimethylphosphorylquinoxalin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-5-methoxy-2-(1-methylpyrazol-4-yl)phenyl]piperazin-1-yl]-(1-fluorocyclopropyl)methanone Chemical compound CN1N=CC(C(C=C(C(OC)=C2)NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2N(CC2)CCN2C(C2(CC2)F)=O)=C1 LFEFSMQPZYTOCA-UHFFFAOYSA-N 0.000 claims description 2
- 208000004064 acoustic neuroma Diseases 0.000 claims description 2
- 239000003708 ampul Substances 0.000 claims description 2
- 201000011165 anus cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000000312 duodenum cancer Diseases 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 208000010749 gastric carcinoma Diseases 0.000 claims description 2
- 201000011587 gastric lymphoma Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 208000006359 hepatoblastoma Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 2
- 201000003175 male breast cancer Diseases 0.000 claims description 2
- 208000010907 male breast carcinoma Diseases 0.000 claims description 2
- 208000016035 malignant germ cell tumor of ovary Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000027202 mammary Paget disease Diseases 0.000 claims description 2
- 201000000349 mediastinal cancer Diseases 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 201000008042 ovarian germ cell cancer Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 125000004437 phosphorous atom Chemical group 0.000 claims description 2
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 2
- 201000003437 pleural cancer Diseases 0.000 claims description 2
- 208000020615 rectal carcinoma Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000011096 spinal cancer Diseases 0.000 claims description 2
- 208000014618 spinal cord cancer Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000011294 ureter cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 208000037965 uterine sarcoma Diseases 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- XJTUAMISDRPJAU-UHFFFAOYSA-N 2-N-(3-chloro-1-methylpyrazol-4-yl)-4-N-(5-dimethylphosphorylquinoxalin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(C=C1NC2=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N2)N=C1Cl XJTUAMISDRPJAU-UHFFFAOYSA-N 0.000 claims 1
- ZQWQWGSANKHUNV-UHFFFAOYSA-N 2-N-(5-chloro-1-methylpyrazol-4-yl)-4-N-(5-dimethylphosphorylquinoxalin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(NC2=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N2)=C1Cl ZQWQWGSANKHUNV-UHFFFAOYSA-N 0.000 claims 1
- ISHINQQLQQFPMQ-UHFFFAOYSA-N 2-N-[4-[4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl]-2-methoxy-5-methylphenyl]-4-N-(5-dimethylphosphorylquinoxalin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC(C(N(CC1)CCC1N(CC1)CCN1C1CC1)=C1)=CC(NC2=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N2)=C1OC ISHINQQLQQFPMQ-UHFFFAOYSA-N 0.000 claims 1
- QSAXFAWCBLBWNP-UHFFFAOYSA-N 2-N-[5-[1-(difluoromethyl)pyrazol-4-yl]-2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-4-N-(5-dimethylphosphorylquinoxalin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(C(C1=CN(C(F)F)N=C1)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 QSAXFAWCBLBWNP-UHFFFAOYSA-N 0.000 claims 1
- HQGKHFWCFKTOCW-UHFFFAOYSA-N 2-N-[5-chloro-2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(5-dimethylphosphorylquinoxalin-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(CC1)CCN1C(C(Cl)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 HQGKHFWCFKTOCW-UHFFFAOYSA-N 0.000 claims 1
- SFDGJDBLYNJMFI-UHFFFAOYSA-N 3,1-benzoxazin-4-one Chemical compound C1=CC=C2C(=O)OC=NC2=C1 SFDGJDBLYNJMFI-UHFFFAOYSA-N 0.000 claims 1
- WUHRFTCLYMJXGY-UHFFFAOYSA-N 4-N-(2-cyclopropyl-5-dimethylphosphorylquinolin-6-yl)-2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-(1-methylpyrazol-4-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=C(C6CC6)C=CC5=C4P(C)(C)=O)=N3)=C2OC)=C1 WUHRFTCLYMJXGY-UHFFFAOYSA-N 0.000 claims 1
- DGXFQRYUTYMGCF-UHFFFAOYSA-N 4-N-(4-dimethylphosphorylquinolin-3-yl)-2-N-[2-methoxy-5-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC2=NC(NC=C3)=C3C(NC(C=NC3=CC=CC=C33)=C3P(C)(C)=O)=N2)=C1OC DGXFQRYUTYMGCF-UHFFFAOYSA-N 0.000 claims 1
- ZMJUDUSFIFYYBW-UHFFFAOYSA-N 4-N-(4-dimethylphosphorylquinolin-3-yl)-2-N-[4-(4-methylpiperazin-1-yl)-5-(1-methylpyrazol-4-yl)-2-(2,2,2-trifluoroethoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC(C=NC4=CC=CC=C44)=C4P(C)(C)=O)=N3)=C2OCC(F)(F)F)=C1 ZMJUDUSFIFYYBW-UHFFFAOYSA-N 0.000 claims 1
- NHDJFHJPEXWLKM-UHFFFAOYSA-N 4-N-(4-dimethylphosphorylquinolin-3-yl)-2-N-[5-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-(2,2,2-trifluoroethoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC2=NC(NC=C3)=C3C(NC(C=NC3=CC=CC=C33)=C3P(C)(C)=O)=N2)=C1OCC(F)(F)F NHDJFHJPEXWLKM-UHFFFAOYSA-N 0.000 claims 1
- FUGBYFPVPPXBDU-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-(6-methyl-5-morpholin-4-yl-3,4-dihydro-2H-chromen-8-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC1=CC(NC2=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N2)=C2OCCCC2=C1N1CCOCC1 FUGBYFPVPPXBDU-UHFFFAOYSA-N 0.000 claims 1
- HTKYVTAKABDXHJ-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-5-(1-methylpyrazol-4-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C(N(CC2)CCC2N2CCN(C)CC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OC)=C1 HTKYVTAKABDXHJ-UHFFFAOYSA-N 0.000 claims 1
- LMNYEBLJGYACOC-OYRHEFFESA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-5-(1-methylpyrazol-4-yl)-4-[(3S,5R)-3,4,5-trimethylpiperazin-1-yl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound C[C@H](C1)N(C)[C@@H](C)CN1C(C(C1=CN(C)N=C1)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 LMNYEBLJGYACOC-OYRHEFFESA-N 0.000 claims 1
- RQEWMZJPDNQMIV-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-5-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC2=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N2)=C1OC RQEWMZJPDNQMIV-UHFFFAOYSA-N 0.000 claims 1
- YDYJCHBHMDLCKN-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-5-methyl-4-[4-(4-propan-2-ylpiperazin-1-yl)piperidin-1-yl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC(C)N(CC1)CCN1C(CC1)CCN1C(C(C)=C1)=CC(OC)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 YDYJCHBHMDLCKN-UHFFFAOYSA-N 0.000 claims 1
- VVNARKBEBYZHQU-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-6-(1-methylpiperidin-4-yl)-5-(1-methylpyrazol-4-yl)pyridin-3-yl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C=C2NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C(C3CCN(C)CC3)N=C2OC)=C1 VVNARKBEBYZHQU-UHFFFAOYSA-N 0.000 claims 1
- VMXFKOYIECMHIQ-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-6-(4-methylpiperazin-1-yl)-5-(1,3-oxazol-4-yl)pyridin-3-yl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN(CC1)CCN1C(N=C(C(NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1)=C1)OC)=C1C1=COC=N1 VMXFKOYIECMHIQ-UHFFFAOYSA-N 0.000 claims 1
- BXGQDWSBTGNTQU-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[4-(4-methylpiperazin-1-yl)-5-(1-methylpyrazol-4-yl)-2,3-dihydro-1-benzofuran-7-yl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C=C(C2=C3CCO2)NC2=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N2)=C3N2CCN(C)CC2)=C1 BXGQDWSBTGNTQU-UHFFFAOYSA-N 0.000 claims 1
- WGFXLYVRZNQKLX-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[4-(4-methylpiperazin-1-yl)-5-(1-methylpyrazol-4-yl)-2-(2,2,2-trifluoroethoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OCC(F)(F)F)=C1 WGFXLYVRZNQKLX-UHFFFAOYSA-N 0.000 claims 1
- KXKOYCSQOLEYOO-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[5-(1-methylpyrazol-4-yl)-4-(4-morpholin-4-ylpiperidin-1-yl)-2-(2,2,2-trifluoroethoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CN1N=CC(C(C(N(CC2)CCC2N2CCOCC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OCC(F)(F)F)=C1 KXKOYCSQOLEYOO-UHFFFAOYSA-N 0.000 claims 1
- NTXMDGVEXHMHFF-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[5-ethyl-2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CCC(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC2=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N2)=C1OC NTXMDGVEXHMHFF-UHFFFAOYSA-N 0.000 claims 1
- VFUAPDXZDMCDFX-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[5-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-(2,2,2-trifluoroethoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC2=NC(NC=C3)=C3C(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=N2)=C1OCC(F)(F)F VFUAPDXZDMCDFX-UHFFFAOYSA-N 0.000 claims 1
- PYTYUCQGBMCYDP-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-6-N-[2-methoxy-5-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-1H-pyrrolo[2,3-b]pyridine-4,6-diamine Chemical compound CC(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC2=CC(NC3=CC=C4N=CC=NC4=C3P(C)(C)=O)=C(C=CN3)C3=N2)=C1OC PYTYUCQGBMCYDP-UHFFFAOYSA-N 0.000 claims 1
- HNQSYQFDYGAYCF-UHFFFAOYSA-N 4-N-(5-dimethylphosphorylquinoxalin-6-yl)-6-N-[3-methoxy-5-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyridin-2-yl]-1H-pyrrolo[2,3-b]pyridine-4,6-diamine Chemical compound CN(CC1)CCN1C(CC1)CCN1C(C=C1OC)=CN=C1NC1=CC(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=C(C=CN2)C2=N1 HNQSYQFDYGAYCF-UHFFFAOYSA-N 0.000 claims 1
- PGLQJSMOQJDXKC-UHFFFAOYSA-N 4-N-(8-dimethylphosphorylimidazo[1,2-a]pyridin-7-yl)-2-N-[2-methoxy-5-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine Chemical compound CC(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC2=NC(NC=C3)=C3C(NC(C=CN3C4=NC=C3)=C4P(C)(C)=O)=N2)=C1OC PGLQJSMOQJDXKC-UHFFFAOYSA-N 0.000 claims 1
- QRHZJPVEGGZCOT-UHFFFAOYSA-N 5-[[4-[(5-dimethylphosphorylquinoxalin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-4-methoxy-2-(4-methylpiperazin-1-yl)benzonitrile Chemical compound CN(CC1)CCN1C(C=C(C(NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1)=C1)OC)=C1C#N QRHZJPVEGGZCOT-UHFFFAOYSA-N 0.000 claims 1
- GZOWKGKNKXGVRY-UHFFFAOYSA-N 5-[[4-[(5-dimethylphosphorylquinoxalin-6-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-6-methoxy-2-(4-methylpiperazin-1-yl)pyridine-3-carbonitrile Chemical compound CN(CC1)CCN1C(N=C(C(NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1)=C1)OC)=C1C#N GZOWKGKNKXGVRY-UHFFFAOYSA-N 0.000 claims 1
- SLVXBSWZTZSECA-UHFFFAOYSA-N 6-N-(5-dimethylphosphorylquinoxalin-6-yl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-5-(1-methylpyrazol-4-yl)phenyl]-7H-purine-2,6-diamine Chemical compound CN1N=CC(C(C(N(CC2)CCC2N2CCN(C)CC2)=C2)=CC(NC3=NC(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=C4N=CNC4=N3)=C2OC)=C1 SLVXBSWZTZSECA-UHFFFAOYSA-N 0.000 claims 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- LSZLNKVFKRIJEQ-UHFFFAOYSA-N CC(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC2=NC(NC=C3)=C3C(NC(C=CC3=C4OCCN3C)=C4P(C)(C)=O)=N2)=C1OC Chemical compound CC(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC2=NC(NC=C3)=C3C(NC(C=CC3=C4OCCN3C)=C4P(C)(C)=O)=N2)=C1OC LSZLNKVFKRIJEQ-UHFFFAOYSA-N 0.000 claims 1
- XNBRAAADJCDVFC-UHFFFAOYSA-N CC(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC2=NC(NC=C3)=C3C(NC(C=CN3C4=NC=C3)=C4P(C)(C)=O)=N2)=C1OCC(F)(F)F Chemical compound CC(C(N(CC1)CCC1N1CCN(C)CC1)=C1)=CC(NC2=NC(NC=C3)=C3C(NC(C=CN3C4=NC=C3)=C4P(C)(C)=O)=N2)=C1OCC(F)(F)F XNBRAAADJCDVFC-UHFFFAOYSA-N 0.000 claims 1
- PRWDLQVWTGFYNO-UHFFFAOYSA-N CN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC(C=CN4C5=NC=C4)=C5P(C)(C)=O)=N3)=C2OCC(F)(F)F)=C1 Chemical compound CN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC(C=CN4C5=NC=C4)=C5P(C)(C)=O)=N3)=C2OCC(F)(F)F)=C1 PRWDLQVWTGFYNO-UHFFFAOYSA-N 0.000 claims 1
- FTSFGEYYALCULE-UHFFFAOYSA-N CN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(SC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OC)=C1 Chemical compound CN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(NC3=NC(SC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OC)=C1 FTSFGEYYALCULE-UHFFFAOYSA-N 0.000 claims 1
- UJMNUEIRWOEOIR-OYRHEFFESA-N CN1N=CC(C(C(N2C[C@H](CC3)O[C@H]3C2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OC)=C1 Chemical compound CN1N=CC(C(C(N2C[C@H](CC3)O[C@H]3C2)=C2)=CC(NC3=NC(NC=C4)=C4C(NC4=CC=C5N=CC=NC5=C4P(C)(C)=O)=N3)=C2OC)=C1 UJMNUEIRWOEOIR-OYRHEFFESA-N 0.000 claims 1
- BCHWWUTYRDUGCI-UHFFFAOYSA-N CP(C)(C1=C2N=CC=NC2=CC=C1)=O Chemical compound CP(C)(C1=C2N=CC=NC2=CC=C1)=O BCHWWUTYRDUGCI-UHFFFAOYSA-N 0.000 claims 1
- YAPMFADVVBMBLZ-BGYRXZFFSA-N C[C@H](C1)O[C@@H](C)CN1C(C(C1=CN(C)N=C1)=C1)=CC(OCC(F)(F)F)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 Chemical compound C[C@H](C1)O[C@@H](C)CN1C(C(C1=CN(C)N=C1)=C1)=CC(OCC(F)(F)F)=C1NC1=NC(NC=C2)=C2C(NC2=CC=C3N=CC=NC3=C2P(C)(C)=O)=N1 YAPMFADVVBMBLZ-BGYRXZFFSA-N 0.000 claims 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 claims 1
- 206010027407 Mesothelioma malignant Diseases 0.000 claims 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims 1
- 206010054184 Small intestine carcinoma Diseases 0.000 claims 1
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 abstract description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 67
- 102000001301 EGF receptor Human genes 0.000 description 51
- 108060006698 EGF receptor Proteins 0.000 description 51
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 32
- 238000002360 preparation method Methods 0.000 description 30
- 239000011541 reaction mixture Substances 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- 238000000746 purification Methods 0.000 description 14
- 239000011734 sodium Substances 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 230000035772 mutation Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 7
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 150000002390 heteroarenes Chemical class 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000011368 organic material Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- UCNGGGYMLHAMJG-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 239000005416 organic matter Substances 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 3
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 3
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000006005 fluoroethoxy group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000000366 juvenile effect Effects 0.000 description 3
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- PQZZJAAYJSIWEL-UHFFFAOYSA-N 1-(1,3-benzodioxol-4-yl)-4-methylpiperazine Chemical compound CN1CCN(CC1)C2=C3C(=CC=C2)OCO3 PQZZJAAYJSIWEL-UHFFFAOYSA-N 0.000 description 2
- IPIVRFNYBWTTSA-UHFFFAOYSA-N 1-(5-bromo-7-nitro-1,3-benzodioxol-4-yl)-4-methylpiperazine Chemical compound CN(CC1)CCN1C(C1=C(C([N+]([O-])=O)=C2)OCO1)=C2Br IPIVRFNYBWTTSA-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- MVRQVZQKTOIAGJ-UHFFFAOYSA-N 1-bromo-2-fluoro-5-nitro-4-(2,2,2-trifluoroethoxy)benzene Chemical compound [O-][N+](C(C(OCC(F)(F)F)=C1)=CC(Br)=C1F)=O MVRQVZQKTOIAGJ-UHFFFAOYSA-N 0.000 description 2
- 125000006420 1-fluorocyclopropyl group Chemical group [H]C1([H])C([H])([H])C1(F)* 0.000 description 2
- NJDLLCYZWIZYRX-UHFFFAOYSA-N 1-methyl-4-(7-nitro-1,3-benzodioxol-4-yl)piperazine Chemical compound CN(CC1)CCN1C(C1=C2OCO1)=CC=C2[N+]([O-])=O NJDLLCYZWIZYRX-UHFFFAOYSA-N 0.000 description 2
- CWQACQSKFNFDAG-UHFFFAOYSA-N 2-bromo-1-(2-bromoethoxy)-3-fluorobenzene Chemical compound Fc1cccc(OCCBr)c1Br CWQACQSKFNFDAG-UHFFFAOYSA-N 0.000 description 2
- KRJIGKBETHMDMS-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)-5-(1-methylpyrazol-4-yl)-2-(2,2,2-trifluoroethoxy)aniline Chemical compound CN1N=CC(C(C(N2CCN(C)CC2)=C2)=CC(N)=C2OCC(F)(F)F)=C1 KRJIGKBETHMDMS-UHFFFAOYSA-N 0.000 description 2
- UDVWGWLRNYOMGK-UHFFFAOYSA-N 4-[2-fluoro-5-nitro-4-(2,2,2-trifluoroethoxy)phenyl]-1-methylpyrazole Chemical compound CN1N=CC(C(C=C(C(OCC(F)(F)F)=C2)[N+]([O-])=O)=C2F)=C1 UDVWGWLRNYOMGK-UHFFFAOYSA-N 0.000 description 2
- VZPMQHSDFWAZHP-UHFFFAOYSA-N 4-bromo-1,3-benzodioxole Chemical compound BrC1=CC=CC2=C1OCO2 VZPMQHSDFWAZHP-UHFFFAOYSA-N 0.000 description 2
- HCBQXDCGBLXQST-UHFFFAOYSA-N 4-fluoro-2,3-dihydro-1-benzofuran Chemical compound FC1=CC=CC2=C1CCO2 HCBQXDCGBLXQST-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- HEWRWTFEHQYCLJ-UHFFFAOYSA-N 5-bromo-4-fluoro-2,3-dihydro-1-benzofuran Chemical compound C1=C(Br)C(F)=C2CCOC2=C1 HEWRWTFEHQYCLJ-UHFFFAOYSA-N 0.000 description 2
- CMISEYRTAJFMNP-UHFFFAOYSA-N 5-bromo-4-fluoro-7-nitro-2,3-dihydro-1-benzofuran Chemical compound [O-][N+](C(C1=C2CCO1)=CC(Br)=C2F)=O CMISEYRTAJFMNP-UHFFFAOYSA-N 0.000 description 2
- IAKRFIMABCZOJK-UHFFFAOYSA-N 7-(4-methylpiperazin-1-yl)-6-(1-methylpyrazol-4-yl)-1,3-benzodioxol-4-amine Chemical compound CN1N=CC(C(C=C(C2=C3OCO2)N)=C3N2CCN(C)CC2)=C1 IAKRFIMABCZOJK-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- GUUMKXADAPPBKT-UHFFFAOYSA-N CN1N=CC(C(C=C(C(OC)=C2)[N+]([O-])=O)=C2N2CCC3(CCNCC3)CC2)=C1 Chemical compound CN1N=CC(C(C=C(C(OC)=C2)[N+]([O-])=O)=C2N2CCC3(CCNCC3)CC2)=C1 GUUMKXADAPPBKT-UHFFFAOYSA-N 0.000 description 2
- OEALQBKSALLHLV-UHFFFAOYSA-N CN1N=CC(C2=CC(N)=C3OCCC3=C2N2CCOCC2)=C1 Chemical compound CN1N=CC(C2=CC(N)=C3OCCC3=C2N2CCOCC2)=C1 OEALQBKSALLHLV-UHFFFAOYSA-N 0.000 description 2
- ROEOEXWYKMHRQC-UHFFFAOYSA-N CN1N=CC(C2=CC([N+]([O-])=O)=C3OCCC3=C2N2CCOCC2)=C1 Chemical compound CN1N=CC(C2=CC([N+]([O-])=O)=C3OCCC3=C2N2CCOCC2)=C1 ROEOEXWYKMHRQC-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 101150003085 Pdcl gene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- WDRMTDDHSLCBEP-UHFFFAOYSA-N [O-][N+](C(C=C1Br)=C2OCCC2=C1N1CCOCC1)=O Chemical compound [O-][N+](C(C=C1Br)=C2OCCC2=C1N1CCOCC1)=O WDRMTDDHSLCBEP-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 2
- IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229960003278 osimertinib Drugs 0.000 description 2
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- XVPMRLUXTWSMCO-UHFFFAOYSA-N tert-butyl 9-(2-bromo-5-methoxy-4-nitrophenyl)-3,9-diazaspiro[5.5]undecane-3-carboxylate Chemical compound BrC1=C(C=C(C(=C1)[N+](=O)[O-])OC)N1CCC2(CCN(CC2)C(=O)OC(C)(C)C)CC1 XVPMRLUXTWSMCO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- JNYWVERKQKRXSL-PHDIDXHHSA-N (1r,4r)-2-oxa-5-azabicyclo[2.2.2]octane Chemical compound C1C[C@]2([H])CN[C@@]1([H])CO2 JNYWVERKQKRXSL-PHDIDXHHSA-N 0.000 description 1
- CJQNJRRDTPULTL-KNVOCYPGSA-N (1r,5s)-3-azabicyclo[3.2.1]octane Chemical compound C1[C@@]2([H])CC[C@]1([H])CNC2 CJQNJRRDTPULTL-KNVOCYPGSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical compound C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- DHSGXAGGBXJPEL-UHFFFAOYSA-N 1-bromo-2-fluoro-4-methoxy-5-nitrobenzene Chemical compound COC1=CC(F)=C(Br)C=C1[N+]([O-])=O DHSGXAGGBXJPEL-UHFFFAOYSA-N 0.000 description 1
- NDCPERCVXDYEFU-UHFFFAOYSA-N 1-fluorocyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(F)CC1 NDCPERCVXDYEFU-UHFFFAOYSA-N 0.000 description 1
- YIRPUQUUZFETBH-UHFFFAOYSA-N 1-methyl-4-[5-(1-methylpyrazol-4-yl)-7-nitro-1,3-benzodioxol-4-yl]piperazine Chemical compound CN1N=CC(C(C=C(C2=C3OCO2)[N+]([O-])=O)=C3N2CCN(C)CC2)=C1 YIRPUQUUZFETBH-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- MYKQKWIPLZEVOW-UHFFFAOYSA-N 11h-benzo[a]carbazole Chemical compound C1=CC2=CC=CC=C2C2=C1C1=CC=CC=C1N2 MYKQKWIPLZEVOW-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- ZKAMEFMDQNTDFK-UHFFFAOYSA-N 1h-imidazo[4,5-b]pyrazine Chemical compound C1=CN=C2NC=NC2=N1 ZKAMEFMDQNTDFK-UHFFFAOYSA-N 0.000 description 1
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
- RTMMSCJWQYWMNK-UHFFFAOYSA-N 2,2,2-trifluoroethyl trifluoromethanesulfonate Chemical compound FC(F)(F)COS(=O)(=O)C(F)(F)F RTMMSCJWQYWMNK-UHFFFAOYSA-N 0.000 description 1
- HSSJZWWCSQLAQN-UHFFFAOYSA-N 2-[(2,4-dichloropyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl-trimethylsilane Chemical compound N1=C(Cl)N=C2N(COCC[Si](C)(C)C)C=CC2=C1Cl HSSJZWWCSQLAQN-UHFFFAOYSA-N 0.000 description 1
- QPEJAHMNOVMSOZ-UHFFFAOYSA-N 2-azaspiro[3.3]heptane Chemical compound C1CCC21CNC2 QPEJAHMNOVMSOZ-UHFFFAOYSA-N 0.000 description 1
- LMFRSLRJXLATRL-UHFFFAOYSA-N 2-bromo-3-fluorophenol Chemical compound OC1=CC=CC(F)=C1Br LMFRSLRJXLATRL-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- JPBDMIWPTFDFEU-UHFFFAOYSA-N 3-bromobenzene-1,2-diol Chemical compound OC1=CC=CC(Br)=C1O JPBDMIWPTFDFEU-UHFFFAOYSA-N 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- ZMSFGDZCAYKXOE-UHFFFAOYSA-N 4-bromo-5-fluoro-2-nitrophenol Chemical compound OC1=CC(F)=C(Br)C=C1[N+]([O-])=O ZMSFGDZCAYKXOE-UHFFFAOYSA-N 0.000 description 1
- BNNMDMGPZUOOOE-UHFFFAOYSA-N 4-methylbenzenesulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1 BNNMDMGPZUOOOE-UHFFFAOYSA-N 0.000 description 1
- HFPASWSTLSWIEI-UHFFFAOYSA-N 5-dimethylphosphorylquinoxalin-6-amine Chemical compound P(=O)(C)(C)C1=C(N)C=CC2=NC=CN=C12 HFPASWSTLSWIEI-UHFFFAOYSA-N 0.000 description 1
- MJQSRSOTRPMVKB-UHFFFAOYSA-N 5h-imidazo[4,5-c]pyridazine Chemical compound C1=NNC2=NC=NC2=C1 MJQSRSOTRPMVKB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001120493 Arene Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- KHNYNFUTFKJLDD-UHFFFAOYSA-N Benzo[j]fluoranthene Chemical compound C1=CC(C=2C3=CC=CC=C3C=CC=22)=C3C2=CC=CC3=C1 KHNYNFUTFKJLDD-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102100027280 Fanconi anemia group A protein Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 101000914673 Homo sapiens Fanconi anemia group A protein Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010051925 Intestinal adenocarcinoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028767 Nasal sinus cancer Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 206010061336 Pelvic neoplasm Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000005011 alkyl ether group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004947 monocyclic arenes Chemical class 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- FQOBINBWTPHVEO-UHFFFAOYSA-N pyrazino[2,3-b]pyrazine Chemical compound N1=CC=NC2=NC=CN=C21 FQOBINBWTPHVEO-UHFFFAOYSA-N 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 description 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLKHACHFJMCIRE-UHFFFAOYSA-N tert-butyl 3,9-diazaspiro[5.5]undecane-3-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11CCNCC1 YLKHACHFJMCIRE-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- VJYJJHQEVLEOFL-UHFFFAOYSA-N thieno[3,2-b]thiophene Chemical compound S1C=CC2=C1C=CS2 VJYJJHQEVLEOFL-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- 229940121646 third-generation egfr tyrosine kinase inhibitor Drugs 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000005580 triphenylene group Chemical group 0.000 description 1
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 description 1
- 229930004006 tropane Natural products 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
- C07F9/5325—Aromatic phosphine oxides or thioxides (P-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the present invention relates to heteroaryl derivative compounds and their medicinal uses. Specifically, the present invention relates to a heteroaryl derivative compound having EGFR inhibitory activity.
- Protein kinases are involved in signaling pathways by acting as molecular switches, and the switching between the active and inactive states of the target protein by the kinase in the cell must be smoothly regulated. If the transition between the active and the inactive state is abnormally regulated, the intracellular signal transduction is excessively activated or inactivated to induce uncontrolled cell division and proliferation. In particular, abnormal activation by mutation, amplification and/or overexpression of protein kinase genes causes the development and progression of various tumors or plays a decisive role in the onset of various diseases such as inflammatory diseases, degenerative brain diseases, and autoimmune diseases.
- epidermal growth factor receptor a receptor tyrosine kinase of the ErbB family
- NSCLC non-small cell lung carcinoma
- breast cancer glioma, squamous cell carcinoma of the head and neck, colorectal cancer
- It is abnormally activated in many epithelial cell tumors including intestinal adenocarcinoma, head and neck cancer, gastric cancer and prostate cancer
- activation of the EGFR-tyrosine kinase causes sustained cell proliferation, invasion into surrounding tissues, distant metastasis, angiogenesis, and cell survival has been known to increase
- EGFR mutations EGFR_del19 or EGFR_L858R are the main causes of non-small cell lung cancer and head and neck cancer, and their therapeutic agents Iressa and Tarceva have been developed and are currently being used in clinical practice.
- these drugs were used in patients, acquired resistance resulting from a secondary mutation of EGFR based on the structure of the drug was observed, and it was also found that this is the main cause of drug resistance.
- the first-generation EGFR inhibitors are used for an average of 10 months, acquired resistance called the T790M mutation located in the gatekeeper of the EGFR kinase occurs, so that the first-generation EGFR inhibitors are not effective.
- EGFR_del19_T790M or EGFR_L858R_T790M double mutation occurs, preventing the existing therapeutic agents from exhibiting drug efficacy.
- Osimertinib a third-generation EGFR-TKI target drug that exhibits high reactivity to drug resistance according to T790M mutation, has been developed, but drug resistance has also been reported to occur from this (Clin Cancer Res, 2015, 17:21). ).
- the EGFR C797S mutation has been suggested as one of the main mechanisms causing drug resistance to osimertinib, and it has been reported that about 40% of clinical trial patients have the C797S mutation (Nature Medicine, 2015, 21:560-562).
- Another object of the present invention is to provide a method for preparing the heteroaryl derivative compound.
- Another object of the present invention is to provide a pharmaceutical use of the heteroaryl derivative compound, specifically, a pharmaceutical composition for the treatment or prevention of EGFR-related diseases comprising the heteroaryl derivative compound as an active ingredient, and EGFR-related use of the compound
- a pharmaceutical use of the heteroaryl derivative compound specifically, a pharmaceutical composition for the treatment or prevention of EGFR-related diseases comprising the heteroaryl derivative compound as an active ingredient, and EGFR-related use of the compound
- the present invention was completed by confirming that the heteroaryl derivative compounds represented by Chemical Formula 1 mentioned below inhibit the proliferation of EGFR-activated cells.
- the present invention provides a compound represented by the following formula (1), an optical isomer thereof, or a pharmaceutically acceptable salt thereof:
- X 1 to X 3 are each independently CR a R b , NR c , O, or S;
- R a to R c are each independently -H, -C 1-6 alkyl, -C 1-6 aminoalkyl, -C 1-6 hydroxyalkyl, -C 1-6 haloalkyl, -CN, -NH 2 , -OH, -OC 1-6 alkyl, -halo, -C 3-6 cycloalkyl, or nothing;
- Y 1 to Y 4 are each independently CR d or NR e ⁇ wherein, any one of Y 1 -Y 2 , Y 2 -Y 3 , and Y 3 -Y 4 is connected to each other to form a 5-6 membered aryl, 5 -can form 6-membered heteroaryl, or 5-6 membered heterocycloalkyl, wherein at least one H of said aryl, heteroaryl, or heterocycloalkyl is -C 1-6 alkyl, -C 1-6 amino may be substituted with alkyl, -C 1-6 hydroxyalkyl, -C 1-6 haloalkyl, -CN, -NR 3 R 4 , -OR 5 , -halo, or -C 3-6 cycloalkyl] ⁇ ;
- R d and R e are each independently -H, -C 1-6 alkyl, -C 1-6 aminoalkyl, -C 1-6 hydroxyalkyl, -C 1-6 haloalkyl, -CN, -NR 3 R 4 , -OR 5 , -halo, -C 3-6 cycloalkyl, or nothing;
- Z 1 to Z 5 are each independently CR f , NR g or N ⁇ wherein, any one of Z 1 -Z 2 , Z 2 -Z 3 , Z 3 -Z 4 , and Z 4 -Z 5 is connected to each other can be formed to form a 5-6 membered aryl, 5-6 membered heteroaryl or 5-6 membered heterocycloalkyl, wherein at least one H of the aryl, heteroaryl, or heterocycloalkyl is -C 1-6 alkyl , -C 1-6 aminoalkyl, -C 1-6 hydroxyalkyl, -C 1-6 haloalkyl, -CN, -NR 3 R 4 , -OR 5 , -halo, or -C 3-6 cycloalkyl may be substituted with] ⁇ ;
- R f and R g are each independently -H, -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 1-6 aminoalkyl, -C 1-6 hydroxy alkyl, -C 1-6 haloalkyl, -CN, -NR 3 R 4 , -NO 2 , -OR 5 , -halo, aryl, heteroaryl, -C 3-6 cycloalkyl, or heterocycloalkyl ⁇ wherein , at least one H of aryl or heteroaryl is -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 1-6 aminoalkyl, -C 1-6 hydroxyalkyl , -C 1-6 haloalkyl, -C 3-6 cycloalkyl, heterocycloalkyl, phenyl, or heteroaryl, wherein one or more H of -
- n 0 or 1
- R 1 and R 2 are each independently —H, —C 1-6 alkyl, —C 1-6 alkoxy, —C 1-6 alkylamino, —C 2-12 dialkylamino, or C 3-6 cycloalkyl Or, R 1 and R 2 may be connected to each other to form a 4 to 7 membered ring together with the P atom;
- R 5 is -H, -C 1-6 alkyl, -C 1-6 alkyl-NR 6 R 7 , -C 1-6 aminoalkyl, -C 1-6 hydroxyalkyl, or -C 1-6 haloalkyl ego;
- R 6 and R 7 are each independently —H or —C 1-6 alkyl.
- the compound represented by Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof may be in the following range:
- X 1 to X 3 are each independently CR a R b , NR c , or S;
- R a to R c are each independently -H, -C 1-6 alkyl, -C 1-6 haloalkyl, -CN, -halo, -C 3-6 cycloalkyl, or nothing;
- Y 1 to Y 4 are each independently CR d or NR e ⁇ wherein, any one of Y 1 -Y 2 , Y 2 -Y 3 , and Y 3 -Y 4 is connected to each other to form a 5-6 membered aryl, 5 -can form 6 membered heteroaryl, or 5-6 membered heterocycloalkyl, wherein at least one H of said aryl, heteroaryl, or heterocycloalkyl is -C 1-6 alkyl, -C 1-6 halo may be substituted with alkyl, -halo, or -C 3-6 cycloalkyl] ⁇ ;
- R d and R e are each independently —H, —C 1-6 alkyl, or null;
- Z 1 to Z 5 are each independently CR f , NR g or N ⁇ wherein, any one of Z 1 -Z 2 , Z 2 -Z 3 , Z 3 -Z 4 , and Z 4 -Z 5 is connected to each other can be taken to form a 5-6 membered heterocycloalkyl, wherein at least one H of the heterocycloalkyl is -C 1-6 alkyl, -C 1-6 haloalkyl, -halo, or -C 3-6 cyclo may be substituted with alkyl] ⁇ ;
- R f and R g are each independently -H, -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 1-6 haloalkyl, -CN, -NR 3 R 4 , —NO 2 , —OR 5 , -halo, aryl, heteroaryl, —C 3-6 cycloalkyl, or heterocycloalkyl ⁇ wherein at least one H of the aryl or heteroaryl is —C 1-6 alkyl , -C 1-6 haloalkyl, or -C 3-6 cycloalkyl, wherein one or more H of -C 3-6 cycloalkyl or heterocycloalkyl is -C 1-6 alkyl, -C 1 -6 hydroxyalkyl, -C 1-6 haloalkyl, -C 3-6 cycloalkyl, -C 1-6 alkyl-C 3-6 cycloalkyl
- n 0 or 1
- R 1 and R 2 are each independently —C 1-6 alkyl
- R 5 is —H, —C 1-6 alkyl, —C 1-6 alkyl-NR 6 R 7 , or —C 1-6 haloalkyl;
- R 6 and R 7 are each independently —H or —C 1-6 alkyl.
- the compound represented by Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof may be in the following range:
- X 1 is CR a R b , NR c , or S;
- X 2 is CR a R b ;
- X 3 is CR a R b , NR c , or S;
- each R a to R c is independently -H, -C 1-6 haloalkyl, -CN, -halo, -C 3-6 cycloalkyl, or nothing.
- the compound represented by Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof may be in the following range:
- Y 1 to Y 4 are each independently CR d or NR e ⁇ wherein, any one of Y 1 -Y 2 , Y 2 -Y 3 , and Y 3 -Y 4 is connected to each other to form a 5-6 membered aryl, 5 -can form 6 membered heteroaryl, or 5-6 membered heterocycloalkyl, wherein at least one H of said aryl, heteroaryl, or heterocycloalkyl is -C 1-6 alkyl, -C 1-6 halo may be substituted with alkyl, -halo, or -C 3-6 cycloalkyl] ⁇ ;
- R d and R e are each independently —H, —C 1-6 alkyl, or nothing (null).
- the compound represented by Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof may be in the following range:
- Z 1 to Z 5 are each independently CR f , NR g or N ⁇ wherein, Z 1 -Z 2 may be connected to each other to form a 5-6 membered heterocycloalkyl [wherein, one of the heterocycloalkyls or more H may be substituted with -C 1-6 alkyl, -C 1-6 haloalkyl, or -halo] ⁇ ;
- R f and R g are each independently -H, -C 1-6 alkyl, -C 2-6 alkenyl, -C 2-6 alkynyl, -C 1-6 haloalkyl, -CN, -NR 3 R 4 , —NO 2 , —OR 5 , -halo, aryl, heteroaryl, —C 3-6 cycloalkyl, or heterocycloalkyl ⁇ wherein at least one H of the aryl or heteroaryl is —C 1-6 alkyl , -C 1-6 haloalkyl, -C 3-6 cycloalkyl, heterocycloalkyl, phenyl, or heteroaryl, wherein one or more H of -C 3-6 cycloalkyl or heterocycloalkyl is - C 1-6 alkyl, -C 1-6 hydroxyalkyl, -C 1-6 haloalkyl, -C 3-6 cycloalkyl, -C
- R 5 is —C 1-6 alkyl, —C 1-6 alkyl-NR 6 R 7 , or —C 1-6 haloalkyl;
- R 6 and R 7 are each independently —H or —C 1-6 alkyl.
- the compound represented by Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof may be in the following range:
- R 1 and R 2 are each independently —C 1-6 alkyl.
- the compound represented by Formula 1 may be selected from the group consisting of compounds listed in Table 1 described below.
- alkyl may mean a straight or branched acyclic, cyclic, or saturated hydrocarbon to which they are bonded.
- C 1-6 alkyl can mean an alkyl containing 1 to 6 carbon atoms.
- Acyclic alkyl may include, as an example, methyl, ethyl, n -propyl, n -butyl, isopropyl, sec -butyl, isobutyl, or tert -butyl, etc., It is not limited thereto.
- Cyclic alkyl may be used interchangeably with “cycloalkyl” herein, and may include, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl. doesn't happen
- alkoxy may mean -(O-alkyl) as an alkyl ether group, wherein alkyl is as defined above.
- C 1-6 alkoxy may mean alkoxy containing C 1-6 alkyl, that is, -(OC 1-6 alkyl).
- alkoxy is methoxy ), ethoxy, n -propoxy, isopropoxy, n -butoxy , isobutoxy , sec -butoxy ), or tert - butoxy , etc., but is not limited thereto.
- halo may be F, Cl, Br, or I.
- haloalkyl may mean a straight or branched chain alkyl (hydrocarbon) having one or more halo substituted carbon atoms as defined herein.
- haloalkyl include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl or n-butyl independently substituted with one or more halogens, such as F, Cl, Br, or I. .
- aminoalkyl may mean a straight or branched chain alkyl (hydrocarbon) having a carbon atom substituted with amino-(NR'R"), wherein R' and R" are each independently hydrogen. , and may be selected from the group consisting of C 1-6 alkyl, wherein the selected R′ and R′′ may each independently be substituted or unsubstituted.
- heterocycloalkyl may mean a ring containing 1 to 5 heteroatoms selected from N, O and S as atoms forming the ring, and may be saturated or partially unsaturated.
- unsaturated it may be referred to as a heterocycloalkene.
- heterocycloalkyl may be a single ring or multiple rings such as a spiro ring, a bridged ring or a fused ring.
- heterocycloalkyl may mean a heterocycloalkyl containing 3 to 12 atoms forming a ring
- heterocycloalkyl is pyrrolidine, piperidine, Imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidinone, hydantoin, dioxolane, phthalimide, piperidine, pyrimidine-2,4( 1H , 3H ) -Dione, 1,4-dioxane, morpholine, thiomorpholine, thiomorpholine- S -oxide, thiomorpholine- S , S -oxide, piperazine, pyran, pyridone, 3-pyrroline , thiopyran, pyrone, tetrahydrofuran, tetrahydrothiophene, quinuclidine, tropane, 2-azaspiro[3.3
- arene may mean an aromatic hydrocarbon ring.
- the arene may be a monocyclic arene or a polycyclic arene.
- the ring carbon number of arene may be 5 or more and 30 or less, 5 or more and 20 or less, or 5 or more and 15 or less.
- examples of arenes include benzene, naphthalene, fluorene, anthracene, phenanthrene, bibenzene, terbenzene, quaterbenzene, quinkbenzene, sexbenzene, triphenylene, pyrene, benzofluoranthene, chrysene, etc. , but not limited to these.
- the residue obtained by removing one hydrogen atom from "arene” is referred to as "aryl".
- heteroene may be a ring including at least one of O, N, P, Si, and S as a heterogeneous element.
- the number of ring carbon atoms in the heteroarene may be 2 or more and 30 or less, or 2 or more and 20 or less.
- the hetero arene may be a monocyclic hetero arene or a polycyclic hetero arene.
- the polycyclic heteroarene may have, for example, a two- or three-ring structure.
- heteroarenes include thiophene, purine, pyrrole, pyrazole, imidazole, thiazole, oxazole, isothiazole, oxadiazole, triazole, pyridine, bipyridyl, triazine, acridyl, pyridazine , pyrazine, quinoline, quinazoline, quinoxaline, phenoxazine, phthalazine, pyrimidine, pyridopyrimidine, pyridopyrazine, pyrazinopyrazine, isoquinoline, indole, carbazole, imidazopyridazine, imidazopyridine , imidazopyrimidine, pyrazolopyrimidine, imidazopyrazine or pyrazolopyridine, N -arylcarbazole, N -heteroarylcarbazole, N -alkylcarbazole, be
- heteroarenes may also include bicyclic heterocyclo-arenes, including arene rings fused to heterocycloalkyl rings or heteroarenes fused to cycloalkyl rings.
- heteroaryl the residue obtained by removing one hydrogen atom from the "heteroarene” is referred to as "heteroaryl”.
- enantiomer means a compound of the present invention or a salt thereof having the same chemical formula or molecular formula but sterically different. Each of these optical isomers and mixtures thereof are also included within the scope of the present invention.
- a solid line bond (-) connecting an asymmetric carbon atom is a wedge-shaped solid line bond indicating the absolute configuration of the stereocenter. or wedge-dotted join may include
- the compound of Formula 1 of the present invention may exist in the form of a "pharmaceutically acceptable salt".
- a pharmaceutically acceptable salt As the salt, an acid addition salt formed with a pharmaceutically acceptable free acid is useful.
- pharmaceutically acceptable salt refers to any of the compounds at a concentration having an effective action that is relatively non-toxic and harmless to a patient, and the side effects due to the salt do not reduce the beneficial efficacy of the compound represented by the formula (1). Any organic or inorganic acid addition salt of
- Acid addition salts are prepared by conventional methods, for example by dissolving the compound in an aqueous solution of an excess of acid and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile. Equal molar amounts of compound and acid or alcohol in water may be heated, and then the mixture may be evaporated to dryness, or the precipitated salt may be filtered off with suction.
- a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile.
- an organic acid and an inorganic acid may be used as the free acid, and hydrochloric acid, phosphoric acid, sulfuric acid, or nitric acid may be used as the inorganic acid.
- organic acid methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, Maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, glycolic acid, glue Conic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, or hydroiodic acid, etc.
- the present invention is not limited thereto.
- a pharmaceutically acceptable metal salt can be prepared using a base.
- the alkali metal salt or alkaline earth metal salt is obtained, for example, by dissolving the compound in an excess alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and then evaporating and drying the filtrate.
- it is pharmaceutically suitable to prepare a sodium, potassium, or calcium salt as the metal salt, but is not limited thereto.
- the corresponding silver salt can be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (eg, silver nitrate).
- the pharmaceutically acceptable salts of the present invention include salts of acidic or basic groups that may be present in the compound of Formula 1, unless otherwise indicated.
- pharmaceutically acceptable salts may include sodium, calcium and potassium salts of a hydroxyl group
- other pharmaceutically acceptable salts of an amino group include hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate), and p-toluenesulfonate (tosylate) salts; It can be prepared through a method for preparing a known salt.
- the present invention provides the use of a compound represented by the following formula (1), an optical isomer thereof, or a pharmaceutically acceptable salt thereof.
- the compound represented by Formula 1 of the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof exhibits inhibitory activity against various kinases (Experimental Example 1).
- the heteroaryl derivative represented by Formula 1 since the heteroaryl derivative represented by Formula 1 exhibits excellent inhibitory activity on EGFR (Epidermal Growth Factor Receptor) among various kinases, it treats or prevents EGFR-related diseases, particularly cancer. can be usefully used for Specifically, the compound of Formula 1 can inhibit EGFR wild-type or mutant kinase, which is supported by the experimental examples described below.
- EGFR Epidermal Growth Factor Receptor
- the EGFR mutation is EGFR Del19/T790M, EGFR Del19/T790M/C797S, EGFR L858R/T790M, EGFR L858R, EGFR Exon20 ins NPH, EGFR Exon20 ins SVD, EGFR Exon20 ins FQEA, EGFR Exon20 ins H, and EGFR Exon20 ins A It may be one or more selected from the group consisting of, but is not limited thereto.
- the cancer includes all cancers capable of exhibiting therapeutic or preventive efficacy due to inhibition of EGFR activity, and may be solid cancer or blood cancer.
- pseudomyxoma intrahepatic biliary tract cancer, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, labial cancer, mycosis fungoides, acute myeloid leukemia, acute lymphoblastic leukemia, basal cell cancer, ovarian cancer Epithelial cancer, ovarian germ cell cancer, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colorectal cancer, chronic myelogenous leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, ampulla Barter cancer, bladder cancer, peritoneal cancer, Parat
- the present invention provides a pharmaceutical composition for the treatment or prevention of EGFR-related diseases containing the compound represented by Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- the EGFR-related disease may be cancer.
- the types of cancer are as described above.
- the pharmaceutical composition of the present invention may further include one or more active ingredients exhibiting the same or similar efficacy in addition to the compound represented by Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof.
- the step of administering to a subject in need thereof a therapeutically effective amount of the compound represented by Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof provides a method for treating or preventing EGFR-related diseases, including.
- the subject may be a mammal including a human.
- the term "therapeutically effective amount” refers to an amount of the compound represented by Formula 1 effective for the treatment or prevention of EGFR-related diseases. Specifically, “therapeutically effective amount” means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and effective dose level includes the subject type and severity, age, sex, type of disease, The activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and the rate of excretion, the duration of treatment, factors including concurrently used drugs, and other factors well known in the medical field may be determined according to factors.
- the pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or may be administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with commercially available therapeutic agents.
- the dosage of the pharmaceutical composition of the present invention may be determined by an expert according to various factors such as the patient's condition, age, sex, and complications. Since the active ingredient of the pharmaceutical composition of the present invention is excellent in safety, it can be used even more than the determined dosage.
- the present invention is a compound represented by Formula 1, an optical isomer thereof, or a pharmaceutical thereof for use in the preparation of a medicament for use in the treatment or prevention of EGFR-related diseases
- a use (use) of a commercially acceptable salt may be mixed with an acceptable adjuvant, diluent, carrier, etc., and may have a synergistic action of the active ingredients by being prepared as a complex formulation together with other active agents.
- Embodiments of the present invention may be modified in various other forms, and the scope of the present invention is not limited to the embodiments described below.
- the embodiment of the present invention is provided in order to more completely explain the present invention to those of ordinary skill in the art.
- "including" a certain element means that other elements may be further included, rather than excluding other elements, unless otherwise stated.
- heteroaryl derivative compound of the present invention exhibits excellent inhibitory activity against EGFR, it can be usefully used for the treatment or prevention of EGFR-related diseases.
- room temperature means a temperature of about 20 to 25 °C
- room temperature means a temperature of 15 to 25 °C.
- Concentration or solvent distillation under reduced pressure was performed using a rotary evaporator.
- Step 3 1-methyl-4-(2-(1-methyl-1H-pyrazol-4-yl)-4-nitro-5-(2,2,2-trifluoroethoxy)phenyl)pipe production of razin
- Step 4 5-(1-Methyl-1H-pyrazol-4-yl)-4-(4-methylpiperazin-1-yl)-2-(2,2,2-trifluoroethoxy)aniline manufacture of
- Step 1 Preparation of tert-butyl 9-(2-bromo-5-methoxy-4-nitrophenyl)-3,9-diazaspiro[5.5]undecane-3-carboxylate
- Step 3 Preparation of 3-(5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)-4-nitrophenyl)-3,9-diazaspiro[5.5]undecane
- Step 4 (1-Fluorocyclopropyl)(9-(5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)-4-nitrophenyl)-3,9-diaza Preparation of spiro [5.5] undecan-3-yl) methanone
- Step 5 3-((1-Fluorocyclopropyl)methyl)-9-(5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)-4-nitrophenyl)-3 , 9-diaza spiro [5.5] production of undecane
- Step 6 4-(9-((1-fluorocyclopropyl)methyl)-3,9-diazaspiro[5.5]undecan-3-yl)-2-methoxy-5-(1-methyl Preparation of -1H-pyrazol-4-yl)aniline
- Step 6 Preparation of 6-(1-methyl-1H-pyrazol-4-yl)-7-(4-methylpiperazin-1-yl)benzo[d][1,3]dioxol-4-amine
- Step 1 (6-((2-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)quinoc Preparation of salin-5-yl)dimethylphosphine oxide
- Step 2 Dimethyl(6-((2-((5-(1-methyl-1H-pyrazol-4-yl)-4-(4-methylpiperazin-1-yl)-2-(2, 2,2-trifluoroethoxy)phenyl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl) Preparation of amino) quinoxalin-5-yl) phosphine oxide
- Step 3 Dimethyl(6-((2-((5-(1-methyl-1H-pyrazol-4-yl)-4-(4-methylpiperazin-1-yl)-2-(2, Preparation of 2,2-trifluoroethoxy)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)quinoxalin-5-yl)phosphine oxide
- the following experiments were performed. Specifically, with respect to the compound of Example 2 selected from among the compounds of the examples of the present invention, the enzyme (kinase) selectivity was measured by requesting DiscoverX, and the experiment was conducted using the scanMAX TM Kinase analysis panel. At this time, the concentration of the drug treated with the enzyme was 1 ⁇ M in DMSO, and the control percentage (% control) was determined in the same way as in Equation 1 below.
- the positive control refers to a compound showing a percentage control of 0%
- the negative control indicates a percentage control of 100% with DMSO.
- the enzyme selectivity of the present invention was determined to have activity for each enzyme if the control percentage was ⁇ 30% (ie, less than 30%) for each enzyme.
- the compound of Example 54 had a control percentage of ⁇ 30% (ie, less than 30%) for the following enzymes, and had activity against the following enzymes: EGFR, EGFR (E746-A750del), EGFR (G719C), EGFR (G719S), EGFR (L747-E749del, A750P), EGFR (L747-S752del, P753S), EGFR (L747-T751del, Sins), EGFR (L858R), EGFR (L858R, T790M), EGFR ( L861Q), EGFR (S752-I759del), EGFR (T790M).
- BaF3-EGFR (WT), BaF3-EGFR (Del19/T790M/C797S) cells were seeded in clear bottom white 96-well plates at a volume of 3 ⁇ 10 3 /100 ⁇ l/well, and 12 concentrations were serially diluted in triplicate ( 0.00001 - 2 mM) of the compound and the DMSO control were added at 0.5 ⁇ l/well to a final concentration of 0.00005 - 10 ⁇ M, followed by incubation at 37 ° C. CO 2 in an incubator for 72 hours. After 72 hours, the plate treated with the compound was taken out, and 100 ⁇ l/well of CellTiter-Glo® 2.0 Assay (Promega) solution was treated and mixed well.
- Table 2 shows the results of evaluation of the proliferation inhibitory activity of Ba/F3 cells expressing EGFR mutations.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
실시예 | 구조 | 화합물명 | 1H NMR, MS | 수율 (%) |
HPLC r.t.(min), Purity(%), (method) |
1 | 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.26-9.24 (m, 1H), 8.89 (d, J = 2.0 Hz, 1H), 8.84 (d, J = 2.0 Hz, 1H), 8.12 (s, 1H), 7.87 (s, 1H), 7.82 (s, 1H), 7.70-7.67 (m, 1H), 7.10 (d, J = 3.6 Hz, 1H), 7.04 (s, 1H), 6.77 (d, J = 3.6 Hz, 1H), 4.74-4.67 (m, 1H), 3.91 (s, 3H), 3.64-3.61 (m, 2H), 3.47-3.32 (m, 4H), 3.17-3.12 (m, 2H), 3.05 (s, 3H), 2.22 (s, 3H), 2.18 (s, 3H); MS(ESI): 706 m/z [M+H]+ | 82 | 8.60, 98, (b) |
|
2 | 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-모르폴리노-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, DMSO-d 6) δ 13.25 (s, 1H), 11.41 (s, 1H), 9.63 (dd, J = 9.40 Hz, 1H), 8.85 (d, J = 1.79 Hz, 1H), 8.80 (d, J = 1.79 Hz, 1H), 8.53 (s, 0.1H), 8.19 (s, 1H), 8.08 (s, 1H), 7.91 (s, 1H), 7.70 (s, 1H), 7.68 (d, J = 8.93 Hz, 1H), 7.03-7.00 (m, 2H), 6.47 (s, 1H), 4.88 (q, 2H), 3.84 (s, 3H), 3.77 (t, 4H) 2.87 (t, 4H), 2.09 (s, 3H), 2.06 (s, 3H); MS(ESI): m/z 693 [M+H]+ | 29 | 10.78, 97, (b) |
|
3 | (6-((2-((4-플루오로-5-(1-메틸-1H-피라졸-4-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, DMSO-d 6) δ 13.26 (s, 1H), 11.46 (s, 1H), 9.60 (dd, J = 9.40 Hz, 1H), 8.85 (d, J = 1.81 Hz, 1H), 8.80 (d, J = 1.82 Hz, 1H), 8.49 (s, 0.2H), 8.32 (d, J = 8.44 Hz, 1H), 8.07 (d, J = 1.68 Hz, 1H), 7.82 (d, J = 2.16 Hz, 1H), 7.76 (d, J = 9.80 Hz, 1H), 7.05 (q, 1H), 6.48 (q, 1H), 4.89 (q, 2H), 3.84 (s, 3H), 2.09 (s, 3H), 2.06 (s, 3H); MS(ESI): m/z 626 [M+H]+ | 86 | 11.42, 98, (b) |
|
4 | 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, CD3OD) δ 9.34 (d, J = 5.2 Hz, 1H), 8.87 (d, J = 2.0 Hz, 1H), 8.81 (d, J = 2.0 Hz, 1H), 8.05 (s, 1H), 7.86 (s, 1H), 7.82 (s, 1H), 7.71 (d, J = 9.2 Hz, 1H), 7.08 (d, J = 3.2 Hz, 1H), 6.99 (s, 1H), 6.74 (d, J = 3.6 Hz, 1H), 4.69 (q, J = 8.4 Hz, 2H), 3.86 (s, 3H), 3.38-3.33 (m, 4H), 3.24-3.20 (m, 4H), 2.92 (s, 1H), 2.86 (s, 3H), 2.79 (t, J = 11.2 Hz, 2H), 2.21 (s, 3H), 2.17 (s, 3H), 2.12 (d, J = 12.0 Hz, 2H), 1.87-1.79 (m, 2H), 1.33 (t, J = 7.2 Hz, 2H); MS(ESI): m/z 789 [M+H]+ | 51 | 8.22, 97, (b) |
|
5 | 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.58-9.55 (m, 1H), 8.71 (d, J = 1.6 Hz, 1H), 8.63 (d, J = 1.6 Hz, 1H), 8.51 (d, J = 2.5 Hz, 1H), 7.73 (s, 1H), 7.62-7.58 (m, 2H), 7.16-7.13 (m, 1H), 7.05 (d, J = 8.4 Hz, 1H), 6.98 (d, J = 3.6 Hz, 1H), 6.54 (d, J = 3.6 Hz, 1H), 4.68-4.61 (m, 2H), 3.76 (s, 3H), 2.16 (s, 3H), 2.12 (s, 3H); MS(ESI): m/z 608 [M+H]+ | 56 | 6.78 100 (b) |
|
6 | 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-모르폴리노피페리딘-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.26-9.24 (m, 1H), 8.89 (d, J = 2.0 Hz, 1H), 8.84 (d, J = 2.0 Hz, 1H), 8.12 (s, 1H), 7.87 (s, 1H), 7.82 (s, 1H), 7.70-7.67 (m, 1H), 7.10 (d, J = 3.6 Hz, 1H), 7.04 (s, 1H), 6.77 (d, J = 3.6 Hz, 1H), 4.74-4.67 (m, 1H), 3.91 (s, 3H), 3.64-3.61 (m, 2H), 3.47-3.32 (m, 4H), 3.17-3.12 (m, 2H), 3.05 (s, 3H), 2.22 (s, 3H), 2.18 (s, 3H); MS(ESI): m/z 776 [M+H]+ | 48 | 8.79, 100, (b) |
|
7 | 다이메틸(6-((2-((4-(4-메틸피페라진-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.37-9.32 (m, 1H), 8.89 (d, J = 1.9 Hz, 1H), 8.83 (d, J = 1.9 Hz, 1H), 7.97 (d, J = 9.6 Hz, 1H), 7.57 (d, J = 8.6 Hz, 1H), 7.06 (d, J = 3.6 Hz, 1H), 6.92 (d, J = 2.5 Hz, 1H), 6.87 (dd, J = 8.7, 2.6 Hz, 1H), 6.73 (d, J = 3.5 Hz, 1H), 4.60 (q, J = 8.4 Hz, 2H), 4.08-3.96 (m, 4H), 3.75-3.64 (m, 4H), 3.04 (s, 3H), 2.21 (s, 3H), 2.17 (s, 3H); MS(ESI): m/z 626 [M+H]+ | 63 | 8.25, 100, (b) |
|
8 | 다이메틸(6-((2-((5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.40-9.25 (m, 1H), 8.89 (d, J = 1.6 Hz, 1H), 8.84 (d, J = 1.6 Hz, 1H), 7.98 (d, J = 9.2 Hz, 1H), 7.46 (s, 1H), 7.07 (d, J = 3.6 Hz, 1H), 6.96 (s, 1H), 6.76 (d, J = 3.6 Hz, 1H), 4.62-4.50 (m, 2H), 3.60-6.40 (m, 9H), 3.30-3.20 (m, 2H), 3.00-2.82 (m, 5H), 2.33 (s, 3H), 2.28-2.12 (m, 8H), 2.10-1.92 (m, 2H); MS(ESI): m/z 723 [M+H]+ | 46 | 100* | |
9 | 다이메틸(6-((2-((5-메틸-4-(4-메틸피페라진-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 9.72-9.69 (m, 1H), 8.85 (d, J = 2.0 Hz, 1H), 8.76 (d, J = 2.0 Hz, 1H), 8.42 (s, 1H), 8.09 (s, 1H), 8.04 (d, J = 9.6 Hz, 1H), 7.01 (d, J = 3.6 Hz, 1H), 6.92 (s, 1H), 6.63 (d, J = 3.6 Hz, 1H), 4.67-4.61 (m, 2H), 3.24-3.16 (m, 8H), 2.83 (s, 3H), 2.32 (s, 3H), 2.22 (s, 3H), 2.19 (s, 3H); MS(ESI): m/z 640 [M+H]+ | 20 | 8.67, 100, (b) |
|
10 | (6-((2-((4-((2R,6S)-2,6-다이메틸모르폴리노)-5-(1-메틸-1H-피라졸-4-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.30 (dd, J = 7.2, 3.4 Hz, 1H), 8.86 (d, J = 1.8 Hz, 1H), 8.82 (d, J = 1.8 Hz, 1H), 8.09 (s, 1H), 7.84 (s, 1H), 7.78 (s, 1H), 7.74 (d, J = 9.0 Hz, 1H), 7.07 (d, J = 3.6 Hz, 1H), 6.97 (s, 1H), 6.75 (d, J = 3.5 Hz, 1H), 4.67 (dd, J = 16.9, 8.4 Hz, 2H), 3.95-3.88 (m, 2H), 3.86 (s, 3H), 3.09 (d, J = 10.9 Hz, 2H), 2.50-2.41 (m, 2H), 2.21 (s, 3H), 2.17 (s, 3H); MS(ESI): m/z 721 [M+H]+ | 56 | 11.73, 98, (b) |
|
11 | 다이메틸(6-((2-((5-메틸-4-모르폴리노-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, DMSO-d 6) δ 13.26 (s, 1H), 11.37 (s, 1H), 9.67-9.63 (m, 1H), 8.87 (d, J = 2.0 Hz, 1H), 8.82 (d, J = 2.0 Hz, 1H), 8.02 (d, J = 9.6 Hz, 1H), 7.82 (s, 1H), 7.66 (s, 1H), 7.01 (t, J = 2.4 Hz, 1H), 6.94 (s, 1H), 6.47-6.45 (m, 1H), 4.81 (q, J = 9.2 Hz, 2H), 3.78 (t, J = 4.0 Hz, 4H), 2.89 (t, J = 4.0 Hz, 4H), 2.33 (s, 3H), 2.32 (d, J = 2.0 Hz, 6H); MS(ESI): m/z 627 [M+H]+ | 20 | 11.41, 99, (b) |
|
12 | 다이메틸(6-((2-((5-메틸-4-(4-모르폴리노피페리딘-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, DMSO-d 6) δ 13.26 (s, 1H), 11.36 (s, 1H), 9.67-9.63 (m, 1H), 8.87 (d, J = 1.6 Hz, 1H), 8.82 (d, J = 1.6 Hz, 1H), 8.20 (s, 1H), 8.01 (d, J = 9.6 Hz, 1H), 7.79 (s, 1H), 7.64 (s, 1H), 7.01 (t, J = 3.2 Hz, 1H), 6.90 (s, 1H), 6.46 (t, J = 3.2 Hz, 1H), 4.80 (q, J = 8.8 Hz, 2H), 3.61-3.59 (m, 4H), 3.16-3.11 (m, 4H), 2.67-2.63 (m, 4H), 2.28 (s, 1H), 2.22 (s, 3H), 2.10 (s, 3H), 2.06 (s, 3H), 1.91-1.88 (m, 2H), 1.61-1.57 (m, 2H); MS(ESI): m/z 710 [M+H]+ | 41 | 8.81, 98, (b) |
|
13 | 다이메틸(3-((2-((5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-4-일)포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.86 (d, J = 2.4 Hz, 1H), 8.33 (d, J = 8.4 Hz, 1H), 8.13 (d, J = 8.0 Hz, 1H), 7.83-7.74 (m, 2H), 7.45 (s, 1H), 7.09 (d, J = 3.2 Hz, 1H), 6.89 (s, 1H), 6.72 (d, J = 3.6 Hz, 1H), 4.65-4.58 (m, 2H), 3.50-3.29 (m, 10H), 3.16-3.15 (m, 1H), 2.84 (s, 3H), 2.83-2.81 (m, 2H), 2.13 (s, 3H), 2.12 (s, 3H), 2.11 (s, 3H), 2.11-2.10 (m, 2H), 1.89-1.81 (m, 2H); MS(ESI): m/z 722 [M+H]+ | 75 | 7.84, 100, (b) |
|
14 | 다이메틸(3-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-4-일)포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 10.18 (d, J = 4.8 Hz, 1H), 8.35 (s, 1H), 8.12-8.10 (m, 1H), 7.94-7.91 (m, 1H), 7.80 (s, 1H), 7.73-7.67 (m, 3H), 7.02 (d, J = 3.6 Hz, 1H), 6.93 (s, 1H), 6.55 (d, J = 3.6 Hz, 1H), 4.73-4.65 (m, 2H), 3.54 (s, 3H), 3.16-3.15 (m, 4H), 2.99-2.81 (m, 4H), 2.53 (s, 3H), 1.34 (s, 3H), 1.31 (s, 3H); MS(ESI): m/z 705 [M+H]+ | 34 | 8.25, 100, (b) |
|
15 | (2-사이클로프로필-6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, MeOD-d 4) δ 9.09-9.05 (m, 1H), 8.47 (s, 1H), 8.39 (d, J = 9.2 Hz, 1H), 8.31 (s, 1H), 7.83 (s, 1H), 7.78 (s, 1H), 7.59 (d, J = 9.6 Hz, 1H), 7.29 (d, J = 9.2 Hz, 1H), 6.95-6.92 (m, 2H), 6.50 (d, J = 3.6 Hz, 1H), 4.70-4.64 (m, 2H), 3.74 (s, 3H), 3.05 (s, 4H), 3.01 (s, 4H), 2.67 (s, 3H), 2.29-2.24 (m, 1H), 2.15 (s, 3H), 2.12 (s, 3H), 1.17-1.11 (m, 4H); MS(ESI): m/z 639 [M+H]+ | 19 | 8.24, 98, (b) |
|
16 | (2-사이클로프로필-6-((2-((5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 8.93-8.85 (m, 1H), 8.74 (d, J = 9.0 Hz, 1H), 8.00 (d, J = 9.5 Hz, 1H), 7.49-7.41 (m, 2H), 7.04 (d, J = 3.5 Hz, 1H), 6.88 (s, 1H), 6.67 (d, J = 3.3 Hz, 1H), 4.56 (q, J = 8.4 Hz, 2H), 3.28-3.25 (m, 5H), 3.23-3.15 (m, 2H), 2.92 (t, J = 12.1 Hz, 1H), 2.87-2.79 (m, 5H), 2.40-2.34 (m, 1H), 2.17 (s, 3H), 2.15-2.11 (m, 9H), 1.91-1.82 (m, 2H), 1.32-1.26 (m, 3H), 1.26-1.18 (m, 2H); MS(ESI): m/z 762 [M+H]+ | 51 | 8.07, 99, (b) |
|
17 | 다이메틸(7-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)이미다조[1,2-a]피리딘-8-일)포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 8.74 (dd, J = 7.7, 3.5 Hz, 1H), 8.46 (s, 1H), 8.30 (s, 2H), 7.98 (s, 1H), 7.90 (s, 1H), 7.78 (d, J = 7.7 Hz, 1H), 7.60 (t, J = 1.4 Hz, 1H), 7.45 (d, J = 1.3 Hz, 1H), 6.98 (d, J = 3.6 Hz, 1H), 6.96 (s, 1H), 6.54 (d, J = 3.6 Hz, 1H), 4.71 (q, J = 8.5 Hz, 2H), 3.76 (s, 3H), 3.23-3.09 (m, 8H), 2.83 (s, 3H), 2.15 (s, 3H), 2.12 (s, 3H); MS(ESI): m/z 694 [M+H]+ | 45 | 7.80, 99, (b) |
|
18 | 다이메틸(7-((2-((5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)이미다조[1,2-a]피리딘-8-일)포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 8.91-8.89 (m, 1H), 8.59 (d, J = 7.6 Hz, 1H), 8.01 (s, 1H), 7.78 (d, J = 1.6 Hz, 1H), 7.68 (s, 1H), 7.07 (d, J = 3.6 Hz, 1H), 6.99 (s, 1H), 6.67 (d, J = 3.6 Hz, 1H), 4.68-4.62 (m, 2H), 3.58-3.54 (m, 8H), 3.51-3.50 (m, 2H), 3.35-3.34 (m, 1H), 2.99 (s, 3H), 2.97-2.94 (m, 2H), 2.36 (s, 3H), 2.28-2.25 (m, 2H), 2.18 (s, 3H), 2.15 (s, 3H), 2.07-2.01 (m, 2H); MS(ESI): m/z 711 [M+H]+ | 7 | 96* | |
19 | 다이메틸(4-메틸-7-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)-3,4-다이하이드로-2H-벤조[b][1,4]옥사진-8-일)포스핀 옥사이드 | MS(ESI): m/z 725 [M+H]+ | |||
20 | 다이메틸(4-메틸-7-((2-((5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)-3,4-디하이드로-2H-벤조[b][1,4]옥사진-8-일)포스핀 옥사이드 | MS(ESI): m/z 742 [M+H]+ | |||
21 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Metan ol-d 4) δ 9.34 (dd, J = 9.32 Hz, 1H), 8.87 (d, J = 1.89 Hz, 1H), 8.82 (d, J = 1.90 Hz, 1H), 8.04 (s, 1H), 7.95 (s, 1H), 7.77 (s, 1H), 7.62 (d, J = 10.10 Hz, 1H), 7.08 (d, J = 3.55 Hz, 1H), 6.94 (s, 1H), 6.75 (d, J = 3.54 Hz, 1H), 3.97 (s, 3H), 3.86 (s, 3H), 3.61 (d, J = 12.11 Hz, 2H), 3.45-3.35 (m, 4H), 3.14-3.06 (m, 2H), 3.03 (s, 3H), 2.21 (s, 3H), 2.17 (s, 3H); MS(ESI): m/z 638 [M+H]+ | 80 | 7.85, 99, (b) |
|
22 | (6-((2-((4-(4-사이클로펜틸피페라진-1-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Metanol-d 4) δ 9.60 (dd, J = 9.66 Hz, 1H), 8.80 (d, J = 1.82 Hz, 1H), 8.72 (d, J = 1.84 Hz, 1H), 8.38 (s, 1H), 8.37 (s, 1H), 7.96 (s, 1H), 7.77 (s, 1H), 7.57 (d, J = 9.50 Hz, 1H), 6.99 (d, J = 3.58 Hz, 1H), 6.86 (s, 1H), 6.60 (d, J = 3.55 Hz, 1H), 3.98 (s, 3H), 3.81 (s, 3H), 3.56 (t, 1H), 3.43-3.35 (m, 3H), 3.22-3.11 (m, 4H), 2.23-2.15 (m, 9H), 1.88 (s, 2H), 1.72 (s, 4H); MS(ESI): m/z 692 [M+H]+ | 47 | 8.49, 98, (b) |
|
23 | (6-((2-((4-((2S,6R)-2,6-다이메틸모르폴리노)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.60-9.57 (m, 1H), 8.78 (d, J = 2.0 Hz, 1H), 8.71 (d, J = 2.0 Hz, 1H), 8.33 (s, 1H), 8.00 (s, 1H), 7.79 (s, 1H), 7.57 (d, J = 9.6 Hz, 1H), 6.98 (d, J = 3.6 Hz, 1H), 6.84 (s, 1H), 6.59 (d, J = 3.6 Hz, 1H), 3.97 (s, 3H), 3.90-3.86 (m, 2H), 3.80 (s, 3H), 3.00 (d, J = 10.8 Hz, 2H), 2.42 (t, J = 10.8, 10.8 Hz, 2 H), 2.20 (s, 3H), 2.16 (s, 3H), 1.19 (s, 3H), 1.17 (s, 3H); MS(ESI): m/z 653 [M+H]+ | 17 | 6.41, 93, (b) |
|
24 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, MeOD-d 4) δ 9.60 (dd, J = 9.55 Hz, 1H), 8.78 (d, J = 1.83 Hz, 1H), 8.70 (d, J = 1.87 Hz, 1H), 8.29 (s, 1H), 8.25 (s, 3H), 7.92 (s, 1H), 7.81 (s, 1H), 7.56 (d, J = 9.56 Hz, 1H), 6.98 (d, J = 3.58 Hz, 1H), 6.84 (s, 1H), 6.59 (d, J = 3.54 Hz, 1H), 3.94 (s, 3H), 3.78 (s, 3H), 3.25 (d, J = 11.68 Hz, 2H), 3.14-2.96 (m, 8H), 2.71-2.67 (m, 6H), 2.18 (s, 3H), 2.15 (s, 3H), 2.03 (d, J = 16.73 Hz 2H), 1.77-1.69 (m, 2H): MS(ESI): m/z 721 [M+H]+ | 66 | 7.53, 99, (b) |
|
25 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-모르폴리노페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, free, DMSO-d 6) δ 13.25 (s, 1H), 11.39 (s, 1H), 9.69 (dd, J = 9.6, 4.1 Hz, 1H), 8.85 (d, J = 1.9 Hz, 1H), 8.80 (d, J = 1.9 Hz, 1H), 8.19 (s, 1H), 8.16 (s, 1H), 7.91 (s, 1H), 7.79 (d, J = 9.2 Hz, 1H), 7.67 (s, 1H), 7.01 (dd, J = 3.4, 2.2 Hz, 1H), 6.85 (s, 1H), 6.49 (dd, J = 3.4, 1.8 Hz, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.79-3.71 (m, 4H), 2.95-2.80 (m, 4H), 2.10 (s, 3H), 2.06 (s, 3H); MS(ESI): m/z 625 [M+H]+ | 16 | 9.76, 99, (b) |
|
26 | (6-((2-((4-((1S,4S)-2-옥사-5-아자바이사이클로[2.2.1]헵탄-5-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, Methanol-d 4) δ 9.60 (dd, J = 9.6, 4.4 Hz, 1H), 8.76 (d, J = 1.9 Hz, 1H), 8.70 (d, J = 1.9 Hz, 1H), 8.11 (s, 1H), 7.75 (s, 1H), 7.58-7.53 (m, 2H), 6.94 (d, J = 3.6 Hz, 1H), 6.73 (s, 1H), 6.56 (d, J = 3.6 Hz, 1H), 4.60-4.51 (m, 2H), 4.18-4.16 (m, 1H), 4.05 (d, J = 7.5 Hz, 1H), 3.95 (s, 3H), 3.82 (s, 3H), 3.15-3.02 (m, 2H), 2.17 (s, 3H), 2.14 (s, 3H), 2.04-2.00 (m, 1H), 1.88-1.84 (m, 1H); MS(ESI): m/z 637 [M+H]+ | 8 | 9.29, 98, (b) |
|
27 | (6-((2-((4-((1R,4R))-2-옥사-5-아자바이사이클로[2.2.1]헵탄-5-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, free, Methanol-d 4) δ 9.63 (dd, J = 9.6, 4.5 Hz, 1H), 8.79 (d, J = 1.9 Hz, 1H), 8.72 (d, J = 1.8 Hz, 1H), 8.11 (s, 1H), 7.77 (s, 1H), 7.59 (d, J = 7.1 Hz, 2H), 6.95 (d, J = 3.7 Hz, 1H), 6.75 (s, 1H), 6.59 (d, J = 3.6 Hz, 1H), 4.58 (s, 1H), 4.54 (s, 1H), 4.19 (s, 1H), 4.06 (d, J = 7.6 Hz, 1H), 3.96 (s, 3H), 3.83 (s, 3H), 3.76 (d, J = 7.4 Hz, 1H), 3.14 (s, 1H), 3.07 (d, J = 10.3 Hz, 1H), 2.19 (s, 3H), 2.15 (s, 3H), 2.03 (d, J = 7.8 Hz, 1H), 1.88 (d, J = 8.2 Hz, 1H); MS(ESI): m/z 637 [M+H]+ | 31 | 9.30, 99, (b) |
|
28 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.62-9.58 (m, 1H), 8.82 (d, J = 1.6 Hz, 1H), 8.74 (d, J = 1.6 Hz, 1H), 8.57 (d, J = 2.0 Hz, 1H), 7.77 (s, 1H), 7.74 (d, J = 9.2 Hz, 1H), 7.61 (s, 1H), 7.23-7.20 (m, 1H), 7.06 (s, 1H), 7.04-7.03 (m, 1H), 6.64 (d, J = 3.6 Hz, 1H), 3.99 (s, 3H), 3.80 (s, 3H), 2.23 (s, 3H), 2.19 (s, 3H); MS(ESI): m/z 540 [M+H]+ | 21 | 10.02, 100, (b) |
|
29 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(2-옥사-6-아자스파이로[3.3]헵탄-6-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 9.60 (dd, J = 9.7, 4.4 Hz, 1H), 8.79 (d, J = 1.9 Hz, 1H), 8.74 (d, J = 1.9 Hz, 1H), 8.51 (s, 1H, FA), 7.95 (s, 1H), 7.66 (s, 1H), 7.60 (d, J = 9.4 Hz, 1H), 7.49 (s, 1H), 6.94 (d, J = 3.5 Hz, 1H), 6.57 (d, J = 3.6 Hz, 1H), 6.39 (s, 1H), 4.79 (s, 4H), 3.95 (s, 3H), 3.88 (s, 3H), 3.80 (s, 4H), 2.18 (s, 3H), 2.15 (s, 3H); MS(ESI): m/z 637 [M+H]+ | 49 | 9.06, 99, (b) |
|
30 | (6-((2-((4-((1R,5S)-8-옥사-3-아자바이사이클로[3.2.1]옥탄-3-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, DMSO-d 6) δ 13.27 (s, 1H), 11.39 (s, 1H), 9.72-9.68 (m, 1H), 8.87 (d, J = 2.0 Hz, 1H), 8.82 (d, J = 1.6 Hz, 1H), 8.29 (s, 1H), 8.01 (s, 1H), 7.91 (s, 1H), 7.81 (d, J = 2.4 Hz, 1H), 7.71 (s, 1H), 7.69 (s, 1H), 7.00 (d, J = 2.4 Hz, 1H), 6.89 (s, 1H), 6.49 (d, J = 1.6 Hz, 1H), 4.27 (s, 2H), 3.89 (s, 3H), 3.87 (s, 3H), 2.92-2.91 (m, 2H), 2.85-2.83 (m, 2H), 2.10 (s, 3H), 2.07 (s, 3H), 1.94-1.92 (m, 2H), 1.91-1.88 (m, 2H); MS(ESI): m/z 651 [M+H]+ | 48 | 10.11, 100, (b) |
|
31 | (6-((2-((4-플루오로-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, DMSO-d 6) δ 13.23 (s, 1H), 11.43 (s, 1H), 9.67-9.63 (m, 1H), 8.80 (d, J = 2.0 Hz, 1H), 8.75 (d, J = 2.0 Hz, 1H), 8.45 (s, 1H), 8.39 (d, J = 8.0 Hz, 1H), 7.98 (d, J = 2.0 Hz, 1H), 7.83 (d, J = 9.6 Hz, 1H), 7.77 (s, 1H), 7.75 (s, 1H), 7.04 (s, 1H), 7.01-6.98 (m, 1H), 6.44-6.43 (m, 1H), 3.83 (s, 3H), 3.80 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H); MS(ESI): m/z 558 [M+H]+ | 37 | 10.33, 100, (b) |
|
32 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(2-옥사-7-아자스파이로[3.5]노난-7-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.56-9.53 (m, 1H), 8.82 (d, J = 1.8 Hz, 1H), 8.76 (d, J = 1.8 Hz, 1H), 8.16-8.12 (m, 1H), 8.04 (s, 1H), 7.78 (s, 1H), 7.62-7.58 (m, 1H), 7.00 (d, J = 3.5 Hz, 1H), 6.85 (s, 1H), 6.64 (d, J = 3.6 Hz, 1H), 4.53 (s, 4H), 3.94 (s, 3H), 3.82 (s, 3H), 2.89-2.83 (m, 4H), 2.20 (s, 3H), 2.16 (s, 3H), 2.05-2.01 (m, 4H); MS(ESI): m/z 665 [M+H]+ | 33 | 9.96, 99, (b) |
|
33 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(7-옥사-2-아자스파이로[3.5]노난-2-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, DMSO-d 6) δ 13.20 (s, 1H), 11.27 (s, 1H), 9.71-9.66 (m, 1H), 8.84 (d, J = 1.9 Hz, 1H), 8.79 (d, J = 1.9 Hz, 1H), 7.80-7.76 (m, 1H), 7.74 (s, 1H), 7.66 (s, 1H), 7.61 (s, 1H), 7.51 (s, 1H), 6.95 (dd, J = 3.4, 2.0 Hz, 1H), 6.44 (dd, J = 3.2, 1.3 Hz, 1H), 6.33 (s, 1H), 3.86-3.83 (m, 6H), 3.54-3.51 (m, 4H), 3.42-3.41 (m, 4H), 2.09 (s, 3H), 2.05 (s, 3H), 1.72-1.68 (m, 4H); MS(ESI): m/z 665 [M+H]+ | 16 | 9.72, 100, (b) |
|
34 | 다이메틸(6-((2-((3-(1-메틸-1H-피라졸-4-일)-4-모르폴리노페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, DMSO-d 6) δ 13.29 (s, 1H), 11.42 (s, 1H), 9.94 (dd, J = 10.0, 3.6 Hz, 1H), 9.01 (s, 1H), 8.87 (d, J = 1.8 Hz, 1H), 8.81 (d, J = 1.9 Hz, 1H), 8.24 (s, 1H), 7.95 (dd, J = 5.8, 3.0 Hz, 3H), 7.58 (dd, J = 8.5, 2.5 Hz, 1H), 7.10 (d, J = 8.8 Hz, 1H), 7.02 (dd, J = 3.2, 2.5 Hz, 1H), 6.50 (dd, J = 3.4, 1.8 Hz, 1H), 3.88 (s, 3H), 3.76-3.71 (m, 4H), 2.81-2.76 (m, 4H), 2.11 (s, 3H), 2.07 (s, 3H); MS(ESI): m/z 595 [M+H]+ | 4 | 9.72, 97, (a) |
|
35 | (6-((2-((4-(2-(다이메틸아미노)에톡시)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.60-9.57 (m, 1H), 8.76 (d, J = 1.6 Hz, 1H), 8.68 (d, J = 2.0 Hz, 1H), 8.32 (s, 1H), 7.97 (s, 1H), 7.68 (s, 1H), 7.59 (d, J = 9.6 Hz, 1H), 6.96 (d, J = 3.6 Hz, 1H), 6.81 (s, 1H), 6.57 (d, J = 3.6 Hz, 1H), 4.26-4.24 (m, 2H), 3.96 (s, 3H), 3.81 (s, 3H), 3.00-2.97 (m, 2H), 2.47 (s, 6H), 2.18 (s, 3H), 2.01 (s, 3H); MS(ESI): m/z 627 [M+H]+ | 13 | 7.75, 100, (b) |
|
36 | (6-((2-((4-((2-(다이메틸아미노)에틸)(메틸)아미노)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, CD3OD) δ 9.61-9.58 (m, 1H), 8.81 (d, J = 1.6 Hz, 1H), 8.73 (d, J = 2.0 Hz, 1H), 8.50 (s, 1H), 8.39 (s, 1H), 7.90 (s, 1H), 7.68 (s, 1H), 7.61 (d, J = 9.6 Hz, 1H), 7.02 (s, 1H), 7.00 (d, J = 3.6 Hz, 1H), 6.61 (d, J = 3.6 Hz, 1H), 4.00 (s, 3H), 3.81 (s, 3H), 3.16 (t, J = 6.8 Hz, 2H), 2.80 (s, 3H), 2.72 (s, 6H), 2.65 (s, 2H), 2.19 (s, 3H), 2.16 (s, 3H); MS(ESI): m/z 640 [M+H]+ | 31 | 8.23, 99, (b) |
|
37 | (6-((2-((2-메톡시-4-((2-메톡시에틸)(메틸)아미노)-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, MeOD-d 4) δ 9.44-9.41 (m, 1H), 8.84-8.81 (m, 2H), 8.44 (s, 1H), 7.95 (s, 1H), 7.74 (d, J = 9.6 Hz, 1H), 7.60 (s, 1H), 7.29 (s, 1H), 7.06 (d, J = 3.6 Hz, 1H), 6.68 (d, J = 3.6 Hz, 1H), 4.06 (s, 3H), 3.95 (s, 3H), 3.70 (s, 2H), 3.45 (s, 2H), 3.25 (s, 3H), 3.18 (s, 3H), 2.20 (s, 3H), 2.16 (s, 3H); MS(ESI): m/z 639 [M+H]+ | 64 | 9.12, 99, (b) |
|
38 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-((3S,5R)-3,4,5-트라이메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 9.58 (dd, J = 9.6, 4.4 Hz, 1H), 8.80 (d, J = 1.9 Hz, 1H), 8.73 (d, J = 1.9 Hz, 1H), 8.46 (s, 1H), 8.38 (s, 1H), 7.95 (s, 1H), 7.77 (s, 1H), 7.57 (d, J = 9.4 Hz, 1H), 6.99 (d, J = 3.6 Hz, 1H), 6.86 (s, 1H), 6.60 (d, J = 3.6 Hz, 1H), 3.99 (s, 3H), 3.80 (s, 3H), 3.22 (d, J = 11.2 Hz, 2H), 2.84-2.73 (m, 5H), 2.19 (s, 3H), 2.16 (s, 3H), 1.33 (s, 3H), 1.31 (s, 3H), 0.93-0.74 (m, 2H); MS(ESI): m/z 666 [M+H]+ | 26 | 8.17, 98, (b) |
|
39 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-모르폴리노피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.37-9.35 (m, 1H), 8.86 (d, J = 1.6 Hz, 1H), 8.80 (d, J = 2.0 Hz, 1H), 7.95 (s, 1H), 7.89 (s, 1H), 7.84 (s, 1H), 7.65 (d, J = 9.2 Hz, 1H), 7.06 (d, J = 3.6 Hz, 1H), 6.93 (s, 1H). 6.73 (d, J = 3.6 Hz, 1H), 4.16 (d, J = 12.4 Hz, 2H), 3.93 (s, 3H), 3.82 (s, 3H), 3.63 (d, J = 12.0 Hz, 2H), 3.48-3.32 (m, 6H), 3.13-3.12 (m, 1H), 2.83 (t, J = 11.6 Hz, 2H), 2.28 (d, J = 11.2 Hz, 2H), 2.20 (s, 3H), 2.16 (s, 3H), 1.93-1.85 (m, 2H); MS(ESI): m/z 708 [M+H]+ | 23 | 8.14, 99, (b) |
|
40 | 다이메틸(6-((2-((3-(1-메틸-1H-피라졸-4-일)-4-(4-모르폴리노피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, MeOD-d 4) δ 9.86 (dd, J = 9.59 Hz, 1H), 8.80 (d, J = 1.84 Hz, 1H), 8.72 (d, J = 1.86 Hz, 1H), 8.29 (s, 2H), 8.06 (s, 1H), 7.95 (s, 1H), 7.88 (d, J = 2.52 Hz, 1H), 7.85 (d, J = 9.56 Hz, 1H), 7.44 (dd, J = 8.59 Hz, 1H), 7.14 (d, J = 8.64 1H), 6.97 (d, J = 3.56 Hz, 1H), 6.58 (d, J = 3.56, 1H) 3.90 (d, 7H), 3.27 (t, 6H), 3.05 (t, 1H), 2.72 (t, 2H), 2.20 (d, 8H), 1.83-1.75 (m, 2H); MS(ESI): m/z 678 [M+H]+ | 52 | 8.06, 92, (b) |
|
41 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-((3aR,6aS)-테트라하이드로-1H-퓨로[3,4-c]피롤-5(3H)-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 9.61-9.59 (m, 1H), 8.79 (d, J = 2.0 Hz, 1H), 8.72 (d, J = 2.0 Hz, 1H), 8.22 (s, 1H), 8.20 (s, 1H), 8.10 (s, 1H), 7.66 (s, 1H), 7.56 (d, J = 9.6 Hz, 1H), 6.97 (d, J = 3.6 Hz, 1H), 6.83 (s, 1H), 6.59 (d, J = 3.6 Hz, 1H), 3.96 (s, 3H), 3.90-3.84 (m, 2H), 3.76 (s, 3H), 3.75-3.73 (m, 2H), 3.34-3.32 (m, 2H), 3.06-3.04 (m, 2H), 3.00-2.97 (m, 2H), 2.20 (s, 3H), 2.16 (s, 3H); MS(ESI): 651 m/z [M+H]+ | 14 | 9.89, 95, (b) |
|
42 | (6-((2-((4-(4-사이클로프로필피페라진-1-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, CD3OD) δ 9.60-9.57 (m, 1H), 8.81 (d, J = 2.0 Hz, 1H), 8.73 (d, J = 2.0 Hz, 1H), 8.38 (s, 1H), 8.01 (s, 1H), 7.76 (s, 1H), 7.56 (d, J = 9.6 Hz, 1H), 6.99 (d, J = 3.6 Hz, 1H), 6.85 (s, 1H), 6.60 (d, J = 3.6 Hz, 1H), 3.97 (s, 3H), 3.82 (s, 3H), 3.48-3.47 (m, 5H), 3.13-3.12 (m, 4H), 2.19 (s, 3H), 2.15 (s, 3H), 0.99 (s, 4H); MS(ESI): m/z 644 [M+H]+ | 50 | 4.07, 99, (b) |
|
43 | (R)-(6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(옥타하이드로-2H-피리도[1,2-a]피라진)-2-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 9.58-9.54 (m, 1H), 8.78 (d, J = 2.0 Hz, 1 H), 8.72 (d, J = 1.6 Hz, 1H), 8.40 (s, 1H), 8.28 (s, 1H), 7.96 (s, 1H), 7.77 (s, 1H), 7.55 (d, J = 9.6 Hz, 1H), 6.99 (d, J = 3.6 Hz, 1H), 6.85 (s, 1H), 6.59 (d, J = 3.6 Hz, 1H), 3.99 (s, 3H), 3.82 (s, 3H), 3.48-2.91 (m, 9H), 2.19 (s, 3H), 2.16 (s, 3H), 2.00-1.93 (m, 4H), 1.89-1.86 (m, 2H); MS(ESI): m/z 678 [M+H]+ | 51 | 8.26, 100, (b) |
|
44 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-6-(4-메틸피페라진-1-일)피리딘-3-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, MeOD-d 4) δ 9.57-9.53 (m, 1H), 8.79 (d, J = 1.6 Hz, 1H), 8.71 (d, J = 2 Hz, 1H), 8.66 (s, 1H), 8.31 (s, 2H), 7.94 (s, 1H), 7.75 (s, 1H), 7.66 (d, J = 9.2 Hz, 1H), 6.99 (d, J = 3.6 Hz, 1H), 6.58 (d, J = 3.6 Hz, 1H), 4.05 (s, 3H), 3.83 (s, 3H), 3.35 (s, 8H), 2.92 (s, 3H), 2.18 (s, 3H), 2.15 (s, 3H); MS(ESI): m/z 639 [M+H]+ | 60 | 8.74, 97, (b) |
|
45 | (6-((2-((3-메톡시-6-(1-메틸-1H-피라졸-4-일)-5-(4-메틸피페라진-1-일)피리딘-2-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | MS(ESI): m/z 639 [M+H]+ | |||
46 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-6-(1-메틸피페리딘-4-일)피리딘-3-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | MS(ESI): m/z 638 [M+H]+ | |||
47 | (6-((2-((5-(1-에틸-1H-피라졸-4-일)-2-메톡시-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, DMSO-d 6) δ 9.66 (dd, J = 9.54 Hz, 1H), 8.78 (d, J = 1.86 Hz, 1H), 8.70 (d, J = 1.88 Hz, 1H), 8.36 (s, 1H), 8.33 (s, 1H), 8.01 (s, 1H), 7.84 (s, 1H), 7.60 (d, J = 9.48 Hz, 1H), 6.98 (d, J = 3.60 Hz, 1H), 6.87 (s, 1H), 6.59 (d, J = 3.56 Hz, 1H), 4.12-4.07 (m, 2H), 3.98 (s, 3H), 3.22-3.08 (m, 4H), 2.90 (s, 3H), 2.19 (s, 3H), 2.15 (s, 3H), 1.35 (t, 3H); MS(ESI): m/z 652 [M+H]+ | 56 | 8.14, 99, (b) |
|
48 | (6-((2-((4-(4-에틸피페라진-1-일)-5-(1-아이소프로필-1H-피라졸-4-일)-2-메톡시페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, Neutral, MeOD-d 4) δ 9.68-9.65 (m, 1H), (d, J = 1.6 Hz, 1H), 8.67 (d, J = 2 Hz, 1H), 8.27 (s, 1H), 8.07 (s, 1H), 7.84 (s, 1H), 7.59 (d, J = 9.6 Hz, 1H), 6.96 (d, J = 3.6 Hz, 1H), 6.88 (s, 1H), 6.58 (d, J = 3.6 Hz, 1H), 4.44-4.37 (m, 1H), 3.96 (s, 3H), 2.99 (s, 4H), 2.67 (s, 4H), 2.59-2.53 (s, 1H), 2.18 (s, 3H), 2.14 (s, 3H), 1.39 (s, 3H), 1.38 (s, 3H), 1.17 (tr, d = 7.2 Hz, 3H); MS(ESI): m/z 680 [M+H]+ | 33 | 8.44, 98, (b) |
|
49 | (6-((2-((5-(1-아이소프로필-1H-피라졸-4-일)-2-메톡시-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, CD3OD) δ 9.69-9.65 (m, 1H), 8.78 (d, J = 2.0 Hz, 1H), 8.70 (d, J = 2.0 Hz, 1H), 8.31 (d, J = 4.0 Hz, 3H), 7.97 (s, 1H), 7.88 (s, 1H), 7.62 (d, J = 9.2 Hz, 1H), 6.98 (d, J = 3.6 Hz, 1H), 6.87 (s, 1H), 6.60 (d, J = 3.2 Hz, 1H), 4.44-4.38 (m, 1H), 3.97 (s, 3H), 3.25 (s, 4H), 3.15 (s, 4H), 2.86 (s, 3H), 2.18 (s, 3H), 2.14 (s, 3H), 1.36 (s, 3H), 1.35 (s, 3H); MS(ESI): m/z 666 [M+H]+ | 27 | 8.12, 95, (b) |
|
50 | (6-((2-((5-(1-(다이플루오로메틸)-1H-피라졸-4-일)-2-메톡시-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 9.58 (dd, J = 9.6, 4.3 Hz, 1H), 8.80 (d, J = 1.9 Hz, 1H), 8.71 (d, J = 1.9 Hz, 1H), 8.43 (s, 1H), 8.41 (s, 1H), 8.28 (s, 1H), 8.10 (s, 1H), 7.71 (d, J = 9.6 Hz, 1H), 7.33 (t, J = 59.9 Hz, 1H), 6.99 (d, J = 3.6 Hz, 1H), 6.92 (s, 1H), 6.60 (d, J = 3.6 Hz, 1H), 4.00 (s, 3H), 3.11-2.99 (m, 8H), 2.69 (s, 3H), 2.20 (s, 3H), 2.16 (s, 3H); MS(ESI): m/z 674 [M+H]+ | 20 | 9.70, 100, (b) |
|
51 | (6-((5-클로로-2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 8.88 (d, J = 2.0 Hz, 1H), 8.80 (d, J = 1.6 Hz, 1H), 8.01-8.57 (m, 1H), 8.22 (s, 1H), 7.79 (s, 1H), 7.67 (d, J = 9.2 Hz, 1H), 7.40 (s, 1H), 7.06 (s, 1H), 6.84 (s, 1H), 3.97 (s, 3H), 3.72 (s, 3H), 3.55-3.50 (m, 2H), 3.35-3.28 (m, 4H), 3.05-2.98 (m, 5H), 2.21 (s, 3H), 2.17 (s, 3H); MS(ESI): m/z 672 [M+H]+ | 44 | 8.55, 99, (b) |
|
52 | 4-((5-(다이메틸포스포릴)퀴녹살린-6-일)아미노)-2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1)-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-5-카보나이트릴 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 8.87 (d, J = 1.6 Hz, 1H), 8.80 (d, J = 2.0 Hz, 1H), 8.64-8.61 (m, 1H), 8.34 (s, 1H), 7.83 (s, 1H), 7.81 (s, 1H), 7.72 (d, J = 9.6 Hz, 1H), 7.49 (s, 1H), 6.84 (s, 1H), 3.97 (s, 3H), 3.74 (s, 3H), 3.57-3.50 (m, 2H), 3.30-3.27 (m, 4H), 3.04-2.98 (m, 5H), 2.20 (s, 3H), 2.16 (s, 3H); MS(ESI): m/z 663 [M+H]+ | 39 | 8.34, 100, (b) |
|
53 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-5-(트라이플루오로메틸)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 8.84 (d, J = 2.0 Hz, 1H), 8.74 (d, J = 2.0 Hz, 1H), 8.39 (s, 1H), 8.32 (s, 1H), 8.30-8.27 (m, 1H), 7.75 (s, 1H), 7.68 (d, J = 9.6 Hz, 1H), 7.53 (s, 1H), 7.29 (s, 1H), 6.79 (s, 1H), 3.93 (s, 3H), 3.68 (s, 3H), 3.12 (s, 4H), 3.02 (s, 4H), 2.78 (s, 3H), 2.17 (s, 3H), 2.14 (s, 3H); MS(ESI): m/z 706 [M+H]+ | 27 | 9.12, 99, (b) |
|
54 | (6-((2-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, DMSO-d 6) δ 13.24 (s, 1H), 11.33 (s, 1H), 9.73-9.69 (m, 1H), 8.86 (d, J = 1.6 Hz, 1H), 8.81 (d, J = 1.6 Hz, 1H), 8.20 (s, 1H), 8.07 (d, J = 9.6 Hz, 1H), 7.85 (s, 1H), 7.60 (s, 1H), 6.99 (t, J = 3.2 Hz, 1H), 6.74 (s, 1H), 6.47 (t, J = 3.2 Hz, 1H), 3.81 (s, 3H), 3.12-3.09 (m, 2H), 2.68-2.62 (m, 4H), 2.60-2.52 (m, 4H), 2.34-2.28 (m, 3H), 2.34 (s, 3H), 2.28 (s, 3H), 2.16 (s, 3H), 2.09 (s, 3H), 1.90-1.85 (m, 2H), 1.63-1.55 (m, 2H); MS(ESI): m/z 655 [M+H]+ | 50 | 4.07, 99, (a) |
|
55 | (6-((2-((5-에틸-2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3- d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, DMSO-d 6) δ 13.23 (s, 1H), 11.33 (s, 1H), 9.70 (dd, J = 9.5, 4.0 Hz, 1H), 8.86 (d, J = 1.9 Hz, 1H), 8.81 (d, J = 1.9 Hz, 1H), 8.23 (s, 2H), 8.06 (d, J = 9.5 Hz, 1H), 7.91 (s, 1H), 7.63 (s, 1H), 6.99-6.97 (m, 1H), 6.80 (s, 1H), 6.48-6.46 (m, 1H), 3.82 (s, 3H), 3.06-3.00 (m, 2H), 2.74-2.68 (m, 2H), 2.62 (q, J = 7.5 Hz, 2H), 2.56-2.46 (m, 3H), 2.38-2.30 (m, 6H), 2.16 (s, 3H), 2.10 (s, 3H), 2.06 (s, 3H), 1.89-1.83 (m, 2H), 1.64-1.53 (m, 2H), 1.14 (t, J = 7.5 Hz, 3H); MS(ESI): m/z 669 [M+H]+ | 49 | 4.38, 98, (a) |
|
56 | (6-((2-((5-클로로-2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 9.68 (dd, J = 9.6, 4.3 Hz, 1H), 8.82 (d, J = 1.9 Hz, 1H), 8.74 (s, 1H), 8.42 (s, 1H), 8.41 (s, 1H), 8.21 (d, J = 9.5 Hz, 1H), 6.99 (d, J = 3.6 Hz, 1H), 6.82 (s, 1H), 6.61 (d, J = 3.6 Hz, 1H), 3.95 (s, 3H), 3.49-3.40 (m, 3H), 3.10-2.95 (m, 7H), 2.80-2.71 (m, 3H), 2.67 (s, 3H), 2.21 (s, 3H), 2.17 (s, 3H), 2.11-2.02 (m, 2H), 1.91-1.77 (m, 2H); MS(ESI): m/z 675 [M+H]+ | 66 | 4.17, 100, (a) |
|
57 | (6-((2-((2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 9.64 (dd, J = 9.5, 4.2 Hz, 1H), 8.74 (s, 1H), 8.67 (s, 1H), 8.45 (s, 2H), 7.97 (d, J = 9.6 Hz, 1H), 7.91 (d, J = 8.6 Hz, 1H), 6.92 (d, J = 2.9 Hz, 1H), 6.67 (s, 1H), 6.56-6.50 (m, 1H), 3.87 (s, 3H), 3.71-3.62 (m, 2H), 3.14-2.85 (m, 8H), 2.75-2.58 (m, 6H), 2.17 (s, 3H), 2.14 (s, 3H), 2.03-1.96 (m, 2H), 1.76-1.66 (m, 2H); MS(ESI): m/z 641 [M+H]+ | 99 | 3.86, 99, (a) |
|
58 | 다이메틸(6-((2-((4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, DMSO-d 6) δ 13.26 (s, 1H), 11.35 (s, 1H), 9.96 (dd, J = 9.7, 3.7 Hz, 1H), 8.87 (s, 2H), 8.82 (d, J = 1.7 Hz, 1H), 8.21 (s, 2H), 8.11 (d, J = 9.6 Hz, 1H), 7.62 (d, J = 8.8 Hz, 2H), 7.02-6.95 (m, 1H), 6.92 (d, J = 9.0 Hz, 2H), 6.50-6.42 (m, 1H), 3.63 (d, J = 11.9 Hz, 4H), 2.65-2.55 (m, 5H), 2.30 (d, J = 18.4 Hz, 4H), 2.15 (s, 3H), 2.11 (s, 3H), 2.07 (s, 3H), 1.85 (d, J = 10.8 Hz, 2H), 1.62-1.45 (m, 2H); MS(ESI): m/z 611 [M+H]+ | 32 | 3.79, 99, (a) |
|
59 | (6-((2-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)싸이에노[3,2-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, DMSO-d 6) δ 13.35 (s, 1H), 9.43-9.41 (m, 1H), 8.89 (s, 1H), 8.86 (s, 1H), 8.13 (d, J = 5.2 Hz, 1H), 8.02 (d, J = 9.2 Hz, 1H), 7.98 (s, 1H), 7.66 (s, 1H), 7.22 (d, J = 5.2 Hz, 1H), 6.77 (s, 1H), 3.80 (s, 3H), 3.14-3.11 (m, 2H), 2.67-2.65 (m, 2H), 2.58 (s, 3H), 2.36-2.32 (m, 9H), 2.19 (s, 3H), 2.10 (s, 3H), 1.89-1.87 (m, 2H), 1.66-1.62 (m, 2H); MS(ESI): m/z 611 [M+H]+ | 39 | 100* | |
60 | (6-((2-((4-(4-(4-사이클로프로필피페라진-1-일)피페리딘-1-일)-2-메톡시-5-메틸페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, DMSO-d 6) δ 13.24 (s, 1H), 11.33 (s, 1H), 9.71 (dd, J = 9.6, 4.0 Hz, 1H), 8.86 (d, J = 1.9 Hz, 1H), 8.81 (d, J = 1.9 Hz, 1H), 8.18 (s, 1H, FA), 8.06 (d, J = 9.6 Hz, 1H), 7.86 (s, 1H), 7.58 (s, 1H), 6.98 (dd, J = 3.4, 2.3 Hz, 1H), 6.75 (s, 1H), 6.47 (dd, J = 3.4, 1.9 Hz, 1H), 3.82 (s, 3H), 3.35-3.31 (m, 4H), 3.11 (d, J = 10.8 Hz, 3H), 2.73-2.59 (m, 3H), 2.30-2.22 (m, 1H), 2.21 (s, 3H), 2.10 (s, 3H), 2.06 (s, 3H), 1.86 (d, J = 12.4 Hz, 2H), 1.67-1.50 (m, 3H), 0.48-0.32 (m, 2H), 0.31-0.22 (m, 2H); MS(ESI): m/z 681 [M+H]+ | 45 | 4.35, 99, (a) |
|
61 | (6-((2-((4-(4-(4-에틸피페라진-1-일)피페리딘-1-일)-2-메톡시-5-메틸페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, DMSO-d 6) δ 9.52-9.42 (m, 1H), 8.89 (d, J = 2 Hz, 1H), 8.83 (d, J = 1.6 Hz, 1H), 8.07 (d, J = 9.6 Hz, 1H), 7.60 (s, 1H), 7.06 (d, J = 3.6 Hz, 1H), 6.93 (s, 1H), 6.75 (d, J = 3.6 Hz, 1H), 3.98 (s, 3H), 3.48-3.10 (m, 10 H), 3.04-3.10 (m, 4H), 2.32 (s, 3H), 2.24-2.10 (m, 9H), 2.00-1.88 (m, 2H), 1.37 (t, J = 7.2 Hz, 3H); MS(ESI): m/z 669 [M+H]+ | 41 | 4.15, 99, (a) |
|
62 | (6-((2-((4-(4-(4-아이소프로필피페라진-1-일)피페리딘-1-일)-2-메톡시-5-메틸페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, DMSO-d 6) δ 9.50-9.40 (m, 1H), 8.89 (d, J = 2 Hz, 1H), 8.84 (d, J = 2 Hz, 1H), 8.07 (d, J = 9.6 Hz, 1H), 7.57 (s, 1H), 7.06 (d, J = 3.6 Hz, 1H), 6.94 (s, 1H), 6.75 (d, J = 3.6 Hz, 1H), 3.89 (s, 3H), 3.60-3.30 (m, 9 H), 3.10-2.90 (m, 4H), 2.32 (s, 3H), 2.20-2.10 (m, 9H), 2.02-1.98 (m, 2H), 1.39 (s, 3H), 1.38 (s, 3H); MS(ESI): m/z 683 [M+H]+ | 56 | 4.10, 99, (a) |
|
63 | (6-((6-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-1H-피롤로[2,3-b]피리딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, DMSO-d 6) δ 12.12 (s, 1H), 11.11 (s, 1H), 8.81 (d, J = 1.9 Hz, 1H), 8.74 (d, J = 1.9 Hz, 1H), 8.18-8.07 (m, 3H), 8.04 (s, 1H), 7.64 (s, 1H), 6.97 (dd, J = 3.3, 2.5 Hz, 1H), 6.76 (s, 1H), 6.69 (s, 1H), 6.28 (dd, J = 3.4, 2.1 Hz, 1H), 3.80 (s, 3H), 3.05 (d, J = 11.6 Hz, 2H), 2.61 (t, J = 11.6 Hz, 2H), 2.41-2.34 (m, 7H), 2.31-2.25 (m, 2H), 2.20 (s, 3H), 2.17 (s, 3H), 2.05 (s, 3H), 2.02 (s, 3H), 1.84 (d, J = 11.4 Hz, 2H), 1.62-1.50 (m, 2H); MS(ESI): m/z 654 [M+H]+ | 53 | 3.96, 99, (a) |
|
64 | (6-((6-((2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-1H-피롤로[2,3-b]피리딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 8.77 (d, J = 2 Hz, 1H), 8.68 (d, J = 2 Hz, 1H), 8.33 (s, 2H), 8.12-8.00 (m, 2H), 6.68 (s, 1H), 6.72-6.38 (m, 3H), 3.98-3.60 (m, 5H), 3.40-3.30 (m, 1H), 3.20-2.88 (m, 8H), 2.80-2.70 (m, 5H), 2.20-2.10 (m, 6H), 2.08-1.98 (m, 2H), 1.80-1.72 (m, 2H); MS(ESI): m/z 640 [M+H]+ | 36 | 3.78, 99, (a) |
|
65 | (6-((6-((3-메톡시-5-(4-(4-메틸피페라진-1-일)피페리딘-1-일)피리딘-2-일)아미노)-1H-피롤로[2,3-b]피리딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 8.82 (d, J = 1.7 Hz, 1H), 8.74 (d, J = 1.8 Hz, 1H), 8.50 (s, 1H), 8.32 (dd, J = 9.4, 4.1 Hz, 1H), 8.19 (d, J = 9.4 Hz, 1H), 7.70 (s, 1H), 7.45 (s, 1H), 7.23 (s, 1H), 7.17 (d, J = 3.4 Hz, 1H), 6.58 (d, J = 3.4 Hz, 1H), 4.01 (s, 3H), 3.72 (d, J = 11.7 Hz, 2H), 3.03-2.83 (m, 7H), 2.82-2.72 (m, 2H), 2.65-2.55 (m, 4H), 2.18 (s, 3H), 2.15 (s, 3H), 2.07-2.00 (m, 2H), 1.77-1.64 (m, 2H); MS(ESI): m/z 641 [M+H]+ | 5 | 3.84, 97, (a) |
|
66 | (6-((2-((5-플루오로-2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, DMSO-d 6) δ 13.28 (s, 1H), 11.47 (s, 1H), 9.74 (dd, J = 9.5, 4.1 Hz, 1H), 8.87 (d, J = 1.9 Hz, 1H), 8.83 (d, J = 1.9 Hz, 1H), 8.27-8.06 (m, 3H), 7.67 (s, 1H), 7.03 (dd, J = 3.4, 2.3 Hz, 1H), 6.72 (d, J = 8.3 Hz, 1H), 6.49 (dd, J = 3.4, 1.9 Hz, 1H), 3.88 (s, 3H), 3.35-3.31 (m, 6H), 2.70 (t, J = 9.3 Hz, 2H), 2.56-2.53 (m, 2H), 2.36-2.33 (m, 2H), 2.32-2.23 (m, 1H), 2.17 (s, 3H), 2.11 (s, 3H), 2.07 (s, 3H), 1.86 (d, J = 11.3 Hz, 2H), 1.65-1.51 (m, 2H); MS(ESI): m/z 659 [M+H]+ | 40 | 4.30, 99, (a) |
|
67 | (6-((2-((5-아이소프로필-2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 9.64 (dd, J = 9.6, 4.3 Hz, 1H), 8.81 (d, J = 1.9 Hz, 1H), 8.72 (d, J = 1.9 Hz, 1H), 8.46 (s, 1H), 8.07-8.02 (m, 2H), 6.96 (d, J = 3.6 Hz, 1H), 6.85 (s, 1H), 6.59 (d, J = 3.6 Hz, 1H), 4.58 (s, 3H), 3.88 (s, 3H), 3.14-3.09 (m, 4H), 3.01-2.88 (m, 4H), 2.86-2.80 (m, 3H), 2.66-2.65 (m, 1H), 2.59-2.55 (m, 2H), 2.20 (s, 3H), 2.16 (s, 3H), 2.09-2.03 (m, 2H), 1.83-1.73 (m, 2H), 1.17 (d, J = 6.9 Hz, 6H); MS(ESI): m/z 683 [M+H]+ | 28 | 8.10, 100, (a) |
|
68 | (6-((2-((2-메톡시-5-메틸페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 9.77-9.73 (m, 1H), 8.84 (d, J = 2.0 Hz, 1H), 8.76 (d, J = 1.6 Hz, 1H), 8.53 (s, 1H), 8.18 (s, 1H), 8.16 (d, J = 9.6 Hz, 1H), 7.01 (d, J = 3.6 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 6.84 (d, J = 8.4 Hz, 1H), 6.63 (d, J = 3.6 Hz, 1H), 3.93 (s, 3H), 2.32 (s, 3H), 2.23 (s, 3H), 2.19 (s, 3H); MS(ESI): m/z 474 [M+H]+ | 21 | 11.03, 100, (b) |
|
69 | (6-((2-((2-에톡시-5-(트라이플루오로메틸)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, Neutral, MeOD-d 4) δ 9.66-9.62 (m, 1H), 8.82 (d, J = 2 Hz, 1H), 8.79 (d, J = 2 Hz, 1H), 8.75 (d, J = 2 Hz, 1H), 8.14 (d, J = 9.6 Hz, 1H), 7.25-7.23 (m, 1H), 7.12 (d, J = 8.4 Hz, 1H), 7.03 (d, J = 3.6 Hz, 1H), 6.64 (d, J = 3.6 Hz, 1H), 4.30-4.25 (m, 2H), 2.21 (s, 3H), 2.18 (s, 3H), 1.55 (tr, J = 6.8 Hz, 3H), 1.32-1.24 (m, 3H); MS(ESI): m/z 542 [M+H]+ | 80 | 13.96, 99, (b) |
|
70 | (6-((2-((2-메톡시-4-(4-메틸피페라진-1-일)-5-(피리딘-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.39-9.36 (m, 1H), 8.71 (d, J = 2.0 Hz, 1H), 8.63 (d, J = 2.0 Hz, 1H), 8.38 (s, 1H), 8.27 (s, 1H), 8.52 (s, 1H), 7.60-7.59 (m, 3H), 6.89 (d, J = 3.6 Hz, 1H), 6.80 (s, 1H), 6.49 (d, J = 3.2 Hz, 1H), 4.54-4.53 (m, 2H), 3.94 (s, 3H), 3.03-2.98 (m, 6H), 2.69 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H); MS(ESI): m/z 635 [M+H]+ | 29 | 7.38, 100, (b) |
|
71 | (6-((2-((2-메톡시-4-(4-메틸피페라진-1-일)-5-(퀴놀린-3-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.56 (s, 1H), 9.25-9.22 (m, 1H), 8.67 (d, J = 2.0 Hz, 2H), 8.53 (d, J = 1.6 Hz, 2H), 8.12 (d, J = 8.4 Hz, 1H), 7.90 (t, J = 7.2 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.59 (t, J = 7.6 Hz, 1H), 7.49 (d, J = 9.2 Hz, 1H), 7.10 (s, 1H), 7.09 (s, 1H), 6.67 (d, J = 3.6 Hz, 1H), 4.12 (s, 3H), 3.51-3.48 (m, 2H), 3.37-3.35 (m, 2H), 3.18-3.06 (m, 4H), 2.98 (s, 3H), 2.21 (s, 3H), 2.19 (s, 3H); MS(ESI): m/z 685 [M+H]+ | 73 | 7.97, 100, (b) |
|
72 | (6-((2-((4-메톡시-6-(4-메틸피페라진-1-일)-[1,1'-바이페닐]-3-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, Neutral, DMSO-d 6) δ 13.24 (s, 1H), 11.32 (s, 1H), 9.69-9.66 (m, 1H), 8.84 (d, J = 2 Hz, 1H), 8.79 (d, J = 2 Hz, 1H), 7.90 (s, 1H), 7.81 (d, J = 8.8 Hz, 1H), 7.72 (s, 1H), 7.65 (d, J = 7.2 Hz, 2H), 7.36 (tr, J = 7.6 Hz, 2H), 7.24 (tr, J = 7.2 Hz, 1H), 6.97-6.95 (m, 1H), 6.79 (s, 1H), 6.47-6.46 (m, 1H), 4.13-4.09 (m, 2H), 3.90 (s, 3H), 3.17 (s, 3H), 3.15 (s, 3H), 2.81 (s, 4H), 2.27 (s, 4H), 2.15 (s, 3H), 2.08 (s, 3H), 2.05 (s, 3H); MS(ESI): m/z 634 [M+H]+ | 78 | 8.78, 99, (b) |
|
73 | N-(5-((4-((5-(다이메틸포스포릴)퀴녹살린-6-일)아미노)-7H-피롤로[2,3-d]피리미딘-2-일)아미노)-4-메톡시-2-(4-메틸피페라진-1-일)페닐)아크릴아마이드 | 1H NMR (400 MHz, TFA salt, DMSO-d 6) δ 13.24 (s, 1H), 11.35 (s, 1H), 9.70-9.67 (m, 1H), 9.09 (s, 1H), 8.85-8.79 (m, 2H), 8.42-8.39 (m, 1H), 8.08 (d, J = 9.6 Hz, 1H), 7.75 (s, 1H), 6.97 (s, 1H), 6.87 (s, 1H), 6.64-6.57 (m, 1H), 6.47 (s, 1H), 6.14-6.09 (m, 1H), 5.66 (d, J = 11.2 Hz, 1H), 4.13-4.06 (m, 1H), 3.84 (s, 3H), 3.16 (d, J = 5.2 Hz, 2H), 2.89-2.87 (m, 2H), 2.26 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H); MS(ESI): m/z 627 [M+H]+ | 18 | 7.87, 100, (b) |
|
74 | N-(5-((4-((5-(다이메틸포스포릴)퀴녹살린-6-일)아미노)-7H-피롤로[2,3-d]피리미딘-2-일)아미노)-4-메톡시-2-(4-메틸피페라진-1-일)페닐)프로피온아마이드 | MS(ESI): m/z 629 [M+H]+ | |||
75 | (6-((2-((5-(퓨란-3-일)-2-메톡시-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 9.61 (dd, J = 9.6, 4.3 Hz, 1H), 8.80 (d, J = 1.9 Hz, 1H), 8.71 (d, J = 1.9 Hz, 1H), 8.48 (s, 1H, FA), 8.32 (s, 1H), 7.92 (s, 1H), 7.74 (d, J = 9.6 Hz, 1H), 7.37 (t, J = 1.6 Hz, 1H), 6.98 (d, J = 3.6 Hz, 1H), 6.87 (s, 1H), 6.85 (d, J = 1.2 Hz, 1H), 6.60 (d, J = 3.6 Hz, 1H), 3.98 (s, 3H), 3.35-3.33 (m, 2H), 3.14-2.99 (m, 6H), 2.68 (s, 3H), 2.19 (s, 3H), 2.16 (s, 3H); MS(ESI): m/z 624 [M+H]+ | 35 | 8.46, 98, (b) |
|
76 | (6-((2-((2-메톡시-4-(4-메틸피페라진-1-일)-5-(싸이오펜-3-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.57 (dd, J = 9.5, 4.3 Hz, 1H), 8.80 (d, J = 1.9 Hz, 1H), 8.72 (d, J = 1.9 Hz, 1H), 8.37 (s, 1H), 7.63 (d, J = 9.6 Hz, 1H), 7.54 (m, 2H), 7.37 (dd, J = 4.9, 3.0 Hz, 1H), 6.98 (d, J = 3.6 Hz, 1H), 6.83 (s, 1H), 6.60 (d, J = 3.6 Hz, 1H), 4.00 (s, 3H), 3.31-3.15 (m, 8H), 2.94 (s, 3H), 2.19 (s, 3H), 2.15 (s, 3H); MS(ESI): m/z 640 [M+H]+ | 71 | 8.69, 97, (b) |
|
77 | (6-((2-((5-(아이소옥사졸-4-일)-2-메톡시-6-(4-메틸피페라진-1-일)피리딘-3-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | MS(ESI): m/z 626 [M+H]+ | |||
78 | (6-((2-((2-메톡시-6-(4-메틸피페라진-1-일)-5-(옥사졸-4-일)피리딘-3-일)아미노)-7H-피롤로[2,3 -d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | MS(ESI): m/z 626 [M+H]+ | |||
79 | (6-((2-((5-에티닐-2-메톡시-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, MeOD-d 4) δ9.72-9.69 (m, 1H), 8.84 (d, J = 2.0 Hz, 1H), 8.76 (d, J = 2.0 Hz, 1H), 8.44 (s, 1H), 8.27 (d, J = 9.6 Hz, 1H), 7.01 (d, J = 3.6 Hz, 1H), 6.74 (s, 1H), 6.63 (d, J = 3.6 Hz, 1H), 4.01 (s, 3H), 3.63 (s, 1H), 3.51-3.41 (m, 8H), 2.89 (s, 3H), 2.19 (s, 3H), 2.18 (s, 3H); MS(ESI): m/z 582 [M+H]+ | 8 | 8.24, 95, (b) |
|
80 | 5-((4-((5-(다이메틸포스포릴)퀴녹살린-6-일)아미노)-7H-피롤로[2,3-d]피리미딘-2-일)아미노)-6-메톡시-2-(4-메틸피페라진-1-일)니코티노나이트릴 | MS(ESI): m/z 584 [M+H]+ | |||
81 | 5-((4-((5-(다이메틸포스포릴)퀴녹살린-6-일)아미노)-7H-피롤로[2,3-d]피리미딘-2-일)아미노)-4-메톡시-2-(4-메틸피페라진-1-일)벤조나이트릴 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.66 (dd, J = 9.6, 4.2 Hz, 1H), 8.83 (d, J = 1.9 Hz, 1H), 8.81 (s, 1H), 8.75 (d, J = 1.8 Hz, 1H), 8.24 (d, J = 9.6 Hz, 1H), 7.02 (d, J = 3.5 Hz, 1H), 6.86 (s, 1H), 6.63 (d, J = 3.5 Hz, 1H), 4.07 (s, 4H), 3.43 (s, 8H), 2.95 (s, 3H), 2.21 (s, 3H), 2.17 (s, 3H); MS(ESI): m/z 583 [M+H]+ | 60 | 8.52, 99, (b) |
|
82 | (6-((2-((2-메톡시-4-(4-메틸피페라진-1-일)-5-바이닐페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.43 (dd, J = 9.5, 3.7 Hz, 1H), 8.87 (d, J = 1.7 Hz, 1H), 8.81 (d, J = 1.7 Hz, 1H), 8.02 (s, 1H), 7.96 (d, J = 9.7 Hz, 1H), 7.11 (dd, J = 17.8, 11.0 Hz, 1H), 7.06 (d, J = 3.6 Hz, 1H), 6.87 (s, 1H), 6.73 (d, J = 3.5 Hz, 1H), 5.56 (d, J = 17.4 Hz, 1H), 5.14 (d, J = 11.3 Hz, 1H), 3.93 (s, 3H), 3.66 (d, J = 12.4 Hz, 2H), 3.45 (t, J = 11.6 Hz, 4H), 3.19 (d, J = 12.0 Hz, 2H), 3.04 (s, 3H), 2.21 (s, 3H), 2.17 (s, 3H); MS(ESI): m/z 584 [M+H]+ | 6 | 8.31, 91, (b) |
|
83 | (6-((2-((5-사이클로프로필-2-메톡시-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.41-9.32 (m, 1H), 8.88 (d, J = 1.9 Hz, 1H), 8.82 (d, J = 1.8 Hz, 1H), 8.00 (d, J = 9.4 Hz, 1H), 7.24 (s, 1H), 7.05 (d, J = 3.6 Hz, 1H), 6.88 (s, 1H), 6.72 (d, J = 3.5 Hz, 1H), 3.89 (s, 3H), 3.65 (dd, J = 21.4, 12.9 Hz, 4H), 3.52-3.39 (m, 2H), 3.20 (t, J = 11.9 Hz, 2H), 3.04 (s, 3H), 2.31-2.22 (m, 1H), 2.21 (s, 3H), 2.18 (s, 3H), 0.96-0.85 (m, 2H), 0.65-0.58 (m, 2H); MS(ESI): m/z 597 [M+H]+ | 86 | 8.34, 99, (b) |
|
84 | (6-((2-((5-에틸-2-메톡시-6-(1-메틸피페리딘-4-일)피리딘-3-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | MS(ESI): m/z 586 [M+H]+ | |||
85 | (6-((2-((5-에틸-2-메톡시-6-(4-메틸피페라진-1-일)피리딘-3-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.41-9.39 (m, 1H), 8.87 (d, J = 2.0 Hz, 1H), 8.81 (d, J = 1.6 Hz, 1H), 8.16 (d, J = 10.4 Hz, 1H), 8.06 (d, J = 9.6 Hz, 1H), 7.05 (d, J = 3.6 Hz, 1H), 6.70 (d, J = 3.2 Hz, 1H), 3.99 (s, 3H), 3.63-3.54 (m, 4H), 3.42-3.33 (m, 4H), 3.01 (s, 3H), 2.69-2.64 (m, 2H), 2.20 (s, 3H), 2.17 (s, 3H), 1.17 (t, J = 7.6 Hz, 3H); MS(ESI): m/z 587 [M+H]+ | 87 | 8.69, 98, (b) |
|
86 | (6-((2-((5-에틸-2-메톡시-6-(1'-메틸-[1,4'-바이피페리딘]-4-일)피리딘-3-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | MS(ESI): m/z 669 [M+H]+ | |||
87 | (6-((2-((5-에틸-2-메톡시-6-(4-(4-메틸피페라진-1-일)피페리딘-1-일)피리딘-3-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.42-9.40 (m, 1H), 8.90 (d, J = 2.0 Hz, 1H), 8.85 (d, J = 1.6 Hz, 1H), 8.09 (d, J = 9.6 Hz, 1H), 8.03 (s, 1H), 7.09 (d, J = 3.6 Hz, 1H), 6.76 (d, J = 3.6 Hz, 1H), 4.00 (s, 3H), 3.69-3.66 (m, 2H), 3.37-3.16 (m, 11H), 2.88 (s, 3H), 2.72-2.67 (m, 2H), 2.23 (s, 3H), 2.20 (s, 3H), 2.18-2.17 (m, 2H), 2.01-1.95 (m, 2), 1.22 (t, J = 7.6 Hz, 3H); MS(ESI): m/z 670 [M+H]+ | 50 | 8.14, 99, (b) |
|
88 | (6-((2-((5-(1-사이클로프로필-1H-피라졸-4-일)-2-메톡시-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, MeOD-d 4) δ 9.35-9.33 (m, 1H), 8.89 (d, J = 1.6 Hz, 1H), 8.84 (d, J = 1.6 Hz, 1H), 8.05 (s, 1H), 7.92 (s, 1H), 7.86 (s, 1H), 7.63-7.61 (m, 1H), 7.10 (d, J = 3.6 Hz, 1H), 3.97 (s, 3H), 3.65-3.62 (m, 3H), 3.60-3.58 (m, 2H), 3.47-3.44 (m, 2H), 3.16-3.13 (m, 2H), 3.10 (s, 2H), 2.23 (s, 3H), 2.19 (s, 3H), 0.99-0.97 (m, 4H); MS(ESI): m/z 664 [M+H]+ | 58 | 8.19, 100, (b) |
|
89 | (3-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-4-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 10.23 (d, J = 4.6 Hz, 1H), 8.48 (s, 1H), 8.43 (s, 1H), 8.12-8.08 (m, 1H), 7.94-7.90 (m, 1H), 7.80 (s, 1H), 7.72-7.66 (m, 3H), 6.99 (d, J = 3.5 Hz, 1H), 6.83 (s, 1H), 6.53 (d, J = 3.5 Hz, 1H), 3.96 (s, 3H), 3.65 (s, 3H), 3.36-3.33 (m, 2H), 3.06-2.97 (m, 4H), 2.64 (s, 3H), 2.25 (s, 3H), 2.21 (s, 3H); MS(ESI): m/z 637 [M+H]+ | 4 | 7.49, 99, (b) |
|
90 | (3-((2-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-4-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.99 (d, J = 4.1 Hz, 1H), 8.30 (d, J = 8.5 Hz, 1H), 8.10 (d, J = 7.8 Hz, 1H), 7.85-7.69 (m, 3H), 7.01 (d, J = 3.5 Hz, 1H), 6.78 (s, 1H), 6.60 (d, J = 3.4 Hz, 1H), 3.89 (s, 3H), 3.24 (d, J = 9.9 Hz, 4H), 3.11-2.68 (m, 12H), 2.20 (s, 3H), 2.16 (s, 3H), 2.07 (d, J = 11.1 Hz, 2H), 1.99 (s, 3H), 1.81 (dd, J = 22.7, 11.5 Hz, 2H); MS(ESI): m/z 654 [M+H]+ | 81 | 7.19, 99, (b) |
|
91 | (2-사이클로프로필-6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 8.94 (dd, J = 9.1, 4.0 Hz, 1H), 8.69 (d, J = 9.0 Hz, 1H), 7.91 (d, J = 13.4 Hz, 2H), 7.75-7.69 (m, 2H), 7.42 (d, J = 9.2 Hz, 1H), 7.05 (d, J = 3.6 Hz, 1H), 6.90 (s, 1H), 6.67 (d, J = 3.5 Hz, 1H), 3.95 (s, 3H), 3.82 (s, 3H), 3.61-3.55 (m, 2H), 3.41-3.34 (m, 4H), 3.09-3.04 (m, 2H), 3.02 (s, 3H), 2.41-2.34 (m, 1H), 2.18 (s, 3H), 2.14 (s, 3H), 1.35-1.20 (m, 4H); MS(ESI): m/z 677 [M+H]+ | 30 | 7.59, 99, (b) |
|
92 | (2-사이클로프로필-6-((2-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 8.90 (m, 1H), 8.67 (d, J = 9.2 Hz, 1H), 8.38 (s, 1H), 8.03 (d, J = 9.6 Hz, 1H), 7.87 (s, 1H), 7.33 (d, J = 9.2 Hz, 1H), 6.92 (d, J = 3.6 Hz, 1H), 6.70 (s, 1H), 6.51 (d, J = 3.6 Hz, 1H), 3.86 (s, 3H), 3.16-3.12 (m, 4H), 3.00 (s, 5H), 2.72 (t, J = 11.6 Hz, 4H), 2.63 (s, 3H), 2.30-2.25 (m, 1H), 2.10 (s, 3H), 2.06 (s, 3H), 2.02-1.95 (m, 8H), 1.80-1.71 (m, 2H), 1.16-1.13 (m, 4H); MS(ESI): m/z 695 [M+H]+ | 47 | 7.37, 98, (b) |
|
93 | (7-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)이미다조[1,2-a]피리딘-8-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, MeOD-d 4) δ 8.77 (s, 1H), 8.22 (d, J = 7.6 Hz, 1H), 8.02 (s, 1H), 8.01 (s, 1H), 7.93-7.90 (m, 2H), 7.77 (d, J = 1.6 Hz, 1H), 7.06 (d, J = 3.6 Hz, 1H), 6.92 (s, 1H), 6.63 (d, J = 3.6 Hz, 1H), 3.96 (s, 3H), 3.89 (s, 3H), 3.59-3.56 (m, 2H), 3.38-3.28 (m, 4H), 3.13-3.06 (m, 2H), 3.01 (s, 3H), 2.16 (s, 3H), 2.12 (s, 3H); MS(ESI): m/z 626 [M+H]+ | 53 | 7.16, 99, (b) |
|
94 | (7-((2-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3- d]피리미딘-4-일)아미노)이미다조[1,2-a]피리딘-8-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 8.92 (dd, J = 7.62 Hz, 1H), 8.39 (dd, J = 7.74 Hz, 1H), 8.31 (s, 2H), 8.07 (s, 1H), 7.70 (t, 1H), 7.45 (d, J = 1.24 Hz, 1H), 6.94 (d, J = 3.59 Hz 1H), 6.76 (s, 1H), 6.53 (d, J = 3.57 Hz, 1H), 3.89 (s, 3H), 3.23 (d, J = 11.9 Hz, 2H), 3.14-2.97 (m, 7H), 2.77 (t, 3H), 2.69 (s, 3H), 2.26 (s, 3H), 2.15 (s, 3H), 2.12 (s, 3H), 2.08 (d, J = 11.13 Hz, 2H), 1.84-1.75 (m, 2H); MS(ESI): m/z 643 [M+H]+ | 42 | 6.77, 99, (b) |
|
95 | (7-((2-((2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)이미다조[1,2-a]피리딘-8-일)다이메틸포스핀 옥사이드 | MS(ESI): m/z 629 [M+H]+ | |||
96 | 다이메틸(7-((2-((4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)이미다조[1,2-a]피리딘-8-일)포스핀 옥사이드 | MS(ESI): m/z 599 [M+H]+ | |||
97 | (7-((2-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)싸이에노[3,2-d]피리미딘-4-일)아미노)이미다조[1,2-a]피리딘-8-일)다이메틸포스핀 옥사이드 | MS(ESI): m/z 660 [M+H]+ | |||
98 | (7-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)-4-메틸-3,4-다이하이드로-2H-벤조[b][1,4]옥사진-8-일)다이메틸포스핀 옥사이드 | MS(ESI): m/z 657 [M+H]+ | |||
99 | (7-((2-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3- d]피리미딘-4-일)아미노)-4-메틸-3,4-다이하이드로-2H-벤조[b][1,4]옥사진-8-일)다이메틸포스핀 옥사이드 | MS(ESI): m/z 674 [M+H]+ | |||
100 | (7-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-8-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, DMSO-d 6) δ 13.27 (s, 1H), 11.35 (s, 1H), 9.46-9.43 (m, 1H), 8.84-8.82 (m, 1H), 8.23-8.17 (m, 3H), 8.05 (s, 1H), 7.93 (s, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.56 (s, 1H), 7.44-7.41 (m, 1H), 6.99-6.98 (m, 1H), 6.83 (s, 1H), 6.48-6.46 (m, 1H), 3.88 (s, 3H), 3.79 (s, 3H), 2.87-2.86 (m, 4H); MS(ESI): m/z 637 [M+H]+ | 59 | 8.34, 100, (b) |
|
101 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 9.30-9.27 (m, 1H), 8.79-8.77 (m, 1H), 8.58 (d, J = 8.8 Hz, 1H), 8.39 (s, 1H), 8.36 (s, 1H), 7.89 (s, 1H), 7.75 (s, 1H), 7.74-7.73 (m, 1H), 7.71-7.59 (m, 1H), 6.98 (d, J = 3.6 Hz, 1H), 6.87 (s, 1H), 6.57 (d, J = 3.6 Hz, 1H), 3.99 (s, 3H), 3.76 (s, 3H), 3.32-3.19 (m, 8H), 2.86 (s, 3H), 2.22 (s, 3H), 2.18 (s, 3H); m/z 667 [M+H]+ | 36 | 7.75, 100, (b) |
|
102 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)-2,3-다이메틸페닐)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 8.45 (s, 1H), 8.34-8.31 (m, 1H), 7.92 (s, 1H), 7.67 (s, 1H), 6.90-6.84 (m, 3H), 6.41 (d, J = 3.6 Hz, 1H), 3.98 (s, 3H), 3.92 (s, 3H), 3.35-3.28 (m, 4H), 3.16-3.13 (m, 4H), 2.89 (s, 3H), 2.44 (s, 3H), 2.23 (s, 3H), 2.03 (s, 3H), 2.01 (s, 3H); MS(ESI): m/z 614 [M+H]+ | 31 | 7.69, 100, (b) |
|
103 | (3-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)-1,5-나프티리딘-4-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, MeOD-d 4) δ 10.62 (d, J = 4.4Hz, 1H), 8.90-8.88 (m, 1H), 8.46 (s, 1H), 8.22-8.20 (m, 1H), 7.99 (s, 1H), 7.97 (s, 1H), 7.62-7.59 (m, 1H), 7.00 (d, J = 3.6 Hz, 1H), 6.83 (s, 1H), 6.56 (d, J = 3.6 Hz, 1H), 3.97 (s, 3H), 3.72 (s, 3H), 3.49-3.47 (m, 2H), 3.15-3.08 (m, 2H), 2.95 (s, 3H), 2.25 (s, 3H), 2.22 (s, 3H); MS(ESI): m/z 638 [M+H]+ | 14 | 8.15, 97, (b) |
|
104 | (6-((2-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-9H-퓨린-6-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.47-9.43 (m, 1H), 8.83 (d, J = 2.0 Hz, 1H), 8.76 (d, J = 1.6 Hz, 1H), 8.07 (d, J = 9.6 Hz, 1H), 7.94 (s, 1H), 7.89 (s, 1H), 6.76 (s, 1H), 3.87 (s, 3H), 3.21 (d, J = 11.6 Hz, 2H), 2.87-2.62 (m, 9H), 2.52 (s, 3H), 2.24-2.14 (m, 10H), 2.06-2.03 (m, 3H), 1.80-1.59 (m, 2H); MS(ESI): m/z 656 [M+H]+ | 5 | 3.85, 100, (a) |
|
105 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-9H-퓨린-6-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.37-9.34 (m, 1H), 8.81 (d, J = 1.6 Hz, 1H), 8.75 (d, J = 2.0 Hz, 1H), 8.25 (s, 1H), 7.99 (s, 1H), 7.91 (s, 1H), 7.69 (s, 1H), 7.63 (d, J = 9.2 Hz, 1H), 6.85 (s, 1H), 3.93 (s, 3H), 3.85 (s, 3H), 3.34-3.33 (m, 2H), 2.69-2.61 (m, 5H), 2.38 (s, 3H), 2.35-2.02 (m, 12H), 1.67-1.59 (m, 4H); MS(ESI): m/z 722 [M+H]+ | 4 | 3.88, 100, (a) |
|
106 | 다이메틸(6-((2-((3-(4-메틸-1H-이미다졸-1-일)-5-(트라이플루오로메틸)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.68-9.65 (m, 1H), 9.38 (d, J = 1.6 Hz, 1H), 8.80 (d, J = 2.0 Hz, 1H), 8.73 (d, J = 2.0 Hz, 1H), 8.68 (t, J = 2.0 Hz, 1H), 8.10 (s, 1H), 7.95 (d, J = 9.6 Hz, 1H), 7.81 (t, J = 1.2 Hz, 1H), 7.54 (s, 1H), 7.02 (d, J = 3.6 Hz, 1H), 6.59 (d, J = 3.6 Hz, 1H), 2.39 (d, J = 1.6 Hz, 3H), 2.19 (s, 3H), 2.16 (s, 3H); MS(ESI): m/z 578 [M+H]+ | 41 | 6.04, 100, (b) |
|
107 | 다이메틸(6-((2-((4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)-3-(트라이플루오로메틸)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 9.93-9.89 (m, 1H), 8.81 (d, J = 2.0 Hz, 1H), 8.73 (d, J = 2.0 Hz, 1H), 8.32 (s, 1H), 8.13 (s, 1H), 8.11 (d, J = 2.8 Hz, 1H), 7.93-7.90 (m, 1H), 7.43 (d, J = 8.4 Hz, 1H), 6.99 (d, J = 3.6 Hz, 1H), 6.61 (d, J = 3.6 Hz, 1H), 3.13-3.09 (m, 4H), 3.03 (s, 5H), 2.89-2.78 (m, 4H), 2.66 (s, 3H), 2.20 (s, 3H), 2.16 (s, 3H), 2.04-2.02 (m, 2H), 1.81-1.72 (m, 2H); MS(ESI): m/z 679 [M+H]+ | 54 | 8.45, 99, (b) |
|
108 | (6-((2-((4-(9-(1-플루오로-2-메틸프로판-2-일)-3,9-다이아자스파이로[5.5]운데칸-3-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.61 (dd, J = 9.5, 4.3 Hz, 1H), 8.80 (d, J = 1.9 Hz, 1H), 8.72 (d, J = 2.0 Hz, 1H), 8.27 (s, 1H), 7.98 (s, 1H), 7.83 (s, 1H), 7.57 (d, J = 9.7 Hz, 1H), 6.98 (d, J = 3.6 Hz, 1H), 6.91 (s, 1H), 6.60 (d, J = 3.6 Hz, 1H), 3.96 (s, 3H), 3.79 (s, 3H), 3.35-3.31 (m, 6H), 2.96-2.89 (m, 4H), 2.19 (s, 3H), 2.16 (s, 3H), 1.93-1.65 (m, 8H), 1.53 (s, 3H), 1.47 (s, 3H); MS(ESI): m/z 766 [M+H]+ | 36 | 8.76, 96, (b) |
|
109 | (6-((2-((4-(4-(1-플루오로-2-메틸프로판-2-일)피페라진-1-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 9.61 (dd, J = 9.54 Hz, 1H), 8.77 (d, J = 1.89 Hz, 1H), 8.70 (d, J = 1.92 Hz, 1H), 8.30 (s, 1H), 7.99 (s, 1H), 7.79 (s, 1H), 7.57 (d, J = 9.54 Hz 1H), 6.96 (d, J = 3.58 Hz, 1H), 6.87 (s, 1H), 6.58 (d, J = 3.56 Hz, 1H), 3.96 (s, 3H), 3.79 (s, 3H), 3.01 (t, 4H), 2.88-2.83 (m, 4H), 2.76 (d, J = 22.29 Hz, 2H), 2.18 (s, 3H), 2.15 (s, 3H), 1.44 (s, 3H), 1.39 (s, 3H); MS(ESI): m/z 698 [M+H]+ | 54 | 8.49, 99, (b) |
|
110 | (6-((2-((4-(9-(1-하이드록시-2-메틸프로판-2-일)-3,9-다이아자스파이로[5.5]운데칸-3-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.59 (dd, J = 9.5, 4.2 Hz, 1H), 8.81 (d, J = 1.9 Hz, 1H), 8.73 (d, J = 1.9 Hz, 1H), 8.23 (s, 1H), 7.98 (s, 1H), 7.83 (s, 1H), 7.58 (d, J = 9.6 Hz, 1H), 6.99 (d, J = 3.6 Hz, 1H), 6.92 (s, 1H), 6.62 (d, J = 3.6 Hz, 1H), 3.96 (s, 3H), 3.79 (s, 3H), 3.67 (s, 2H), 3.46 (dd, J = 6.8, 4.3 Hz, 1H), 3.33 (d, J = 1.7 Hz, 2H), 3.25-3.15 (m, 3H), 2.98-2.91 (m, 4H), 2.20 (s, 3H), 2.16 (s, 3H), 2.15-2.08 (m, 2H), 1.86-1.80 (m, 2H), 1.79-1.68 (m, 2H), 1.68-1.60 (m, 2H), 1.39 (s, 6H); MS(ESI): m/z 764 [M+H]+ | 57 | 8.39, 97, (b) |
|
111 | (9-(4-((4-((5-(다이메틸포스포릴)퀴녹살린-6-일)아미노)-7H-피롤로[2,3-d]피리미딘-2-일)아미노)-5-메톡시-2-(1-메틸-1H-피라졸-4-일)페닐)-3,9-다이아자스파이로[5.5]운데칸-3-일)(1-플루오로사이클로프로필)메탄온 | 1H NMR (400 MHz, free base, Methanol-d 4) δ 9.57-9.54 (m, 1H), 8.73 (d, J = 2.0 Hz, 1H), 8.67 (d, J = 2.0 Hz, 1H), 8.26 (s, 1H), 7.96 (s, 1H), 7.78 (s, 1H), 7.52 (d, J = 9.6 Hz, 1H), 6.95 (d, J = 3.6 Hz, 1H), 6.85 (s, 1H), 6.55 (d, J = 4.0 Hz, 1H), 3.93 (s, 3H), 3.78 (s, 3H), 3.62-3.60 (m, 4H), 2.89-2.86 (m, 4H), 2.17-2.13 (m, 8H), 1.69-1.61 (m, 8H), 1.30-1.18 (m, 3H); MS(ESI): m/z 778 [M+H]+ | 31 | 11.08, 100, (b) |
|
112 | (4-(4-((4-((5-(다이메틸포스포릴)퀴녹살린-6-일)아미노)-7H-피롤로[2,3-d]피리미딘-2-일)아미노)-5-메톡시-2-(1-메틸-1H-피라졸-4-일)페닐)피페라진-1-일)(1-플루오로사이클로프로필)메탄온 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.35-9.34 (m, 1H), 8.85 (d, J = 2.0 Hz, 1H), 8.82 (d, J = 2.0 Hz, 1H), 8.12 (s, 1H), 7.84 (s, 1H), 7.79 (s, 1H), 7.62-7.66 (m, 1H), 7.06 (d, J = 3.6 Hz, 1H), 6.93 (s, 1H), 6.74 (d, J = 3.2 Hz, 1H), 3.93-3.86 (m, 10H), 3.04-3.01 (m, 4H), 2.20 (s, 3H), 2.16-2.15 (m, 4H), 1.29-1.25 (m, 4H); MS(ESI): m/z 710 [M+H]+ | 10 | 10.55, 98, (b) |
|
113 | (6-((2-((4-(4-((1-플루오로사이클로프로필)메틸)피페라진-1-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.55-9.51 (m, 1H), 8.79 (d, J = 2.0 Hz, 1H), 8.72 (d, J = 2.0 Hz, 1H), 8.33 (s, 1H), 7.95 (s, 1H), 7.76 (s, 1H), 7.56 (d, J = 9.6 Hz, 1H), 6.60 (d, J = 3.6 Hz, 1H), 3.98 (s, 3H), 3.80-3.75 (m, 7H), 2.18-2.14 (m, 10H), 1.38-1.25 (m, 4H), 1.05-0.99 (m, 2H); MS(ESI): m/z 696 [M+H]+ | 13 | 8.36, 100, (b) |
|
114 | (6-((2-((4-(9-((1-플루오로사이클로프로필)메틸)-3,9-다이아자스파이로[5.5]운데칸-3-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA, Methanol-d 4) δ 9.60-9.57 (m, 1H), 8.77 (d, J = 2.0 Hz, 1H), 8.70 (d, J = 2.0 Hz, 1H), 8.26 (s, 1H), 7.96 (s, 1H), 7.81 (s, 1H), 7.56 (d, J = 9.6 Hz, 1H), 6.97 (d, J = 3.6 Hz, 1H), 6.89 (s, 1H), 6.58 (d, J = 3.6 Hz, 1H), 3.95 (s, 3H), 3.78 (s, 3H), 3.46 (d, J = 21.2 Hz, 2H), 3.30-3.24 (m, 3H), 2.93-2.90 (m, 4H), 2.18-2.14 (m, 8H), 1.86 (s, 4H), 1.72 (s, 4H), 1.32-1.20 (m, 2H), 0.91-0.87 (m, 2H); MS(ESI): m/z 764 [M+H]+ | 18 | 8.74, 100, (b) |
|
115 | (6-((2-((5-(1-사이클로프로필-1H-피라졸-4-일)-2-메톡시-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, MeOD-d 4) δ 9.35-9.33 (m, 1H), 8.89 (d, J = 1.6 Hz, 1H), 8.84 (d, J = 1.6 Hz, 1H), 8.05 (s, 1H), 7.92 (s, 1H), 7.86 (s, 1H), 7.63-7.61 (m, 1H), 7.10 (d, J = 3.6 Hz, 1H), 3.97 (s, 3H), 3.65-3.62 (m, 3H), 3.60-3.58 (m, 2H), 3.47-3.44 (m, 2H), 3.16-3.13 (m, 2H), 3.10 (s, 2H), 2.23 (s, 3H), 2.19 (s, 3H), 0.99-0.97 (m, 4H); MS(ESI): m/z 664 [M+H]+ | 58 | 8.19, 100, (b) |
|
116 | 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)-2,3-다이하이드로벤조퓨란-7-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, MeOD-d 4) δ 9.42-9.30 (m, 1H), 8.89 (d, J = 2 Hz, 1H), 8.84 (d, J = 2 Hz, 1H), 7.91 (s, 1H), 7.80-7.70 (m, 3H), 7.09 (d, J =3.6 Hz, 1H), 6.76 (d, J = 3.6 Hz, 1H), 4.69 (t, J = 8.8 Hz, 2H), 3.62-3.14 (m, 12H), 3.01 (s, 3H), 2.30-2.10 (m, 7H); m/z 650 [M+H]+ | 58 | 100* | |
117 | 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)-2,3-다이하이드로벤조퓨란-7-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, MeOD-d 4) δ 9.66-9.63 (m, 1H), 8.78 (d, J = 2 Hz, 1H), 8.71 (d, J = 1.6 Hz, 1H), 7.97 (s, 1H), 7.83 (s, 1H), 7.73 (s, 1H), 7.64 (d, J = 9.6 Hz, 1H), 6.96 (d, J = 3.6 Hz, 1H), 6.59 (d, J = 3.6 Hz, 1H), 4.61 (tr, J = 8.4 Hz, 2H), 3.81 (s, 3H), 3.45 (tr, J = 8.4 Hz, 2H), 3.17-3.14 (m, 2H), 3.06-3.00 (m, 9H), 2.65 (s, 4H), 2.18 (s, 3H), 2.15 (s, 3H), 1.95 (d, J = 10.8 Hz, 2H), 1.71-1.62 (m, 2H); MS(ESI): m/z 733 [M+H]+ | 28 | 7.50, 98, (b) |
|
118 | (6-((2-((4-(4-사이클로펜틸피페라진-1-일)-5-(1-메틸-1H-피라졸-4-일)-2,3-다이하이드로벤조퓨란-7-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | MS(ESI): m/z 704 [M+H]+ | |||
119 | 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-모르폴리노-2,3-다이하이드로벤조퓨란-7-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | MS(ESI): m/z 637 [M+H]+ | |||
120 | 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-모르폴리노피페리딘-1-일)-2,3-다이하이드로벤조퓨란-7-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, MeOD-d 4) δ 9.62-9.59 (m, 1H), 8.75 (d, J = 2.0 Hz, 1H), 8.69 (d, J = 2.0 Hz, 1H), 8.26 (s, 1H), 8.02 (s, 1H), 7.78 (s, 1H), 7.66 (s, 1H), 7.60 (d, J = 9.2 Hz, 1H), 6.97 (d, J = 3.6 Hz, 1H), 6.57 (d, J = 3.6 Hz, 1H), 4.58 (t, J = 8.4, 8.4 Hz, 2H), 3.90-3.88 (m, 4H), 3.82 (s, 3H), 3.39-3.34 (m, 2H), 3.33-3.11 (m, 6H), 2.99-2.96 (m, 3H), 2.17 (s, 3H), 2.14 (s, 3H), 2.08-2.05 (m, 2H), 1.71-1.68 (m, 2H); MS(ESI): m/z 720 [M+H]+ | 42 | 8.02, 96, (b) |
|
121 | 다이메틸(6-((2-((5-메틸-4-(4-메틸피페라진-1-일)-2,3-다이하이드로벤조퓨란-7-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, MeOD-d 4) δ 9.75-9.71 (m, 1H), 8.80 (d, J = 2 Hz, 1H), 8.71 (d, J = 1.6 Hz, 1H), 8.02 (d, J = 9.2 Hz, 1H), 7.75 (s, 1H), 6.69 (d, J = 3.6 Hz, 1H), 6.58 (d, J = 3.6 Hz, 1H), 4.60 (tr, J = 8.4 Hz, 2H), 3.43-3.37 (m, 5H), 2.94 (s, 3H), 2.29 (s, 3H), 2.19 (s, 3H), 2.16 (s, 3H); MS(ESI): m/z 584 [M+H]+ | 57 | 7.95, 98, (b) |
|
122 | 다이메틸(6-((2-((5-메틸-4-모르폴리노-2,3-다이하이드로벤조퓨란-7-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, DMSO-d 4) δ 13.24 (s, 1H), 11.31 (S, 1H), 9.80-9.76 (m, 1H), 8.86 (d, J = 2.0 Hz, 1H), 8.80 (d, J = 1.6 Hz, 1H), 8.02 (d, J = 9.6 Hz, 1H), 7.78 (s, 1H), 7.51 (s, 1H), 6.97 (t, J = 2.4 Hz, 1H), 6.47 (t, J = 1.6 Hz, 1H), 4.52 (t, J = 8.4 Hz, 2H), 3.73 (s, 4H), 3.42 (t, J = 8.8 Hz, 2H), 2.98 (s, 4H), 2.25 (s, 3H), 2.10 (s, 3H), 2.06 (s, 3H) : MS(ESI): m/z 571 [M+H]+ | 20 | 10.63, 96, (b) |
|
123 | 다이메틸(6-((2-((6-(1-메틸-1H-피라졸-4-일)-5-(4-메틸피페라진-1-일)크로만-8-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | MS(ESI): m/z 664 [M+H]+ | |||
124 | 다이메틸(6-((2-((6-(1-메틸-1H-피라졸-4-일)-5-(4-(4-메틸피페라진-1-일)피페리딘-1-일)크로만-8- 일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | MS(ESI): m/z 747 [M+H]+ | |||
125 | 다이메틸(6-((2-((6-(1-메틸-1H-피라졸-4-일)-5-모르폴리노크로만-8-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | MS(ESI): m/z 651 [M+H]+ | |||
126 | 다이메틸(6-((2-((6-(1-메틸-1H-피라졸-4-일)-5-(4-모르폴리노피페리딘-1-일)크로만-8-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | MS(ESI): m/z 734 [M+H]+ | |||
127 | 다이메틸(6-((2-((6-메틸-5-(4-메틸피페라진-1-일)크로만-8-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | MS(ESI): m/z 598 [M+H]+ | |||
128 | 다이메틸(6-((2-((6-메틸-5-모르폴리노크로만-8-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | MS(ESI): m/z 585 [M+H]+ | |||
129 | 다이메틸(6-((2-((6-(1-메틸-1H-피라졸-4-일)-7-(4-메틸피페라진-1-일)벤조[d][1,3]다이옥솔-4-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.49 (dd, J = 9.5, 4.2 Hz, 1H), 8.86 (d, J = 1.8 Hz, 1H), 8.79 (d, J = 1.8 Hz, 1H), 7.98 (s, 1H), 7.82-7.69 (m, 2H), 7.40 (s, 1H), 7.07 (d, J = 3.6 Hz, 1H), 6.71 (d, J = 3.5 Hz, 1H), 6.04 (s, 2H), 3.88 (s, 3H), 3.62-3.51 (m, 4H), 3.01 (s, 3H), 2.66 (s, 4H), 2.20 (s, 3H), 2.17 (s, 3H); MS(ESI): m/z 652 [M+H]+ | 32 | 7.89, 99, (b) |
|
130 | 다이메틸(6-((2-((7-(1-메틸-1H-피라졸-4-일)-8-(4-메틸피페라진-1-일)-2,3-다이하이드로벤조[b][1,4]다이옥신-5-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.48 (dd, J = 9.4, 4.0 Hz, 1H), 8.85 (d, J = 1.9 Hz, 1H), 8.79 (d, J = 1.9 Hz, 1H), 7.89 (s, 1H), 7.83 (s, 1H), 7.64 (s, 1H), 7.61 (s, 1H), 7.06 (d, J = 3.6 Hz, 1H), 6.70 (d, J = 3.6 Hz, 1H), 4.40 (s, 4H), 3.85 (s, 3H), 3.54-3.49 (m, 2H), 3.30-3.20 (m, 6H), 2.99 (s, 3H), 2.21 (s, 3H), 2.17 (s, 3H); MS(ESI): m/z 665 [M+H]+ | 16 | 8.10, 100, (b) |
|
131 | 다이메틸(6-((2-((8-(1-메틸-1H-피라졸-5-일)-2,3-다이하이드로벤조[b][1,4]다이옥신-5-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, DMSO-d 6) δ 13.30 (s, 1H), 11.55 (s, 1H), 9.81 (dd, J = 9.55 Hz, 1H), 8.87 (d, J = 1.84 Hz, 1H), 8.82 (d, J = 1.85 Hz, 1H), 8.41 (s, 0.3H), 8.19 (d, J = 9.52 Hz, 1H), 8.06 (d, J = 8.48 Hz, 1H), 7.84 (s, 1H), 7.44 (d, J = 1.76 Hz, 1H), 7.06 (q, 1H), 6.87 (d, J = 8.44 Hz, 1H), 6.53 (q, 1H), 6.26 (d, J = 1.80 Hz, 1H), 4.41 (t, 2H), 4.33 (t, 2H), 3.71 (s, 3H), 2.11 (s, 3H), 2.08 (s, 3H); MS(ESI): m/z 568 [M+H]+ | 32 | 10.63, 99, (b) |
|
132 | 다이메틸(6-((2-((7-(1-메틸-1H-피라졸-4-일)-8-모르폴리노-2,3-다이하이드로벤조[b][1,4]다이옥신-5-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.40-9.38 (m, 1H), 8.86 (d, J = 2.0 Hz, 1H), 8.82 (d, J = 2.0 Hz, 1H), 8.05 (s, 1H), 7.72 (s, 1H), 7.70 (s, 1H), 7.50 (s, 1H), 7.08 (d, J = 3.6 Hz, 1H), 6.76 (d, J = 3.2 Hz, 1H), 4.35 (s, 4H), 3.85 (s, 3H), 3.80 (s, 4H), 3.34-3.32 (m, 4H), 2.20 (s, 3H), 2.17 (s, 3H); MS(ESI): m/z 653 [M+H]+ | 83 | 10.07, 99, (b) |
|
133 | N-(5-(4-(4-사이클로프로필피페라진-1-일)피페리딘-1-일)-8-((4-((5-(다이메틸포스포릴)퀴녹살린-6-일)아미노)-7H-피롤로[2,3-d]피리미딘-2-일)아미노)-2,3-다이하이드로벤조[b][1,4]다이옥신-6-일)아크릴아마이드 | 1H NMR (400 MHz, FA salt, MeOD-d 4) δ 9.73-9.69 (m, 1H), 8.94 (s, 1H), 8.80 (d, J = 2 Hz, 1H), 8.71 (d, J = 1.6 Hz, 1H), 8.05 (d, J = 9.6 Hz, 1H), 7.01 (d, J = 3.6 Hz, 1H), 6.60 (d, J = 3.6 Hz, 1H), 6.45-6.38 (m, 1H), 6.11 (d, J = 16.8 Hz, 1H), 5.67 (d, J = 10.8 Hz, 1H), 4.64 (s, 4H), 4.38-4.33 (m, 4H), 3.49-3.47 (m, 3H), 3.22-2.92 (m, 12H), 2.20-2.14 (m, 8H), 1.86-1.82 (m, 3H), 0.57-0.56 (m, 2H), 0.47-0.46 (m, 2H); MS(ESI): m/z 764 [M+H]+ | 20 | 8.51, 98, (b) |
|
134 | (6-((2-((8-(4-(4-사이클로프로필피페라진-1-일)피페리딘-1-일)-7-나이트로-2,3-다이하이드로벤조[b][1,4]다이옥신-5-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, MeOD-d 4) δ 9.66-9.62 (m, 1H), 8.79 (d, J = 2 Hz, 1H), 8.71 (d, J = 1.6 Hz, 1H), 8.44 (s, 1H), 8.12 (d, J = 9.6 Hz, 1H), 7.00 (d, J = 3.6 Hz, 1H), 6.58 (d, J = 3.6 Hz, 1H), 4.48 (d, J = 2.4 Hz, 2H), 4.39 (s, 2H), 3.21-3.13 (m, 5H), 2.91 (s, 4H), 2.20 (s, 3H), 2.16 (s, 3H), 2.11-2.08 (m, 2H), 1.82-1.74 (m, 3H), 0.56 (d, J = 5.2 Hz, 2H), 0.46 (d, J = 2.4 Hz, 2H); MS(ESI): m/z 740 [M+H]+ | 26 | 9.58, 98, (b) |
|
135 | 다이메틸(6-((2-((6-(1-메틸-1H-피라졸-4-일)-8-모르폴리노-2,3-다이하이드로벤조[b][1,4]다이옥신-5-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드 | 1H NMR (400 MHz, FA salt, Methanol-d 4) δ 9.45 (s, 1H), 8.76 (d, J = 2.0 Hz, 1H), 8.70 (d, J = 1.6 Hz, 1H), 8.23 (s, 1H), 7.85 (d, J = 10.0 Hz, 1H), 7.80 (s, 1H), 7.70 (s, 1H), 6.90 (d, J = 3.6 Hz, 1H), 6.85 (s, 1H), 6.52 (d, J = 3.6 Hz, 1H), 4.24 (d, J = 7.2 Hz, 4H), 3.92 (t, J = 4.4 Hz, 4H), 3.75 (s, 1H), 3.22 (t, J = 4.4 Hz, 4H), 2.14 (s, 3H), 2.11 (s, 3H); MS(ESI): m/z 653 [M+H]+ | 35 | 8.80, 99, (b) |
|
136 | (6-((2-((3-클로로-1-메틸-1H-피라졸-4-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | MS(ESI): m/z 468 [M+H]+ | |||
137 | (6-((2-((5-클로로-1-메틸-1H-피라졸-4-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.59 (s, 1H), 8.86 (d, J = 2.0 Hz, 1H), 8.81 (d, J = 1.6 Hz, 1H), 8.15 (d, J = 9.2 Hz, 1H), 7.80 (s, 1H), 7.03 (d, J = 3.2 Hz, 1H), 6.71 (d, J = 3.6 Hz, 1H), 3.94 (s, 3H), 2.21 (s, 3H), 2.17 (s, 3H); MS(ESI): m/z 468 [M+H]+ | 44 | 9.15, 99, (b) |
|
138 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(2-메틸아이소옥사졸리딘-3-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | 1H NMR (400 MHz, Methanol-d 4) δ 9.60-9.56 (m, 1H), 8.80 (d, J = 1.9 Hz, 1H), 8.76 (d, J = 1.9 Hz, 1H), 8.44 (s, 1H), 7.70-7.62 (m, 2H), 7.42 (s, 1H), 7.23 (s, 1H), 6.99 (d, J = 3.6 Hz, 1H), 6.61 (d, J = 3.6 Hz, 1H), 4.10 (t, J = 7.2 Hz, 2H), 4.01 (s, 3H), 3.96-3.93 (m, 1H), 3.90 (s, 3H), 2.79-2.71 (m, 1H), 2.51 (s, 3H), 2.36-2.29 (m, 1H), 2.19 (s, 3H), 2.16 (s, 3H); MS(ESI): m/z 625 [M+H]+ | 30 | 9.29, 99, (b) |
|
139 | (S)-(6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(2-메틸아이소옥사졸리딘-3-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | MS(ESI): m/z 625 [M+H]+ | |||
140 | (R)-(6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(2-메틸아이소옥사졸리딘-3-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | MS(ESI): m/z 625 [M+H]+ | |||
141 | (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)싸이에노[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀옥사이드 | 1H NMR (400 MHz, TFA salt, Methanol-d 4) δ 9.51 (dd, J = 9.6, 4.3 Hz, 1H), 8.81 (d, J = 1.9 Hz, 1H), 8.76 (d, J = 1.9 Hz, 1H), 8.10 (s, 1H), 7.99 (s, 1H), 7.76 (s, 1H), 7.56 (d, J = 9.2 Hz, 1H), 7.49 (d, J = 6.0 Hz, 1H), 7.19 (d, J = 6.0 Hz, 1H), 6.89 (s, 1H), 3.95 (s, 3H), 3.81 (s, 3H), 3.01 (s, 4H), 2.68 (s, 4H), 2.42 (s, 3H), 2.19 (s, 3H), 2.15 (s, 3H); MS(ESI): m/z 655 [M+H]+ | 8 | 9.38, 97, (b) |
|
142 | (6-((2-((4-(4-(1-하이드록시-2-메틸프로판-2-일)피페라진-1-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드 | MS(ESI): m/z 696 [M+H]+ | 68 | 8.04, 99, (b) |
실시예 | Enzyme (IC50, μM) |
Ba/F3 (GI50, μM) |
|
EGFR Del19/T790M/C797S |
EGFR WT | EGFR Del19/T790M/C797S |
|
1 | A | C | B |
2 | A | C | A |
3 | A | C | C |
4 | A | C | B |
5 | B | B | C |
6 | A | C | A |
7 | - | C | C |
8 | A | C | A |
9 | A | C | C |
10 | - | C | A |
11 | - | C | C |
12 | - | C | C |
13 | A | C | C |
14 | - | C | C |
21 | A | C | A |
22 | A | C | A |
23 | A | C | A |
24 | A | C | A |
25 | A | C | A |
26 | A | C | A |
27 | A | C | A |
28 | A | C | A |
29 | A | C | C |
30 | A | C | A |
31 | A | C | C |
32 | A | C | A |
33 | A | C | C |
34 | A | C | A |
35 | A | C | A |
36 | A | C | A |
40 | - | B | A |
41 | A | C | A |
42 | - | C | A |
43 | A | B | A |
44 | A | C | A |
47 | A | C | A |
48 | A | C | C |
49 | - | C | C |
50 | A | C | A |
51 | - | C | B |
52 | - | C | C |
53 | - | C | C |
54 | A | C | A |
55 | A | C | A |
56 | A | C | A |
57 | - | B | B |
58 | - | C | B |
59 | - | C | C |
60 | A | C | A |
61 | A | C | B |
62 | A | C | B |
63 | - | C | C |
64 | - | C | C |
65 | - | C | C |
66 | - | C | C |
67 | - | C | C |
68 | A | C | C |
69 | C | C | C |
70 | A | C | C |
71 | A | C | C |
72 | A | C | C |
73 | A | B | C |
75 | A | C | C |
76 | A | C | C |
81 | A | C | C |
82 | A | C | C |
83 | A | C | C |
89 | A | C | C |
90 | C | C | |
104 | A | C | C |
105 | A | C | C |
106 | A | C | C |
109 | - | C | A |
111 | C | C | A |
112 | B | C | A |
113 | A | C | A |
114 | A | C | A |
115 | A | C | B |
116 | A | C | A |
117 | A | C | A |
120 | A | B | A |
121 | - | C | C |
122 | A | C | C |
129 | - | C | A |
130 | - | C | A |
131 | C | C | C |
133 | A | A | C |
134 | A | B | C |
135 | C | C | C |
137 | A | C | C |
Claims (13)
- 하기 화학식 1로 표시되는 화합물, 이의 광학 이성질체, 또는 이의 약학적으로 허용가능한 염:[화학식 1]상기 화학식 1에서,X1 내지 X3는 각각 독립적으로 CRaRb, NRc, O, 또는 S이고;Ra 내지 Rc는 각각 독립적으로 -H, -C1-6알킬, -C1-6아미노알킬, -C1-6하이드록시알킬, -C1-6할로알킬, -CN, -NH2, -OH, -O-C1-6알킬, -할로, -C3-6사이클로알킬, 또는 아무 것도 아니고(null);Y1 내지 Y4는 각각 독립적으로 CRd 또는 NRe이고 {여기서, Y1-Y2, Y2-Y3, 및 Y3-Y4 중 어느 하나는 서로 연결되어 5-6원 아릴, 5-6원 헤테로아릴, 또는 5-6원 헤테로사이클로알킬을 형성할 수 있음 [이때, 상기 아릴, 헤테로아릴, 또는 헤테로사이클로알킬의 하나 이상의 H는 -C1-6알킬, -C1-6아미노알킬, -C1-6하이드록시알킬, -C1-6할로알킬, -CN, -NR3R4, -OR5, -할로, 또는 -C3-6사이클로알킬로 치환될 수 있음]};Rd 및 Re는 각각 독립적으로 -H, -C1-6알킬, -C1-6아미노알킬, -C1-6하이드록시알킬, -C1-6할로알킬, -CN, -NR3R4, -OR5, -할로, -C3-6사이클로알킬, 또는 아무 것도 아니고(null);Z1 내지 Z5는 각각 독립적으로 CRf, NRg 또는 N이고 {여기서, Z1-Z2, Z2-Z3, Z3-Z4, 및 Z4-Z5 중 어느 하나는 서로 연결되어 5-6원 아릴, 5-6원 헤테로아릴 또는 5-6원 헤테로사이클로알킬을 형성할 수 있음 [이때, 상기 아릴, 헤테로아릴, 또는 헤테로사이클로알킬의 하나 이상의 H는 -C1-6알킬, -C1-6아미노알킬, -C1-6하이드록시알킬, -C1-6할로알킬, -CN, -NR3R4, -OR5, -할로, 또는 -C3-6사이클로알킬로 치환될 수 있음]};Rf 및 Rg는 각각 독립적으로 -H, -C1-6알킬, -C2-6알케닐, -C2-6알키닐, -C1-6아미노알킬, -C1-6하이드록시알킬, -C1-6할로알킬, -CN, -NR3R4, -NO2, -OR5, -할로, 아릴, 헤테로아릴, -C3-6사이클로알킬, 또는 헤테로사이클로알킬이고 {여기서, 상기 아릴 또는 헤테로아릴의 하나 이상의 H는 -C1-6알킬, -C2-6알케닐, -C2-6알키닐, -C1-6아미노알킬, -C1-6하이드록시알킬, -C1-6할로알킬, -C3-6사이클로알킬, 헤테로사이클로알킬, 페닐, 또는 헤테로아릴로 치환될 수 있고, 상기 -C3-6사이클로알킬 또는 헤테로사이클로알킬의 하나 이상의 H는 -C1-6알킬, -C1-6아미노알킬, -C1-6하이드록시알킬, -C1-6할로알킬, -C3-6사이클로알킬, -C1-6알킬-C3-6사이클로알킬, -C(=O)-C3-6사이클로알킬, 또는 헤테로사이클로알킬로 치환될 수 있음 (이때, 상기 -C3-6사이클로알킬, -C1-6알킬-C3-6사이클로알킬, -C(=O)-C3-6사이클로알킬, 헤테로사이클로알킬 고리의 하나 이상의 H는 -C1-6알킬, -C1-6아미노알킬, -C1-6하이드록시알킬, -C1-6할로알킬, -C3-6사이클로알킬, 또는 -할로로 치환될 수 있음)]};m은 0 또는 1이고;R1 및 R2는 각각 독립적으로 -H, -C1-6알킬, -C1-6알콕시, -C1-6알킬아미노, -C2-12디알킬아미노, 또는 C3-6사이클로알킬이거나, 또는 상기 R1 및 R2는 서로 연결되어 P 원자와 함께 4 내지 7원 고리를 형성할 수 있고;R3 및 R4는 각각 독립적으로 -H, -C1-6알킬, -C1-6알킬-NR6R7, -C1-6알킬-O-C1-6알킬, -C(=O)-C1-6알킬, 또는 -C(=O)-C2-6알케닐이고;R5는 -H, -C1-6알킬, -C1-6알킬-NR6R7, -C1-6아미노알킬, -C1-6하이드록시알킬, 또는 -C1-6할로알킬이고;R6 및 R7은 각각 독립적으로 -H 또는 -C1-6알킬이다.
- 제 1 항에 있어서,X1 내지 X3는 각각 독립적으로 CRaRb, NRc, 또는 S이고;Ra 내지 Rc는 각각 독립적으로 -H, -C1-6알킬, -C1-6할로알킬, -CN, -할로, -C3-6사이클로알킬, 또는 아무 것도 아니고(null);Y1 내지 Y4는 각각 독립적으로 CRd 또는 NRe이고 {여기서, Y1-Y2, Y2-Y3, 및 Y3-Y4 중 어느 하나는 서로 연결되어 5-6원 아릴, 5-6원 헤테로아릴, 또는 5-6원 헤테로사이클로알킬을 형성할 수 있음 [이때, 상기 아릴, 헤테로아릴, 또는 헤테로사이클로알킬의 하나 이상의 H는 -C1-6알킬, -C1-6할로알킬, -할로, 또는 -C3-6사이클로알킬로 치환될 수 있음]};Rd 및 Re는 각각 독립적으로 -H, -C1-6알킬, 또는 아무 것도 아니고(null);Z1 내지 Z5는 각각 독립적으로 CRf, NRg 또는 N이고 {여기서, Z1-Z2, Z2-Z3, Z3-Z4, 및 Z4-Z5 중 어느 하나는 서로 연결되어 5-6원 헤테로사이클로알킬을 형성할 수 있음 [이때, 상기 헤테로사이클로알킬의 하나 이상의 H는 -C1-6알킬, -C1-6할로알킬, -할로, 또는 -C3-6사이클로알킬로 치환될 수 있음]};Rf 및 Rg는 각각 독립적으로 -H, -C1-6알킬, -C2-6알케닐, -C2-6알키닐, -C1-6할로알킬, -CN, -NR3R4, -NO2, -OR5, -할로, 아릴, 헤테로아릴, -C3-6사이클로알킬, 또는 헤테로사이클로알킬이고 {여기서, 상기 아릴 또는 헤테로아릴의 하나 이상의 H는 -C1-6알킬, -C1-6할로알킬, 또는 -C3-6사이클로알킬로 치환될 수 있고, 상기 -C3-6사이클로알킬 또는 헤테로사이클로알킬의 하나 이상의 H는 -C1-6알킬, -C1-6하이드록시알킬, -C1-6할로알킬, -C3-6사이클로알킬, -C1-6알킬-C3-6사이클로알킬, -C(=O)-C3-6사이클로알킬, 또는 헤테로사이클로알킬로 치환될 수 있음 (이때, 상기 -C3-6사이클로알킬, -C1-6알킬-C3-6사이클로알킬, -C(=O)-C3-6사이클로알킬, 헤테로사이클로알킬 고리의 하나 이상의 H는 -C1-6알킬, -C3-6사이클로알킬, 또는 -할로로 치환될 수 있음)]};m은 0 또는 1이고;R1 및 R2는 각각 독립적으로 -C1-6알킬이고;R3 및 R4는 각각 독립적으로 -H, -C1-6알킬, -C1-6알킬-NR6R7, -C1-6알킬-O-C1-6알킬, -C(=O)-C1-6알킬, 또는 -C(=O)-C2-6알케닐이고;R5는 -H, -C1-6알킬, -C1-6알킬-NR6R7, 또는 -C1-6할로알킬이고;R6 및 R7은 각각 독립적으로 -H 또는 -C1-6알킬인;화합물, 이의 광학 이성질체, 또는 이의 약학적으로 허용가능한 염.
- 제 1 항에 있어서,X1은 CRaRb, NRc, 또는 S이고;X2는 CRaRb이고;X3는 CRaRb, NRc, 또는 S이고;Ra 내지 Rc는 각각 독립적으로 -H, -C1-6할로알킬, -CN, -할로, -C3-6사이클로알킬, 또는 아무 것도 아닌 것인(null);화합물, 이의 광학 이성질체, 또는 이의 약학적으로 허용가능한 염.
- 제 1 항에 있어서,Y1 내지 Y4는 각각 독립적으로 CRd 또는 NRe이고 {여기서, Y1-Y2, Y2-Y3, 및 Y3-Y4 중 어느 하나는 서로 연결되어 5-6원 아릴, 5-6원 헤테로아릴, 또는 5-6원 헤테로사이클로알킬을 형성할 수 있음 [이때, 상기 아릴, 헤테로아릴, 또는 헤테로사이클로알킬의 하나 이상의 H는 -C1-6알킬, -C1-6할로알킬, -할로, 또는 -C3-6사이클로알킬로 치환될 수 있음]};Rd 및 Re는 각각 독립적으로 -H, -C1-6알킬, 또는 아무 것도 아닌 것인(null);화합물, 이의 광학 이성질체, 또는 이의 약학적으로 허용가능한 염.
- 제 1 항에 있어서,Z1 내지 Z5는 각각 독립적으로 CRf, NRg 또는 N이고 {여기서, Z1-Z2는 서로 연결되어 5-6원 헤테로사이클로알킬을 형성할 수 있음 [이때, 상기 헤테로사이클로알킬의 하나 이상의 H는 -C1-6알킬, -C1-6할로알킬, 또는 -할로로 치환될 수 있음]};Rf 및 Rg는 각각 독립적으로 -H, -C1-6알킬, -C2-6알케닐, -C2-6알키닐, -C1-6할로알킬, -CN, -NR3R4, -NO2, -OR5, -할로, 아릴, 헤테로아릴, -C3-6사이클로알킬, 또는 헤테로사이클로알킬이고 {여기서, 상기 아릴 또는 헤테로아릴의 하나 이상의 H는 -C1-6알킬, -C1-6할로알킬, -C3-6사이클로알킬, 헤테로사이클로알킬, 페닐, 또는 헤테로아릴로 치환될 수 있고, 상기 -C3-6사이클로알킬 또는 헤테로사이클로알킬의 하나 이상의 H는 -C1-6알킬, -C1-6하이드록시알킬, -C1-6할로알킬, -C3-6사이클로알킬, -C1-6알킬-C3-6사이클로알킬, -C(=O)-C3-6사이클로알킬, 또는 헤테로사이클로알킬로 치환될 수 있음 (이때, 상기 -C3-6사이클로알킬, -C1-6알킬-C3-6사이클로알킬, -C(=O)-C3-6사이클로알킬, 헤테로사이클로알킬 고리의 하나 이상의 H는 -C1-6알킬, -C3-6사이클로알킬, 또는 -할로로 치환될 수 있음)]};R3 및 R4는 각각 독립적으로 -H, -C1-6알킬, -C1-6알킬-NR6R7, -C1-6알킬-O-C1-6알킬, -C(=O)-C1-6알킬, 또는 -C(=O)-C2-6알케닐이고;R5는 -C1-6알킬, -C1-6알킬-NR6R7, 또는 -C1-6할로알킬이고;R6 및 R7은 각각 독립적으로 -H 또는 -C1-6알킬인;화합물, 이의 광학 이성질체, 또는 이의 약학적으로 허용가능한 염.
- 제 1 항에 있어서,R1 및 R2는 각각 독립적으로 -C1-6알킬인;화합물, 이의 광학 이성질체, 또는 이의 약학적으로 허용가능한 염.
- 제 1 항에 있어서,상기 화학식 1로 표시되는 화합물이 하기 화합물로 이루어진 군으로부터 선택된 것인, 화합물, 이의 광학 이성질체, 또는 이의 약학적으로 허용 가능한 염:(1) 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(2) 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-모르폴리노-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(3) (6-((2-((4-플루오로-5-(1-메틸-1H-피라졸-4-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(4) 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(5) 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(6) 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-모르폴리노피페리딘-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(7) 다이메틸(6-((2-((4-(4-메틸피페라진-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(8) 다이메틸(6-((2-((5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(9) 다이메틸(6-((2-((5-메틸-4-(4-메틸피페라진-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(10) (6-((2-((4-((2R,6S)-2,6-다이메틸모르폴리노)-5-(1-메틸-1H-피라졸-4-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(11) 다이메틸(6-((2-((5-메틸-4-모르폴리노-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(12) 다이메틸(6-((2-((5-메틸-4-(4-모르폴리노피페리딘-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(13) 다이메틸(3-((2-((5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-4-일)포스핀 옥사이드;(14) 다이메틸(3-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-4-일)포스핀 옥사이드;(15) (2-사이클로프로필-6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-5-일)다이메틸포스핀 옥사이드;(16) (2-사이클로프로필-6-((2-((5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-5-일)다이메틸포스핀 옥사이드;(17) 다이메틸(7-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)이미다조[1,2-a]피리딘-8-일)포스핀 옥사이드;(18) 다이메틸(7-((2-((5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)이미다조[1,2-a]피리딘-8-일)포스핀 옥사이드;(19) 다이메틸(4-메틸-7-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)-3,4-다이하이드로-2H-벤조[b][1,4]옥사진-8-일)포스핀 옥사이드;(20) 다이메틸(4-메틸-7-((2-((5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)-2-(2,2,2-트라이플루오로에톡시)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)-3,4-디하이드로-2H-벤조[b][1,4]옥사진-8-일)포스핀 옥사이드;(21) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(22) (6-((2-((4-(4-사이클로펜틸피페라진-1-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(23) (6-((2-((4-((2S,6R)-2,6-다이메틸모르폴리노)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(24) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(25) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-모르폴리노페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(26) (6-((2-((4-((1S,4S)-2-옥사-5-아자바이사이클로[2.2.1]헵탄-5-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(27) (6-((2-((4-((1R,4R))-2-옥사-5-아자바이사이클로[2.2.1]헵탄-5-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(28) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(29) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(2-옥사-6-아자스파이로[3.3]헵탄-6-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(30) (6-((2-((4-((1R,5S)-8-옥사-3-아자바이사이클로[3.2.1]옥탄-3-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(31) (6-((2-((4-플루오로-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(32) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(2-옥사-7-아자스파이로[3.5]노난-7-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(33) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(7-옥사-2-아자스파이로[3.5]노난-2-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(34) 다이메틸(6-((2-((3-(1-메틸-1H-피라졸-4-일)-4-모르폴리노페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(35) (6-((2-((4-(2-(다이메틸아미노)에톡시)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(36) (6-((2-((4-((2-(다이메틸아미노)에틸)(메틸)아미노)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(37) (6-((2-((2-메톡시-4-((2-메톡시에틸)(메틸)아미노)-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(38) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-((3S,5R)-3,4,5-트라이메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(39) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-모르폴리노피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(40) 다이메틸(6-((2-((3-(1-메틸-1H-피라졸-4-일)-4-(4-모르폴리노피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(41) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-((3aR,6aS)-테트라하이드로-1H-퓨로[3,4-c]피롤-5(3H)-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(42) (6-((2-((4-(4-사이클로프로필피페라진-1-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(43) (R)-(6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(옥타하이드로-2H-피리도[1,2-a]피라진)-2-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(44) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-6-(4-메틸피페라진-1-일)피리딘-3-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(45) (6-((2-((3-메톡시-6-(1-메틸-1H-피라졸-4-일)-5-(4-메틸피페라진-1-일)피리딘-2-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(46) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-6-(1-메틸피페리딘-4-일)피리딘-3-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(47) (6-((2-((5-(1-에틸-1H-피라졸-4-일)-2-메톡시-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(48) (6-((2-((4-(4-에틸피페라진-1-일)-5-(1-아이소프로필-1H-피라졸-4-일)-2-메톡시페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(49) (6-((2-((5-(1-아이소프로필-1H-피라졸-4-일)-2-메톡시-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(50) (6-((2-((5-(1-(다이플루오로메틸)-1H-피라졸-4-일)-2-메톡시-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(51) (6-((5-클로로-2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(52) 4-((5-(다이메틸포스포릴)퀴녹살린-6-일)아미노)-2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1)-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-5-카보나이트릴;(53) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-5-(트라이플루오로메틸)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(54) (6-((2-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(55) (6-((2-((5-에틸-2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3- d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(56) (6-((2-((5-클로로-2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(57) (6-((2-((2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(58) 다이메틸(6-((2-((4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(59) (6-((2-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)싸이에노[3,2-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(60) (6-((2-((4-(4-(4-사이클로프로필피페라진-1-일)피페리딘-1-일)-2-메톡시-5-메틸페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(61) (6-((2-((4-(4-(4-에틸피페라진-1-일)피페리딘-1-일)-2-메톡시-5-메틸페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(62) (6-((2-((4-(4-(4-아이소프로필피페라진-1-일)피페리딘-1-일)-2-메톡시-5-메틸페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(63) (6-((6-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-1H-피롤로[2,3-b]피리딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(64) (6-((6-((2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-1H-피롤로[2,3-b]피리딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(65) (6-((6-((3-메톡시-5-(4-(4-메틸피페라진-1-일)피페리딘-1-일)피리딘-2-일)아미노)-1H-피롤로[2,3-b]피리딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(66) (6-((2-((5-플루오로-2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(67) (6-((2-((5-아이소프로필-2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(68) (6-((2-((2-메톡시-5-메틸페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(69) (6-((2-((2-에톡시-5-(트라이플루오로메틸)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(70) (6-((2-((2-메톡시-4-(4-메틸피페라진-1-일)-5-(피리딘-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(71) (6-((2-((2-메톡시-4-(4-메틸피페라진-1-일)-5-(퀴놀린-3-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(72) (6-((2-((4-메톡시-6-(4-메틸피페라진-1-일)-[1,1'-바이페닐]-3-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(73) N-(5-((4-((5-(다이메틸포스포릴)퀴녹살린-6-일)아미노)-7H-피롤로[2,3-d]피리미딘-2-일)아미노)-4-메톡시-2-(4-메틸피페라진-1-일)페닐)아크릴아마이드;(74) N-(5-((4-((5-(다이메틸포스포릴)퀴녹살린-6-일)아미노)-7H-피롤로[2,3-d]피리미딘-2-일)아미노)-4-메톡시-2-(4-메틸피페라진-1-일)페닐)프로피온아마이드;(75) (6-((2-((5-(퓨란-3-일)-2-메톡시-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(76) (6-((2-((2-메톡시-4-(4-메틸피페라진-1-일)-5-(싸이오펜-3-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(77) (6-((2-((5-(아이소옥사졸-4-일)-2-메톡시-6-(4-메틸피페라진-1-일)피리딘-3-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(78) (6-((2-((2-메톡시-6-(4-메틸피페라진-1-일)-5-(옥사졸-4-일)피리딘-3-일)아미노)-7H-피롤로[2,3 -d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(79) (6-((2-((5-에티닐-2-메톡시-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(80) 5-((4-((5-(다이메틸포스포릴)퀴녹살린-6-일)아미노)-7H-피롤로[2,3-d]피리미딘-2-일)아미노)-6-메톡시-2-(4-메틸피페라진-1-일)니코티노나이트릴;(81) 5-((4-((5-(다이메틸포스포릴)퀴녹살린-6-일)아미노)-7H-피롤로[2,3-d]피리미딘-2-일)아미노)-4-메톡시-2-(4-메틸피페라진-1-일)벤조나이트릴;(82) (6-((2-((2-메톡시-4-(4-메틸피페라진-1-일)-5-바이닐페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(83) (6-((2-((5-사이클로프로필-2-메톡시-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(84) (6-((2-((5-에틸-2-메톡시-6-(1-메틸피페리딘-4-일)피리딘-3-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(85) (6-((2-((5-에틸-2-메톡시-6-(4-메틸피페라진-1-일)피리딘-3-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(86) (6-((2-((5-에틸-2-메톡시-6-(1'-메틸-[1,4'-바이피페리딘]-4-일)피리딘-3-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(87) (6-((2-((5-에틸-2-메톡시-6-(4-(4-메틸피페라진-1-일)피페리딘-1-일)피리딘-3-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(88) (6-((2-((5-(1-사이클로프로필-1H-피라졸-4-일)-2-메톡시-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(89) (3-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-4-일)다이메틸포스핀 옥사이드;(90) (3-((2-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-4-일)다이메틸포스핀 옥사이드;(91) (2-사이클로프로필-6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-5-일)다이메틸포스핀 옥사이드;(92) (2-사이클로프로필-6-((2-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-5-일)다이메틸포스핀 옥사이드;(93) (7-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)이미다조[1,2-a]피리딘-8-일)다이메틸포스핀 옥사이드;(94) (7-((2-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3- d]피리미딘-4-일)아미노)이미다조[1,2-a]피리딘-8-일)다이메틸포스핀 옥사이드;(95) (7-((2-((2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)이미다조[1,2-a]피리딘-8-일)다이메틸포스핀 옥사이드;(96) 다이메틸(7-((2-((4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)이미다조[1,2-a]피리딘-8-일)포스핀 옥사이드;(97) (7-((2-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)싸이에노[3,2-d]피리미딘-4-일)아미노)이미다조[1,2-a]피리딘-8-일)다이메틸포스핀 옥사이드;(98) (7-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)-4-메틸-3,4-다이하이드로-2H-벤조[b][1,4]옥사진-8-일)다이메틸포스핀 옥사이드;(99) (7-((2-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-7H-피롤로[2,3- d]피리미딘-4-일)아미노)-4-메틸-3,4-다이하이드로-2H-벤조[b][1,4]옥사진-8-일)다이메틸포스핀 옥사이드;(100) (7-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-8-일)다이메틸포스핀 옥사이드;(101) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴놀린-5-일)다이메틸포스핀 옥사이드;(102) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)-2,3-다이메틸페닐)다이메틸포스핀 옥사이드;(103) (3-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)-1,5-나프티리딘-4-일)다이메틸포스핀 옥사이드;(104) (6-((2-((2-메톡시-5-메틸-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-9H-퓨린-6-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(105) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)아미노)-9H-퓨린-6-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(106) 다이메틸(6-((2-((3-(4-메틸-1H-이미다졸-1-일)-5-(트라이플루오로메틸)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(107) 다이메틸(6-((2-((4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)-3-(트라이플루오로메틸)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(108) (6-((2-((4-(9-(1-플루오로-2-메틸프로판-2-일)-3,9-다이아자스파이로[5.5]운데칸-3-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(109) (6-((2-((4-(4-(1-플루오로-2-메틸프로판-2-일)피페라진-1-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(110) (6-((2-((4-(9-(1-하이드록시-2-메틸프로판-2-일)-3,9-다이아자스파이로[5.5]운데칸-3-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(111) (9-(4-((4-((5-(다이메틸포스포릴)퀴녹살린-6-일)아미노)-7H-피롤로[2,3-d]피리미딘-2-일)아미노)-5-메톡시-2-(1-메틸-1H-피라졸-4-일)페닐)-3,9-다이아자스파이로[5.5]운데칸-3-일)(1-플루오로사이클로프로필)메탄온;(112) (4-(4-((4-((5-(다이메틸포스포릴)퀴녹살린-6-일)아미노)-7H-피롤로[2,3-d]피리미딘-2-일)아미노)-5-메톡시-2-(1-메틸-1H-피라졸-4-일)페닐)피페라진-1-일)(1-플루오로사이클로프로필)메탄온;(113) (6-((2-((4-(4-((1-플루오로사이클로프로필)메틸)피페라진-1-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(114) (6-((2-((4-(9-((1-플루오로사이클로프로필)메틸)-3,9-다이아자스파이로[5.5]운데칸-3-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(115) (6-((2-((5-(1-사이클로프로필-1H-피라졸-4-일)-2-메톡시-4-(4-메틸피페라진-1-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(116) 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)-2,3-다이하이드로벤조퓨란-7-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(117) 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)-2,3-다이하이드로벤조퓨란-7-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(118) (6-((2-((4-(4-사이클로펜틸피페라진-1-일)-5-(1-메틸-1H-피라졸-4-일)-2,3-다이하이드로벤조퓨란-7-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(119) 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-모르폴리노-2,3-다이하이드로벤조퓨란-7-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(120) 다이메틸(6-((2-((5-(1-메틸-1H-피라졸-4-일)-4-(4-모르폴리노피페리딘-1-일)-2,3-다이하이드로벤조퓨란-7-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(121) 다이메틸(6-((2-((5-메틸-4-(4-메틸피페라진-1-일)-2,3-다이하이드로벤조퓨란-7-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(122) 다이메틸(6-((2-((5-메틸-4-모르폴리노-2,3-다이하이드로벤조퓨란-7-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(123) 다이메틸(6-((2-((6-(1-메틸-1H-피라졸-4-일)-5-(4-메틸피페라진-1-일)크로만-8-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(124) 다이메틸(6-((2-((6-(1-메틸-1H-피라졸-4-일)-5-(4-(4-메틸피페라진-1-일)피페리딘-1-일)크로만-8- 일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(125) 다이메틸(6-((2-((6-(1-메틸-1H-피라졸-4-일)-5-모르폴리노크로만-8-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(126) 다이메틸(6-((2-((6-(1-메틸-1H-피라졸-4-일)-5-(4-모르폴리노피페리딘-1-일)크로만-8-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(127) 다이메틸(6-((2-((6-메틸-5-(4-메틸피페라진-1-일)크로만-8-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(128) 다이메틸(6-((2-((6-메틸-5-모르폴리노크로만-8-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(129) 다이메틸(6-((2-((6-(1-메틸-1H-피라졸-4-일)-7-(4-메틸피페라진-1-일)벤조[d][1,3]다이옥솔-4-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(130) 다이메틸(6-((2-((7-(1-메틸-1H-피라졸-4-일)-8-(4-메틸피페라진-1-일)-2,3-다이하이드로벤조[b][1,4]다이옥신-5-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(131) 다이메틸(6-((2-((8-(1-메틸-1H-피라졸-5-일)-2,3-다이하이드로벤조[b][1,4]다이옥신-5-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(132) 다이메틸(6-((2-((7-(1-메틸-1H-피라졸-4-일)-8-모르폴리노-2,3-다이하이드로벤조[b][1,4]다이옥신-5-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(133) N-(5-(4-(4-사이클로프로필피페라진-1-일)피페리딘-1-일)-8-((4-((5-(다이메틸포스포릴)퀴녹살린-6-일)아미노)-7H-피롤로[2,3-d]피리미딘-2-일)아미노)-2,3-다이하이드로벤조[b][1,4]다이옥신-6-일)아크릴아마이드;(134) (6-((2-((8-(4-(4-사이클로프로필피페라진-1-일)피페리딘-1-일)-7-나이트로-2,3-다이하이드로벤조[b][1,4]다이옥신-5-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(135) 다이메틸(6-((2-((6-(1-메틸-1H-피라졸-4-일)-8-모르폴리노-2,3-다이하이드로벤조[b][1,4]다이옥신-5-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)포스핀 옥사이드;(136) (6-((2-((3-클로로-1-메틸-1H-피라졸-4-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(137) (6-((2-((5-클로로-1-메틸-1H-피라졸-4-일)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(138) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(2-메틸아이소옥사졸리딘-3-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(139) (S)-(6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(2-메틸아이소옥사졸리딘-3-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(140) (R)-(6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(2-메틸아이소옥사졸리딘-3-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드;(141) (6-((2-((2-메톡시-5-(1-메틸-1H-피라졸-4-일)-4-(4-메틸피페라진-1-일)페닐)아미노)싸이에노[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드; 및(142) (6-((2-((4-(4-(1-하이드록시-2-메틸프로판-2-일)피페라진-1-일)-2-메톡시-5-(1-메틸-1H-피라졸-4-일)페닐)아미노)-7H-피롤로[2,3-d]피리미딘-4-일)아미노)퀴녹살린-5-일)다이메틸포스핀 옥사이드.
- 제 1 항 내지 제 7 항 중 어느 하나의 항에 따른 화합물, 이의 광학 이성질체, 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는, 암의 치료 또는 예방용 약학적 조성물.
- 제 8 항에 있어서,EGFR을 억제하는 것인, 약학적 조성물.
- 제 9 항에 있어서,EGFR Del19/T790M, EGFR Del19/T790M/C797S, EGFR L858R/T790M, EGFR L858R, EGFR Exon20 ins NPH, EGFR Exon20 ins SVD, EGFR Exon20 ins FQEA, EGFR Exon20 ins H, 및 EGFR Exon20 ins ASV로 이루어진 군으로부터 선택된 어느 하나 이상을 억제하는 것인, 약학적 조성물.
- 제 8 항에 있어서,상기 암은 가성점액종, 간내 담도암, 간모세포종, 간암, 갑상선암, 결장암, 고환암, 골수이형성증후군, 교모세포종, 구강암, 구순암, 균상식육종, 급성골수성백혈병, 급성림프구성백혈병, 기저세포암, 난소상피암, 난소생식세포암, 남성유방암, 뇌암, 뇌하수체선종, 다발성골수종, 담낭암, 담도암, 대장암, 만성골수성백혈병, 만성림프구백혈병, 망막모세포종, 맥락막흑색종, 바터팽대부암, 방광암, 복막암, 부갑상선암, 부신암, 비부비동암, 비소세포폐암, 설암, 성상세포종, 소세포폐암, 소아뇌암, 소아림프종, 소아백혈병, 소장암, 수막종, 식도암, 신경교종, 신우암, 신장암, 심장암, 십이지장암, 악성 연부조직 암, 악성골암, 악성림프종, 악성중피종, 악성흑색종, 안암, 외음부암, 요관암, 요도암, 원발부위불명암, 위림프종, 위암, 위유암종, 위장관간질암, 윌름스암, 유방암, 육종, 음경암, 인두암, 임신융모질환, 자궁경부암, 자궁내막암, 자궁육종, 전립선암, 전이성 골암, 전이성뇌암, 종격동암, 직장암, 직장유암종, 질암, 척수암, 청신경초종, 췌장암, 침샘암, 카포시 육종, 파제트병, 편도암, 편평상피세포암, 폐선암, 폐암, 폐편평상피세포암, 피부암, 항문암, 횡문근육종, 후두암, 흉막암, 혈액암, 및 흉선암으로 이루어진 군으로부터 선택되는 1종 이상인, 약학적 조성물.
- 암의 치료 또는 예방에 사용하기 위한 약제의 제조에 사용하기 위한, 제 1 항 내지 제 7 항 중 어느 하나의 항에 따른 화합물, 이의 광학 이성질체, 또는 이의 약학적으로 허용 가능한 염의 용도.
- 제 1 항 내지 제 7 항 중 어느 하나의 항에 따른 화합물, 이의 광학 이성질체, 또는 이의 약학적으로 허용 가능한 염의 치료학적으로 유효한 양을, 이를 필요로 하는 대상에게 투여하는 단계를 포함하는, 암을 치료 또는 예방하는 방법.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023539790A JP2024503273A (ja) | 2020-12-29 | 2021-12-29 | ヘテロアリール誘導体化合物およびその用途 |
EP21915825.0A EP4273149A1 (en) | 2020-12-29 | 2021-12-29 | Heteroaryl derivative compound and use thereof |
US18/259,696 US20240067668A1 (en) | 2020-12-29 | 2021-12-29 | Heteroaryl derivative compound and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0186082 | 2020-12-29 | ||
KR20200186082 | 2020-12-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022146027A1 true WO2022146027A1 (ko) | 2022-07-07 |
Family
ID=82260711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/020165 WO2022146027A1 (ko) | 2020-12-29 | 2021-12-29 | 헤테로아릴 유도체 화합물 및 이의 용도 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240067668A1 (ko) |
EP (1) | EP4273149A1 (ko) |
JP (1) | JP2024503273A (ko) |
KR (1) | KR20220097305A (ko) |
WO (1) | WO2022146027A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4129996A4 (en) * | 2020-03-23 | 2023-07-12 | Qilu Pharmaceutical Co., Ltd. | NEW EGFR AMINOPYRIMIDINE INHIBITOR |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019223777A1 (zh) * | 2018-05-24 | 2019-11-28 | 北京赛特明强医药科技有限公司 | 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用 |
CN110526941A (zh) * | 2018-05-24 | 2019-12-03 | 北京赛特明强医药科技有限公司 | 一种含有间氯苯胺类取代基的吡咯并嘧啶类化合物、制备方法及其应用 |
KR20200026782A (ko) * | 2016-08-09 | 2020-03-11 | 홍윤 바이오테크 씨오., 엘티디. | 티에노피리미딘 화합물, 그의 제조 방법, 약학 조성물 및 용도 |
CN111825719A (zh) * | 2019-04-15 | 2020-10-27 | 北京赛特明强医药科技有限公司 | 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用 |
WO2020253862A1 (zh) * | 2019-06-21 | 2020-12-24 | 上海翰森生物医药科技有限公司 | 含氮芳基磷氧化物类衍生物、其制备方法和应用 |
-
2021
- 2021-12-29 JP JP2023539790A patent/JP2024503273A/ja active Pending
- 2021-12-29 WO PCT/KR2021/020165 patent/WO2022146027A1/ko active Application Filing
- 2021-12-29 US US18/259,696 patent/US20240067668A1/en active Pending
- 2021-12-29 EP EP21915825.0A patent/EP4273149A1/en active Pending
- 2021-12-29 KR KR1020210191079A patent/KR20220097305A/ko unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200026782A (ko) * | 2016-08-09 | 2020-03-11 | 홍윤 바이오테크 씨오., 엘티디. | 티에노피리미딘 화합물, 그의 제조 방법, 약학 조성물 및 용도 |
WO2019223777A1 (zh) * | 2018-05-24 | 2019-11-28 | 北京赛特明强医药科技有限公司 | 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用 |
CN110526941A (zh) * | 2018-05-24 | 2019-12-03 | 北京赛特明强医药科技有限公司 | 一种含有间氯苯胺类取代基的吡咯并嘧啶类化合物、制备方法及其应用 |
CN111825719A (zh) * | 2019-04-15 | 2020-10-27 | 北京赛特明强医药科技有限公司 | 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用 |
WO2020253862A1 (zh) * | 2019-06-21 | 2020-12-24 | 上海翰森生物医药科技有限公司 | 含氮芳基磷氧化物类衍生物、其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
CLIN CANCER RES, vol. 17, 2015, pages 21 |
NATURE MEDICINE, vol. 21, 2015, pages 560 - 562 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4129996A4 (en) * | 2020-03-23 | 2023-07-12 | Qilu Pharmaceutical Co., Ltd. | NEW EGFR AMINOPYRIMIDINE INHIBITOR |
Also Published As
Publication number | Publication date |
---|---|
US20240067668A1 (en) | 2024-02-29 |
KR20220097305A (ko) | 2022-07-07 |
EP4273149A1 (en) | 2023-11-08 |
JP2024503273A (ja) | 2024-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112437772B (zh) | Bcl-2抑制剂 | |
JP6430512B2 (ja) | リジン特異的デメチラーゼ−1の阻害剤 | |
CN116194456A (zh) | 作为kras抑制剂的杂环化合物的制备及其应用方法 | |
AU2009217982B2 (en) | Fused heterocyclic derivative and use thereof | |
CA3048376A1 (en) | Bmp-signal-inhibiting compound | |
AU2005260077A1 (en) | Furanopyrimidines | |
JP7335893B2 (ja) | ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのクロメノピリジン誘導体 | |
CN116648452A (zh) | 作为kras抑制剂的杂环化合物的制备及其应用方法 | |
CZ20032937A3 (cs) | Pyrazolo[1,5-a]pyridiny a léčiva s jejich obsahem | |
CA3108676A1 (en) | Carboxamides as ubiquitin-specific protease inhibitors | |
CA3072449A1 (en) | Carboxamides as ubiquitin-specific protease inhibitors | |
CA3199496A1 (en) | Heterocycle derivatives for treating trpm3 mediated disorders | |
KR20200090636A (ko) | 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
KR20200090637A (ko) | 피롤로피리딘 유도체 및 단백질 키나아제 관련 질환의 예방 또는 치료에서의 사용을 위한 이의 용도 | |
TW202332448A (zh) | 噻吩ulk1/2抑制劑及其用途 | |
WO2023011456A1 (en) | Pyrazolopyridinone compounds | |
WO2022131741A1 (ko) | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 | |
WO2022146027A1 (ko) | 헤테로아릴 유도체 화합물 및 이의 용도 | |
US10961238B2 (en) | Modulators of hedgehog (Hh) signaling pathway | |
KR20230074733A (ko) | Myc 패밀리 원종양유전자 단백질의 조정제 | |
WO2022107919A1 (ko) | N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2022139386A1 (ko) | 헤테로아릴 유도체 화합물 및 이의 용도 | |
WO2020235945A1 (ko) | N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
US20240025906A1 (en) | Kinase modulators and methods of use thereof | |
WO2023211256A1 (ko) | 신규한 pim 키나아제 억제 화합물 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21915825 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023539790 Country of ref document: JP Ref document number: 18259696 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021915825 Country of ref document: EP Effective date: 20230731 |